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STATEMENT OF TERMS 
 
Throughout this thesis the following abbreviations have been adopted: 
 
AIDS – Acquired Immune Deficiency Virus 
CAI – Condomless Anal Intercourse 
CBT – Cognitive Behavioural Therapy  
EBD – Event Based Dosing 
HIV – Human Immunodeficiency Virus 
OCD – Obsessive Compulsive Disorder 
PrEP – Pre-Exposure Prophylaxis  
PEP – Post Exposure Prophylaxis  
STI – Sexually Transmitted Infections 
 
 
There are various terms that are commonly used to describe sex between men.  In 
recent years, men who have sex with men (MSM) is widely used within public health 
discourse.  However, this purportedly neutral term is problematic as it obscures the social and 
psychological dimensions of sexuality and may undermine the self-labelling of gay and 
bisexual men.  These dimensions are crucial in the current study and therefore this thesis will 




Aims:  To explore the experiences of low-risk, HIV anxious gay and bisexual men (GBM) 
who use HIV Pre-Exposure Prophylaxis (PrEP) and the impact PrEP use has on their sexual 
behaviour and experience of anxiety. 
Background:  PrEP has demonstrated significant protection against HIV infection among 
GBM who are high-risk and is becoming increasingly popular.    Anecdotal reports suggest 
that low-risk, HIV anxious GBM are using PrEP.    HIV anxiety in GBM is a poorly 
understood phenomenon that is usually conceptualised within cognitive-behavioural models.  
This may neglect the impact of minority status and the specific psychosocial processes 
associated with this, such an internalised homophobia.  PrEP use is associated with less worry 
and improved sexual functioning and it is unknown whether these benefits will be realised 
among PrEP-using, low-risk GBM who are HIV anxious.   
Methodology:   Qualitative methodology was employed within an interpretivist paradigm.  
10 gay men were recruited from sexual health clinics in central London.   Participants were 
included in the current study through either historically or currently meeting diagnostic 
criteria for Illness Anxiety Disorder, were considered low risk for acquiring HIV infection 
and had been using PrEP for at least 3 months.  In-depth semi-structed interviews were 
conducted.  Data was analysed by means of thematic analysis.   
Results:    Twenty-two themes, and accompanying subthemes, were extracted from 
participants’ data.     Participants experienced adversity in adjusting to their sexuality.  These 
experiences may have led to internalised homophobia that impacted perception of sexuality 
and contributed to development of HIV anxiety.  HIV anxiety was characterised by various 
cognitive and behaviour manifestations, as well as shame.    PrEP use was initiated to 





participants experienced less anxiety and improved psychosexual functioning after starting 
PrEP.  
Conclusions:  HIV anxiety in GBM may be a consequence of psychosocial processes 
associated with minority stress.   The experience of HIV anxiety in GBM is not adequately 
captured within current diagnostic classifications or psychological theories and models of 
anxiety disorders.  PrEP use in this group may be better conceptualised as a community 
adaptive coping strategy rather than a safety behaviour.  PrEP therefore may be a useful 




CHAPTER ONE:  INTRODUCTION 
 
Chapter Overview 
The history of the human immunodeficiency virus (HIV) and acquired immune 
deficiency syndrome (AIDS) is one of the most fascinating stories, that not only tells of 
human suffering but also of hope, human perseverance, and the might of science. There have 
been many advances, such as the isolation of the causative virus (i.e., HIV), development of 
highly active anti-retroviral therapy and challenging societal prejudice: HIV has been 
transformed from a terminal illness to a long-term health term condition, which is almost 
always manageable.  
Another great feat in the story of HIV and AIDS is the development of and access to 
pre-exposure prophylaxis (PrEP), which has been hailed as a ‘game changer’ (Nwokolo et al., 
2017). Along with a combination of other HIV prevention strategies, PrEP has already turned 
the tide in the number of new infections among GBM in the UK and is touted to play a key 
role in bringing an end to this devastating epidemic. However, HIV and AIDS has impacted 
GBM across the decades, which has led some in this population to experience excessive 
anxiety relating to HIV, irrespective of their sexual behaviours. This introduction weaves 
together the story of HIV and AIDS, PrEP and ‘HIV anxiety’ among GBM, to frame the 
empirical study. 
 
Part I:  The Early Years & HIV Overview 
A New Gay Disease? 
AIDS was first described as a clinical entity in 1981 (CDC, 1981; Freidman-Kien, 
1981). Initial reports centred on an unusual increase in the incidence of Kaposi sarcoma (KS) 
and Pneumocystis pneumonia (PCP) among GBM in New York and California (see figures 





occasionally observed in specific populations (e.g., KS in older men from the Mediterranean 
or PCP in patients with leukaemia after intensive chemotherapy), the occurrence of these 
diseases as indicators for severe immunodeficiency had not been observed previously in 
otherwise young healthy adults (CDC, 1981).  
 
Figure 1: Extract from Morbidity and Mortality Weekly Report, 1981: 305 
 
Because the initially affected population was GBM, the disease, as well as those with 
the disease, were highly stigmatised (Altman, 1981) (see figure 2). The media referred to the 
syndrome as ‘GRID’, or gay-related immune deficiency (New York Times, 1982). In the 
early 1980s, the term ‘gay plague’ was also widely used, as well as similar terms for the 
associated AIDS-defining clinical conditions, such as “gay cancer” (see figure 3) for KS and 






Figure 2: Extract from The New York Times, 1981: “Rare cancer seen in 41 homosexuals” 
 
 
Figure 3: First AIDS poster (Gay Cancer) by Bobbi Campbell in Castro’s Star Pharmacy 
window, photo credit: Rink. 
 
Initial understanding of the syndrome derived from the work of Selma Ditrz, who 
worked as Assistant Director of Public Health in San Francisco. Ditrz traced GBM who had 
been diagnosed with KS and interviewed them regarding their sexual practices and contacts. 





turn, this finding suggested that a transmittable pathogen may be responsible for AIDS, and 
therefore research intensified on exploring this hypothesis (Loewenberg, 2008).  
As is commonplace in times of fear and uncertainty, scapegoats serve to assist people 
in directing their anger or frustration at otherwise incomprehensible circumstances, with 
AIDS being no exception to this. Many of those interviewed by Ditrz reported having sexual 
contact with a Canadian air steward named Gaetan Dugas. This led rise the so-called ‘patient 
zero’ theory (McKay, 2014): the assertion that Dugas was personally responsible for the 
propagation of AIDS across northern America. An epidemiological study (Auerbach et al., 
1984) detailing a cluster of GBM with AIDS being linked, made a typo, which accelerated 
the traction that the ‘patient zero’ theory was gaining. Specifically, the authors had initially 
labelled Dugas in the study as ‘057’ but replaced this with ‘O’ (denoting ‘outside’, referring 
to the fact he did not reside in either New York City or San Francisco). A mistake in the 
study transcript led to ‘0’ being published instead of the intended ‘O’ (see figure 4) (Johnson, 
2019). Nevertheless, the study did propose that Dugas may have infected some of the other 






Figure 4: Extract from Auerback et al (1984) study linking 40 AIDS patients by sexual 
contact. In the above graphic, Dugas is represented by the circle labelled 0, instead of O 
 
Despite condemnation from public health officials, Dugas continued to be sexually 
active after he was diagnosed with KS. Consequently, there were discussions around legally 
forcing him to abstain from sex to cease the spread of AIDS, which as suggested by Jaspal 
and Bayley (2020), set a very dark precedent in the gay community. It is now widely 
accepted that the ‘patient zero’ theory was both inaccurate and damaging to the gay 
community (McKay, 2014) and perpetuated the stigmatization of GBM and those infected. It 
has since been proven that HIV arrived in northern America many years before Dugan was 






Figure 5: Photograph of Gaetan Dugas (1953-1984), photo credit: Fadoo Productions 
 
A more likely propagator of AIDS was the gay bathhouses in which patrons at the 
time were reported to be having condomless anal intercourse (CAI) with multiple partners in 
a single visit. It is undisputed that this led to an exponential increase in cases in the US and 
Europe, where bathhouses and saunas were central features of gay communities (Woods et 
al., 2010). When it became increasingly clear that sexual behaviour was implicated in the 
spread of AIDS, there were calls from those in the gay community who were becoming 
increasingly worried about the impact AIDS, as well as public health officials, for the 
bathhouses to be closed (see figure 6).  
 
Figure 6: The New York Daily News, 10 November 1985, covered the city’s edict against 
establishments permitting “dangerous sex” 
However, the bathhouses were more than just a sexual meeting place; they were 





and therefore many in the community refused to co-operate with the proposed closures, 
despite the documented dangers (see figure 7). Although some were closed briefly, 
ultimately, they could continue to operate if they displayed posters highlighting the dangers 
of having sex without a condom (Raspal & Bayley, 2020). Despite attendance falling during 
this period, bathhouses continued to provide a key role in the transmission of new infections 
(Berube, 2003).  
 
Figure 7: Protest at City Hall, San Francisco, against the closing of gay bathhouses to prevent 
the spread of HIV/AIDS, 15 October 1984, photo credit: Arthur Frisch/The Chronicles 
 
A Global Epidemic  
Although initially AIDS was exclusively observed in GBM, cases in non-GBM 
populations started to appear.  Cases were emerging in those with haemophilia (CDC, 1982), 
people who were injecting drugs, such as heroin, and Haitian immigrants (CDC, 1982). This 
led to researchers briefly referring to AIDS as the ‘4H disease’ (Cohen, 2006). In 1983, 
doctors in Kinshasa, Zaire (now known as the Democratic Republic of the Congo), reported a 
surge of opportunistic infections in the general population. This prompted US-based 





transmitted through heterosexual sex. The World Health Organisation (WHO) held its first 
meeting in November 1983 to assess the global AIDS situation and begin international 
surveillance (WHO, 1984). At this meeting, it became apparent that cases of AIDS were 
increasing rapidly and whilst European countries, such as the UK, had similar 
epidemiological patterns as observed in the US (e.g., mostly affecting GBM), other countries, 
such as those in equatorial Africa and the Caribbean, were showing emerging patterns of 
infection in the general population. This represented a shattering realisation around the world: 
HIV was not isolated to only GBM, or other discrete groups deemed to be at risk instead, it 
presented the beginnings of one of the world’s worst health disasters.  
HIV:  The Causative Agent  
Initially, scientists hypothesised lifestyle and behavioural factors associated with 
homosexuality to be causally related to the development of AIDS. Postulated mechanisms 
included the use of amyl nitrate, which is an inhaled form of nitrates used by GBM during 
sex as a muscle relaxant (Durack, 1981). This served to further perpetuate the emerging 
stigma. However, in 1983 HIV was first isolated from the lymph node of gay man (Barre-
Sinoussi et al., 1983; Gallo et al., 1983) and in 1984, HIV was the confirmed causative agent 
of AIDS (Gallo et al., 1984; Montagnier et al., 1984). 
The Pathogenesis of HIV Infection 
HIV is a retrovirus and belongs to the Retroviridae family and genus Lentivirus 
(Sabin and Lungren, 2013). It causes AIDS by interacting with many different cells in the 
human body and escaping the host immune response against it. HIV is transmitted through 
three main routes: sexual transmission, parenterally, and mother-to-child transmission (Shaw 
and Hunter, 2012). The sequence occurring in infection involves an interaction of HIV not 
only with CD4+ lymphocyte on cells but also with several other cellular receptors. 





intracellular mechanisms determine the relative expression of viral regulatory and accessory 
genes leading to productive or latent infection. This leads to ongoing replication of the HIV 
virus in the body and depletion of host cells.  
Thus, HIV progressively destroys CD4+ lymphocytes. These lymphocytes are crucial 
in co-ordinating the body’s response against foreign cells, infectious organisms, and cancer. 
Therefore, once HIV destroys enough CD4+ lymphocytes, infected individuals become 
susceptible to attack by multiple infectious organisms. The graph below (see Figure 8) shows 
the trajectory of disease progression, in the absence of effective anti-retroviral treatment.  
 
Figure 8: Natural history of HIV infection 
 
Sexual Transmission 
Sexual transmission is by far the most common mode of transmission. The probability 
of an individual becoming infected via sexual contact depends on the likelihood of them 
having CAI with an infected partner; therefore, sexual behaviour patterns and local 
prevalence of HIV are critical in determining risk. The chances of an individual becoming 
infected with HIV during a single sexual contact varies enormously (Mastro & de Vincenzi, 





female to male transmission (de Vincenzi, 1994; Nicolosi et al., 1994). Receptive sexual 
intercourse is riskier than both insertive anal intercourse and vaginal intercourse, which is 
why infection between GBM is relatively more likely (Caceres & van Griensen, 1994). 
Transmission because of oral sex has been reported; however, this mode of sexual 
transmission is thought to be much less risky than vaginal or anal penetrative sex (Mastro & 
de Vincenzi, 1996).  
Another critical determinant of transmission is how infectious the infected partner is. 
Specifically, higher viral loads (i.e., the quantity of HIV viremia in the blood) at the advanced 
stage of the disease increases the probability of transmission; however, it is at the initial stage 
of the infection (e.g., seroconversion) that an individual has the greatest quantity of HIV 
viremia in sexual fluids and are therefore most infectious (Leynaert et al., 1998).  
Determining the impact of an individual’s treatment status (i.e., whether they were 
taking effective antiretroviral therapy at the time of intercourse) on transmission has been 
researched extensively in the last decade. The first randomised control trial (the HPTN 052 
trial; Cohen et al., 2011) into the risk of transmission in this context, determined that in 
heterosexual couples the risk of transmission was reduced by 96% in those who were taking 
treatment, compared to those who were in the delayed arm. Subsequent follow up of those 
enrolled in the HPTN 052 trial, after which all participants had started treatment, showed that 
HIV-negative partners continued to remain seronegative. Despite encouraging data, only 2% 
of the couples were GBM (Cohen et al., 2016) and therefore results could not be generalised 
to this population, given the relative increased risk of receptive anal intercourse.  
This led to the PARTNER study (PARTNER1; Rodger et al., 2016), which aimed to 
evaluate risk of transmission in the context of the HIV-positive partner taking effective 
treatment on a wide range of sexual behaviours and in broader populations. The first phase 





effective treatment (of which 340 were GBM) and reported on 1,238 couple-years of follow-
up. There were zero transmissions reported. Despite this, due to the relatively low number of 
GBM couple-years follow-up accumulated (compared to heterosexual couples), the upper 
95% CI limit for the transmission rate for GBM was significantly higher than for 
heterosexual couples: 0.84 and 0.46 per 100 couple years-years of follow-up, respectively. 
Consequently, the results did not constitute sufficient evidence to conclude that risk among 
GBM couples, where a partner is on effective HIV treatment, is effectively zero (as it could 
in a heterosexual context).  
To resolve this, the PARTNER study devised a second phase (PARTNER2; Rodger et 
al., 2019) in which it only recruited GBM couples. This phase included 777 couples and a 
total of 76,088 episodes of CAI. The results reported that there were 15 new HIV infections 
among those who were seronegative at enrolment; however, of these infections none were 
phylogenetically linked within-couple transmissions and therefore there were zero within-
couple transmissions. These results have determined that it is not possible for an HIV-
positive partner on effective HIV treatment (resulting in undetectable levels of HIV viremia 
in the blood) to sexually transmit HIV. This led to the multi-national campaign, which is 
endorsed by the medical community, ‘U=U’ (undetectable equals untransmittable).  
Prognosis 
Life expectancy is defined as ‘the average number of years an individual of a given 
age is expected to live if current mortality rates continue to apply’ (Porta, 1998). During the 
early years of the epidemic when effective antiretroviral therapy did not exist, the median 
time of survival following a diagnosis of AIDS rarely exceeded 20 months (Eiden and Lifson, 
1992). A large-scale retrospective study (Babiker et al., 2000) has estimated that the median 
time from seroconversion to AIDS and death is approximately 9 and 10 years, respectively, 





was therefore commonly referred to as a ‘death sentence’ in those early years of the 
epidemic.  
Life expectancy for those with an HIV infection remained poor for much of the 1980s 
and 1990s, despite rapid advances in treatment (which are discussed below). In 1997, HIV 
was in the top 10 causes of death worldwide, partly because treatments were initially largely 
ineffective and because they were not readily available in resource-poor countries, where 
HIV prevalence was higher (Nicholl & Gill, 1999). In the US in 1990, HIV/AIDS was the 
leading cause of death among adults aged 25-44 years old and was responsible for 61% of all 
men within that age parameter who died in San Francisco, California (Selik et al., 1995).  
However, there has been a plethora of studies that have since estimated that life 
expectancy of people infected with HIV is significantly improved (Freedberg et al., 2001; 
Walensky et al., 2006; Lima et al., 2007). It is now widely accepted that people infected with 
HIV infection who are diagnosed early (i.e., before significant damage to the immune system 
has been sustained) and access effective antiretroviral therapy, can expect a life expectancy 
comparable to that if they were HIV-negative (Marcus et al., 2020). However, comparable 
life expectancy does not mean one is free from co-morbidity. Those with a diagnosis of HIV 
infection are still more likely to have co-morbidities such as cardiovascular, kidney, liver, and 
bone disease as well as cancer and neurocognitive impairment (Lerner, 2020). 
Treatment  
Initial attempts to find effective therapeutics were characterised by treatment failures 
and disappointments (Sandstrom & Kaplan, 1987). However, in 1985 a diagnostic blood test 
which could identify antibodies specific to HIV was developed (Ward et al., 1986) and large-
scale clinical trials were initiated to evaluate the use of azidothymidine (AZT) (Furman et al., 
1986; St Clair et al., 1987). Despite AZT being associated with an increased survival at 24 





benefits were no longer observed (Fischl et al., 1990). Despite this, and with no other viable 
therapeutics available, AZT was approved for use in patients with advanced HIV infection in 
1987. Among GBM – where the bulk of disease and death was occurring – anger grew at the 
lack of therapeutics and over reliance on AZT (New York Times, 1989), which was 
exacerbated by initial issues with patients in clinical trials being prescribed doses that were 
too high, causing severe toxicity in many (Yarchoan et al., 1986) (see figure 9).  
 
Figure 9: Man protesting holding placard “Man cannot live on AZT alone”, date unknown. 
 
The next and most significant development in HIV treatment, came with the 
introduction of new drug classes that had a direct effect on the pathogenesis of HIV. This led 
to the concept of ‘triple therapy’ in 1995-1996, where three drugs from across the classes 
were used simultaneously to halt viral replication and therefore preserve the immune system. 
Within a few short years after the introduction of triple therapy, a dramatic decrease in 
morbidity and mortality associated with the inclusion of protease inhibitors to drug regimens 





was termed ‘The Lazarus Effect’ (Mubanda & Richey, 2012), referring to the Raising of 
Lazarus miracle in the Gospel of John (John 11:1-44) in the New Testament, in which Jesus 
raises Lazarus of Bethany from the dead four days after his entombment.  
 
Figure 10: Mortality and frequency of use of combination antiretroviral therapy including a 
protease inhibitor among HIV-infected patients with fewer than 100 CD4+ cells per cubic 
millimetre, according to the Calendar Quarter, from 1994 through June 1997. From Palella et 
al., 1998. 
 
Despite this, these drastic improvements were not without cost. These newly 
developed drug regimens were associated with significant short, mid, and long-term toxicities 
and other adverse effects. In turn, quality of life of patients on these drug regimens was 
significantly impaired, as the treatments required multiple daily dosing and a large quantity of 
pills for some time. In the last decade, however, there have been substantial improvements to 
the tolerability and effectiveness of HIV treatment, with the development of new classes of 
drugs. Single tablet, fixed-dose, once-daily combinations (Arribas et al. 2008; Sax et al., 
2009) have become available, which have in turn improved adherence and thus treatment 
success. To date, there are now over 30 different HIV drugs and formulations across 6 
different drug classes (i- Base,2019), with many more advances currently in development, 







Global Epidemiology.  Globally, an estimated 38.0 million people are living with 
HIV infection in 2019 (WHO, 2019). In 2019, the WHO reported that 1.7 million people 
were newly infected with HIV and there were 700,000 HIV-related deaths. Although the 
number of people living with HIV globally is increasing, there are fewer new infections 
annually (23% reduction since 2010) and significantly fewer people dying because of HIV 
(39% reduction since 2010).  
 
 
Figure 11: Adult HIV Prevalence, 2019 
 
The UK Epidemic.  Forty years have passed since the first AIDS case was reported 
in the UK, in 1981. During that time 164,621 people have been diagnosed (PHE, 2020) and 
there have been 25,352 deaths recorded. As of 2019, there is an estimated 105,200 people 
living with HIV in the UK, with 98,552 accessing HIV care. The proportion of people 
accessing HIV care in 2019 who acquired HIV through heterosexual sex (45,445; 46.5%) is 
very similar to the proportion of people who acquired HIV through sex between men (45,771; 
46.8%). HIV prevalence is significantly higher in urban settings, especially those with large 







Figure 12: Diagnosed HIV prevalence (per 1,000 population aged 15 to 59 years): Local 
authorities in England, 2018 
 
 
In 2019, there were 4,139 people newly diagnosed with HIV infection in the UK (see 
figure 13). New diagnoses have continued to decline in the last decade with a substantial 
decrease over the past two years; decreasing by 10% between 2018 and 2019, and by 34% 
since an observed peak number of infections in 2014 (6,312 newly diagnosed).  
 
 
Figure 13: Number of new HIV diagnoses, AIDS at HIV diagnosis* and deaths in people 






The UK epidemic is like that of other European countries and the US, in that GBM 
are disproportionately affected. To date, there have been 74,485 diagnoses of HIV in GBM 
throughout the UK, and 13,498 deaths (PHE, 2020). In 2018, 1,908 GBM were newly 
diagnosed with HIV, making up 43% of all new HIV diagnoses (see figure 14). This number 
has significantly reduced by 25% since a peak in 2015 and reflects the success of increased 
HIV testing and increase uptake in HIV treatment. Furthermore, the introduction of PrEP, 
which will be discussed later in this chapter, is also likely contributed.  
 
Figure 14: Number of new HIV diagnoses by exposure group*: UK, 2009 to 2018 
 
Despite high prevalence and disease burden in GBM in the UK, HIV diagnoses have 
continued to decline since 2015 and are now at a 20-year low (PHE, 2020). In London, new 
diagnoses have fallen by 52% (from 1,415 in 2015 to 736 in 2018). This is particularly 
significant given that diagnoses had previously been increasing year on year from 2,820 in 
2008 to 3,390 in 2015 (PHE, 2016, 2017). The reported drop has been linked to five sexual 
health clinics in London, including 56 Dean Street in Soho, the largest sexual health and HIV 
clinic in Europe, where diagnoses fell by 71% (PHE, 2019). In a comment to The Lancet, 
Consultant Physicians from the clinic attributed this success to the use of PrEP, as well as 
increased testing and earlier provision of anti-retroviral therapy for those who were diagnosed 






Although it is evident that HIV has been transformed from a terminal illness to a 
chronic infection, with increasingly favourable outcomes, aided by effective treatments, HIV 
prevention remains imperative in the global fight against this disease. The next part of this 
chapter will discuss the history and various approaches to HIV prevention, as applied to 
GBM.  
Part II:  HIV Prevention 
During the early years of the AIDS epidemic, it was those who were diagnosed with 
the disease, along with carers in their communities, who organised the initial preventative 
responses, through the production of leaflets and posters (see Figure 15) to disseminate 
knowledge, albeit some of it speculative (King, 1993). Subsequently, groups of GBM set up 
community groups which continued efforts to prevent infections (Merson et al., 2008). 
However, in the years that followed, aided by political will, global awareness, and a 
substantial increase in resource, HIV prevention became central to the response in the 






Figure 15: Safer Sex, Don’t Dream It... Do It! Terrence Higgins Trust. Leaflet, 1987 
For HIV prevention to have positive outcomes, it needs to be informed by knowledge 
of the virus, as well as broader determinants of the disease; specifically, the socioeconomic, 
cultural, and environmental factors that influence the transmission of HIV, at an individual 
and population level. Consequently, HIV prevention is a combination of biomedical, 
psychological, and structural interventions. For a strategy to be effective, it must be tailored 
to the context and based on scientific evidence (Piot et al., 2008). Those countries who have 
seen significant reductions in reducing HIV infection have used a combination of these 
approaches in a tailored and evidence-informed way (Green et al., 2006; Okie, 2006).  
 
Condoms 
Safer Sex.  Although the term ‘safe sex’ has existed in the English language since the 
1930s, the use of the term as applied to prevention of infection was first used in a 1984 
publication discussing the psychological effect AIDS may have on GBM (Blair, 2017). 





(and in a heterosexual context, pregnancy), it has become synonymous with the male condom 
in the context of HIV prevention.  
Condoms have been the mainstay of HIV prevention from the beginning of the 
epidemic. The evidence base for the effectiveness of the male condom as a physical barrier to 
HIV has significantly grown in the years that followed. As such, condom education and 
distribution constitute the single most significant component of HIV prevention in all 
countries and for all at-risk populations, such as GBM (WHO, 2015). A report compiled by 
the US National Institutes of Health (NIH) published in 2000, estimated that the male 
condom reduces HIV transmission by approximately 85% relative to risk when condomless, 
putting the seroconversion rate at 0.9 per 100 person-years with condom, down from 6.7 per 
100 person-years without (NIH, 2000). The WHO has also reviewed the available evidence 
and estimated the male condom to reduce HIV transmission by 80-95% (WHO, 2008). 
Despite an impressive reduction in HIV transmission yielded by condoms, the effect size is 
significantly less in the context of receptive anal sex (Smith et al., 2015).  
However, although the known failure rate of condoms, GBM were encouraged to 
believe that using a condom was ‘safe sex’ and they could continue engaging in anal sex with 
multiple or anonymous partners. Although condoms were (and are) marketed as prevention, 
in fact they are part of a ‘risk reduction’ strategy. Whilst condoms have been highly effective 
at curtailing new infections at a population level, it is likely that they were adopted as a 
compromise (O’Leary, 2014). Specifically, it is argued that the principal goal of HIV 
prevention for some gay activists was the defence of the gay sexual revolution, and since gay 
liberation was founded on: “...sexual brotherhood of promiscuity... any abandonment of that 
promiscuity would amount to a communal betrayal of gargantuan proportions” (Rotello, 
1997, p109). Furthermore, it is documented that in the early days of the epidemic those 





“to encourage condom use rather than attempt to persuade them to abandon anal 
intercourse... AIDS educators have a responsibility to aim only for the minimum 
necessary changes in individuals’ lives which are needed to reduce the risk of getting 
AIDS” (Rotello, 1997, p109).  
It was assumed by those external to the gay community that the fear of contracting an 
incurable, debilitating disease would be enough to motivate GBM to refrain from ‘unsafe 
sex’. Despite the ‘fear factor’ having a huge impact (which will be discussed in detail later in 
this chapter), some GBM sought to romanticise HIV infection and openly reject the notion of 
‘safe sex’ and by extension, condoms. HIV positive status was often portrayed in gay 
publications as more fun. An editorial in Steam, a magazine aimed at GBM, quotes a man 
who has been positive since the early years of the epidemic: “I’m so sick and tired of these 
Negatives whining about how difficult it is to stay safe. Why don’t they just get over it and 
get Positive” (Rotello, 1997).  Safer sex was also criticised as being some sort of antidote to 
sexual pleasure and curtailed gay and bisexual self-expression. Scott O’Hara, the HIV-
positive Editor of Steam (who subsequently died of AIDS in 1998) wrote:  
“One of my primary goals is the Maximisation of Pleasure, and just as I believe that 
Gay Men Have More Fun, so too do I believe that Positives have learned to have 
much more fun than Negatives. I’m delighted to be Positive... The Negative world is 
defined by fear, ours by Pleasure” (Rotello, 1997).  
 
Reduced Adherence to Condoms.  Despite their wide-spread adoption, condom use 
among GBM is now in decline and CAI is increasing, both in total instances and the number 
of different CAI partners over time (Frost et al., 2008; Galindo et al., 2012). According to the 
research, older GBM are less adherent to condoms and have expressed fatigue with regards to 
HIV prevention that focuses primarily or exclusively on condoms (Balan et al., 2013).  
There are many plausible explanations for the recent decline in condom use. There 
has been a growth in the gay sub-culture of ‘barebacking’ (which describes intentional CAI). 
Epidemiological and behavioural studies have documented a growing prevalence in the 
practice, identifying GBM who, despite awareness of the risks of CAI, choose to have 





Bauermeister 2004), though motivations vary between age and ethnicity (Vosvick et al., 
2016). As barebacking has become a normalised practice, promoted through gay pornography 
and the increased eroticism of CAI, GBM who normally use condoms for anal sex may feel 
pressure to engage in CAI (Halkitis et al., 2008; Adam et al., 2005).  
The belief that condoms may reduce sexual and emotional intimacy is legitimate and 
therefore presents a challenge for HIV prevention efforts. Condoms are frequently cited by 
GBM as having a negative impact on their psychosexual functioning (Klassen et al., 2019).  
Condoms are often perceived as a barrier to sexual satisfaction and arousal, whereas CAI is 
privileged in facilitating sensation, physical pleasure, and deeper levels of eroticism (Golub et 
al., 2010; Eisenberg et al., 2011). This can be attributed to the sensuality associated with 
‘skin-to-skin’ contact as well as the psychological significance that semen can have for some 
GBM and the sexual arousal that can ensue from exchanging semen (Jaspal, 2019). Vincke et 
al. (2001) describe semen exchange as ‘a means of showing devotion, belonging, and 
oneness’ (p.58). A desire for trust, intimacy, commitment, and love may provide further 
motivation, wherein CAI serves as a manifestation of these emotions and a representation of 
the depth of a given relationship (Eisenberg et al., 2011; Carballo-Dieguez et al., 2011).  
Seroadaptive Behaviours 
In recent years, GBM have developed various seroadaptive behavioural strategies to 
reduce their risk of HIV infection which whilst mitigating their sexual risk, may be 
contributing to a reduction in condom use (Grace et al., 2014). These strategies, which are 
possible due to the advances in biomedical approaches, include:  
• Serosorting:  Seeking out sexual partners of the same HIV status and/or engaging in 





• Viral load sorting:  Actively seeking out partners with undetectable HIV viral load 
status or use this information to determine the sexual behaviours between 
serodiscordant partners (Prestage et al., 2012).	
• Negotiated safety: When there is a monogamy agreement between primary partners or 
the exclusion of higher risk sexual behaviours (e.g., anal sex) outside of the primary 
relationship (Vosvick et al., 2016). 	
• Strategic positioning:  When an individual takes the decision to be the insertive 
partner during anal sex as an HIV negative partner in CAI (Grace et al., 2014). 	
Although these seroadaptive behaviours are common among GBM, the efficacy of each is 
not well-studied; furthermore, for these strategies to be effective they rely on explicit 
communication, disclosure, and trust (Vosvick et al., 2016), and this can generate some 
anxiety and uncertainty.  It has been established that many GBM tend to assume or infer the 
HIV status of their partners, without having explicit communication (Adam et al., 2005), 
which can generate false assumptions and lead to HIV transmission and/or discrimination. 
Furthermore, negotiated safety agreements between partners are not always adhered to by one 
or more of the partners, as a significant proportion of HIV transmissions (as much as 68%) 
occur within the context of primary relationships (Goldenberg et al., 2015). 	
HIV Testing  
Alongside condoms, HIV testing has been a key prevention strategy since the test’s 
inception in March 1985. It plays a critical role for two reasons: Firstly, it enables individuals 
to know whether they are HIV positive or not and to modify their sexual behaviour 
accordingly.  Secondly, it provides an opportunity to the individual to have dialogue with a 
health care professional, which has the potential to increase knowledge as to how to manage 





range of psychological and social factors that influence their experience of HIV testing and 
subsequent engagement. Evangeli, Pady, and Wroe (2016) conducted a quantitative 
systematic review of 62 studies. The review highlighted several psychological barriers to 
regular HIV testing:  
• Fear of death and disease because of HIV infection can lead to some individuals 
preferring not to know their HIV status (Lorenc et al., 2011).	
• Some GBM subjectively appraise their HIV risk as low due to a lack of knowledge 
regarding HIV risk factors and/or they do not self-identify as GBM (Bond et al., 
2015). 	
• There is a correlation between endorsement of HIV-related stigma and reduced 
frequency of HIV testing among GBM (Li et al., 2012). Furthermore, GBM may 
avoid testing for HIV to avoid self-association with HIV stigma (Young et al., 2007). 	
• It is recognised that among ethnic minority GBM, prejudice, especially homophobia 
and racism, is associated with declining HIV tests (Bond et al., 2015). 	
Post-Exposure Prophylaxis 
Post-exposure prophylaxis (PEP) is a biomedical approach to HIV prevention which 
involves prescribing a course of anti-retroviral therapy to patients after a high-risk HIV 
exposure. It is thought to be effective at preventing an exposed individual from 
seroconverting and therefore remaining HIV negative (Cresswell et al., 2006).  The 
combination must be initiated within 72 hours post possible exposure and taken for a duration 
of 28 days.  
Despite the concept of PEP being around for many years, it has remained a controversial 





sexual risk-taking and that it undermines public health (Jaspal & Nerlich, 2016). There have 
been no randomised control trials involving human participants to determine how effective 
PEP is at stopping seroconversion, following a sexual exposure to HIV infection. However, 
there are retrospective studies that have demonstrated effectiveness following occupational 
exposure. Specifically, an early study (Cardo et al., 1997) followed up health care workers 
who used zidovudine following a possible occupational exposure and reported that PEP 
reduced seroconversion by 81% (with a confidence interval of 48-94%). Additionally, there 
have been various animal studies that have supported the notion that PEP is efficacious as an 
HIV prevention strategy (Tsai et al., 1995).  In 2006 the UK’s medical organisations that are 
responsible for establishing treatment guidelines relating to sexual health and HIV, the 
British HIV Association (BHIVA) and the British Association of Sexual Health and HIV 
(BASHH) published national guidance on the application of PEP in the context of sexual 
exposure. These guidelines have been updated multiple times since their inception, 
considering increased prevalence, but the current circumstances in which PEP is 
recommended, considered, or not recommended can be seen in Table 1.  	
Furthermore, although the UK’s national guidance on the use of PEP clearly states that 
the treatment should not be used to alleviate anxiety regarding HIV, it has been noted that a 





























Situations in which post-exposure prophylaxis (PEP) is recommended, considered, or not 




Source HIV status 
 HIV positive Unknown HIV status 









































Recommended Not recommended Consider Not 
recommended 
Cunnilingus Not recommended Not recommended Not recommended Not 
recommended 
 
PEP has remained a controversial preventative strategy. Jaspal and Nelrich (2016) 
examined representations of PEP in the British print media, a key source of information 





representations of PEP. Firstly, in some articles PEP was represented as a straight- forward 
‘morning after pill’ which can prevent HIV. Secondly, it was also represented as a dangerous 
public health initiative that had the potential to have counterproductive outcomes by fuelling 
high-risk behaviour. Finally, the third representation positioned health care workers as more 
worthy recipients of PEP and GBM as being less deserving of this preventative tool. Jaspal 
and Nelrich (2016) went on to argue that these representations in the British media, which 
were found to be usually absent of technical information about PEP and its mechanisms of 
action, may lead to a polarisation of perceptions of PEP, while stigmatising those who use 
PEP, and GBM in general.  
Summary  
HIV prevention, especially in the context of GBM, has evolved throughout the 
epidemic and involves a variety of innovative strategies and interventions, across a 
combination approach of biomedical, psychological, and social. Despite condoms initially 
being successful in curtailing new infections, psychological factors relating to desire for 
intimacy and optimal psychosexual functioning have resulted in a lot of GBM finding using 
them consistently a challenge. In the wake of an increase in condomless sex and rising 
infections, HIV prevention needed a new tool: PrEP.  The next part of this chapter will 
discuss the new era of HIV prevention with the inception of PrEP for GBM.  
 
Part III:  Pre-Exposure Prophylaxis  
PrEP is an innovative way for those who are HIV negative, but who are at high risk of 
acquiring it, to prevent HIV infection by taking a daily anti-retroviral pill. PrEP works by 
interrupting the life cycle of HIV to prevent viral infiltration of potential host cells. PrEP has 





including transmission from mother-to-child, post- occupational exposure among health care 
workers, and GBM.  
In the early stages of research, Van Rompay et al. (2001) and Garcia-Lerma et al. 
(2008) found that use of antiretroviral drugs tenofovir disoproxil fumarate (TDF) and 
emtricitabine (FTC) pre-exposure “provided significant protection to macaque monkeys 
exposed repeatedly to an HIV-like virus” (Brooks et al., 2012, p. 87). In turn, these findings 
led to clinical trials of PrEP amongst high-risk populations, specifically GBM (which are 
each discussed below). In practice, oral PrEP is recommended as a two-drug regimen of TDF 
and FTC, co-formulated as a single pill (branded as Truvada®; Gilead, 2004), and taken in 
one of two ways: daily dosing or event-based dosing (BHIVA, 2018; WHO, 2017). Daily 
dosing involves taking one Truvada tablet daily and event-based dosing involves taking two 
Truvada tablets 2-24 hours before anal sex, then a subsequent Truvada tablet 24 hours and 
then 48 hours later (Molina et al., 2015); see figure 17.  
 






It has been suggested that PrEP has infrequent but potentially harmful side effects 
such as nephrotoxicity and reduction in bone mineral density (BHIVA, 2018; Tan et al., 
2017). It is also recognised that drug resistance may develop in those who initiate PrEP with 
undiagnosed HIV infection (Parikh and Mellors, 2016). Consequently, it is imperative that 
individuals engage with baseline and ongoing monitoring, which involves attending their 
sexual health clinic at least every 12 weeks for HIV and renal blood tests, as well as 
screening for other STIs (Tumarkin et al., 2019).  
In the UK, the British HIV Association (BHIVA) and the British Association for 
Sexual Health and HIV (BASHH) published clinical guidance on the use of PrEP. PrEP is 
only recommended for use in GBM who are at an increased risk of HIV infection, through 
CAI (as well as other factors that would deem an individual to be ‘high-risk’).   The specific 
guidelines are detailed in Table 2. However, in practice, many GBM who do not meet the risk 
threshold have opted to take PrEP. To date, it is unknown what has motivated this decision, 
although it is thought that the associated psychological benefits of significantly reducing their 


















Summary table of recommendations for PrEP included in the BHIVA/BASHH ‘Guidelines on 
the use of HIV pre-exposure prophylaxis (PrEP)’ (BHIVA, 2018). 
 
Recommend PrEP 
(i) HIV-negative GBM and trans women who report condomless anal sex in the previous 6 months and on-going 
condomless anal sex. 
(ii) HIV-negative individuals having condomless sex with partners who are HIV positive, unless the partner has 
been on ART for at least 6 months and their plasma viral load is <200 copies/m<.  
Consider PrEP on a case-by-case basis 
PrEP may be offered on a case-by-case basis to HIV-negative individuals considered at increased risk of HIV acquisition 
through a combination of factors that may include the following: 
Population-level indicators 
• Heterosexual black African men and women 
• Recent migrants to the UK 
• Transgender women 
• People who inject drugs 
• People who report sex work or transactional sex 
Clinical indicators 
• Rectal bacterial STI in the previous year 
• Bacterial STI or HCV in the previous year 
• Post-exposure prophylaxis following sexual 
exposure (PEPSE) in the previous year; 
particularly where repeated courses have been used 
 
Sexual behaviours/sexual-network indicators 
• High-risk sexual behaviour: reporting condomless 
sex with partners of unknown HIV status, and 
particularly where this is condomless anal sex or 
with multiple partners 
• Condomless sex with partners from a population 
group or country with high HIV prevalence (see 
UNAID definitions [1]) 
• Condomless sex with sexual partners who may fit 
the criteria of ‘high risk of HIV’ detailed above 
• Engages in chemsex or group sex 
• Reports anticipated future high-risk sexual 
behaviour 
• Condomless vaginal sex should only be considered 
high risk where other contextual factors or 
vulnerabilities are present 
 
Drug use 
• Sharing injecting equipment  
• Injecting in an unsafe setting 
• No access to needle and syringe programmes or 
opioid substitution therapy 
 
Sexual health autonomy 
Other factors that may affect sexual health autonomy 
• Inability to negotiate and/or use condoms (or 
employ other HIV prevention methods) with 
sexual partners 
• Coercive and/or violent power dynamics in 
relationships (e.g., intimate partner/domestic 
violence) 
• Precarious housing or homelessness, and/or other 
factors that may affect material circumstances 





Access to PrEP in the UK 
The WHO updated their guidelines to recommend HIV PrEP as an additional HIV 
prevention strategy (WHO, 2015). Consequently, several countries have included PrEP in 
their national guidelines. In the USA, which was the first country to introduce PrEP in July 
2015, there were an estimated 100,000 people taking PrEP in 2017 (Mera et al., 2017). 





rapidly increasing (Traeger et al., 2019). Belgium has recently made the decision to make 
PrEP available to high-risk populations via a reimbursement scheme (PrEPWatch, 2019). In 
the UK, Scotland was the first to make PrEP available through the NHS, where 2,560 people 
accessing PrEP (97% were GBM) up to 2019 (NHS Scotland, 2020). In England, the 
provision of PrEP has been controversial. Initially, NHS England refused to fund it but later 
lost a high-profile High Court legal battle (National AIDS Trust v. NHS England, 2017).  
In response to the High Court ruling, NHS England implemented PrEP via another 
clinical trial, namely the IMPACT trial. In October 2017, the IMPACT trial launched with 
the aim of recruiting a maximum of 13,000 high risk people from over 200 sexual clinics. 
Unfortunately, the demand for the trial far outweighed supply and the trial quickly become 
oversubscribed, with reports of some GBM travelling elsewhere in the country to access a 
space on trial (NHS England, 2019). In February 2019, NHS England announced that it was 
doubling the number of spaces on the trial to 26,000. Despite this, demand continued to 
outweigh supply which has led to a large cohort of GBM sourcing PrEP are independently.  
In the UK it is legal to buy up to a 3-month personal supply of PrEP without the need 
for a prescription (IwantPrEPnow, 2019). This has led to a large cohort of GBM accessing 
PrEP through online pharmacies via a community-led website (www.iwantprepnow.co.uk). 
Subsequently, sexual health clinics started offering PrEP monitoring on the NHS (NHS 
England, 2017) to mitigate the risk to those taking the drug without appropriate monitoring. 
Furthermore, some NHS clinics offered private prescriptions for generic PrEP to try and 
increase access to PrEP in a safer way. For example, 56 Dean Street in Soho, developed 
‘PrEP Shop’ and by August 2019 was providing generic PrEP to 8,459 GBM (McOwan, 
2020). Whilst there are undoubted benefits to this with regards to increasing access to PrEP 





does mean that GBM who are not high risk (i.e., would not be eligible for PrEP on the NHS) 
are accessing PrEP.  
In August 2019, NHS England gave clinics the go ahead to offer PrEP on the NHS. At 
56 Dean Street in Soho, they had started 12,500 GBM on NHS PrEP by the end of November 
2019 (McOwan, 2020), signalling how popular PrEP is among GBM. As this is a very new 
development, the NHS has yet to collate and report official statistics as to how many GBM 
are accessing PrEP in the UK.  
 
GBM & PrEP:  The Clinical Trials 
The iPrEx Study.  The first large scale clinical trial of PrEP was called the iPrEx 
study (Grant et al., 2010), which was a Phase 3, randomised, double blind, placebo- 
controlled, multi-centre trial. The trial assigned 2,499 GBM and 339 trans-female adults to 
either take a combination of TDF-FTC (n=1251) or placebo (n=1248). Primary outcome was 
HIV infection with a total of 3324 person-years of follow-up. Over the duration of the study, 
100 participants seroconverted to be become HIV positive: 36 in the TDF-FTC arm and 64 in 
the placebo arm, representing a 44% (95% CI 15-63) reduction in HIV incidence using a 
modified intention-to-treat (ITT) analysis, excluding those confirmed HIV positive at 
randomisation. Grant et al. (2010) also reported that efficacy was higher in the per-protocol 
analysis; at visits where adherence was >50% by self-report and pill count/dispensing, 
efficacy was 50% (95% CI 18-70).  
The PROUD Study.  The PROUD study (McCormack et al., 2016) was a Phase 3, 
randomised, open-label, multi-centre trial conducted at 13 sexual health clinics across 
England. The study recruited a total of 544 GBM who were randomly assigned to either the 
immediate arm (where they received daily FTC-TDF immediately; n=275) or the delayed arm 
(where they were given no drug for the first 12 months of enrolment; n=269). The primary 





infection was a secondary outcome. The interim findings from the study were so compelling 
that the trial steering committee recommended that all delayed arm participants should be 
offered the study drug, as it would be unethical to continue depriving those enrolled in this 
arm. A total of 23 participants became infected with HIV over the course of the study: three 
in the immediate arm and 20 in the deferred arm (where they received no study drug), 
representing a rate difference in HIV infection of 7.8 per 100 person-years (90% CI 4.3-11.3). 
The relative risk reduction was 86% (90% CI 9-23) and the number needed to treat over 1 
year to prevent one HIV infection was 13 (90% CI 9-23). Significantly, of the three 
participants who seroconverted in the immediate arm, one was thought to have acquired the 
infection prior to enrolment and the other two were not taking the medication. Protection 
against HIV in the context of perfect adherence was therefore estimated to be close to 100%. 
The IPERGAY Study.  The IPERGAY study (Molina et al., 2015) was a Phase 3 
double-blind, randomised, multi-centre trial conducted in France and Canada. It enrolled 414 
GBM and randomly assigned them to either receiving an on-demand regimen (n=206) or 
placebo (n=206). The on-demand regimen involved taking a double dose of TDF-FTC 2-24 
hours before sex, and a daily dose during the periods of sexual risk and for 48 hours (two 
doses) after the last sexual risk. Participants were followed up every 8 weeks for HIV testing 
and risk- reduction advice, and every 6 months for testing for bacterial STIs for a total of 431 
person- years follow-up. The primary outcome was HIV infection. As in the PROUD study, 
at the interim review, the placebo group was discontinued, and all study participants were 
offered study drug. Over the duration of the study, there were 16 new HIV infections: two in 
the TFD- FTC arm and 14 in the placebo arm, representing a relative risk reduction of 86% 
(95% CI 40- 98%) in the ITT analysis.  
There have other phase 2 studies (Grohskopf et al., 2013), randomised pilot studies 





2017) and observational studies (Hoornenborg and de Bree, 2017) that have all reported 
similar efficacy in protection against HIV in GBM who take the drug as prescribed. Despite 
this, the adoption of PrEP has been met with some resistance.  
 
 
The Impact of PrEP on GBM 
Risk Compensation.  Despite evidence clearly suggesting that GBM who adhere to 
PrEP significantly reduce their risk of HIV infection, along with endorsement from the WHO 
(WHO, 2015), the intervention has not been met without criticism or scepticism. Specifically, 
in response to a Lancet HIV editorial: “PrEP: why are we waiting?” it was suggested that 
clinicians and policy-makers lacked information regarding the “normative aspects” of PrEP 
use (Jansen et al., 2017). They went on to suggest that the reason for PrEP not being widely 
implemented was lack of information regarding “people’s own responsibility to use a 
condom, the relevance of being free of fear of HIV infection when having sex, and the 
relative importance of preventing HIV infection versus a possible rise in other sexually 
transmitted infections because of reduced condom use” (Jansen et al., 2017). This quote 
makes explicit the points that have held PrEP implementation back: moral judgement of sex 
and HIV prevention as a means of controlling sex (Golub et al., 2019).  
In the last decade, other preventative strategies and interventions have all been met 
with similar scepticism due to their perceived risk of being responsible for behaviour change 
that could lead to an increased risk and thus counteract the benefits yielded by the prevention 
strategy. For example, the oral contraceptive pill in the 1950s (Watkins, 2001), the use of 
penicillin to cure syphilis in the 1960s (Farley et al., 2003), needle exchange programmes for 
people who inject drugs in the 1980s and 1990s (Wood et al., 2008), the emergency 
contraceptive pill (Raymond and Weaver, 2008), and more recently the UK’s targeted HPV 





impressive evidence-base for preventing HIV infection among GBM, it has, in common with 
other the other strategies mention above, aroused concern regarding ‘risk compensation’ 
(Auerback and Hoppe, 2015; Koester et al., 2017; Millam et al., 2019).  
Risk homeostasis is defined as ‘a system in which individuals accept a certain level of 
subjectively estimated [or perceived] risk to their health in exchange for benefits they expect 
to receive from [an]... activity’ (Wilde, 1998). In accepting a particular level of risk of an 
adverse event, individuals maintain an approximate risk set point. However, the introduction 
of an intervention that reduces the perceived risk of the behaviour or activity (i.e., PrEP) may 
cause a person to increase other risk behaviours – this is termed ‘risk compensation’ (Wilde, 
1998).  
Risk behaviour has been measured across various outcomes, such as STI diagnoses, 
frequency of CAI and total number of sexual partners. The most clinically relevant outcome 
is STI diagnoses, as these have been deemed a reliable proxy to sexual behaviour. 
Furthermore, self-report of sexual behaviour is subject to reporting bias and is therefore less 
reliable. In the placebo-controlled trials, which by their design controls for behaviour, it is not 
possible to ascertain the impact of PrEP on behaviour, as the participants were unaware if 
they were talking the active drug or not. However, it is possible to evaluate the impact of 
risk-reduction interventions provided to the participants, and there were demonstratable 
benefits in iPrEx (Grant et al., 2010) and the CDC MSM Safety Study (Hosek et al., 2017).  
In the iPrEx study, both arms reported increased condom use over the course of the 
study and reported condom use did not differ between arms (p=0.97) (Grant et al., 2014). The 
observed reduction in risk behaviours may have resulted from most of the participants 
coming from populations with poor access to risk-reduction support. In IPERGAY, there 
were no significant differences between the arms in the proportion of receptive CAI (p=0.40) 





self-reported number of sexual partners in the previous 2 months in the placebo arm, when 
compared to the treatment arm (7.5 vs 8; p=0.001) (Molina et al., 2015; Sagon-Teyssier et al., 
2016). 
In the PROUD study, in which participants knew whether they were taking the study 
drug and that it was at least partially effective, there was no difference between the 
immediate and delayed arms in the total number of sexual partners (p=0.57) in the 3 months 
prior to the 1-year questionnaire, but a greater proportion of the immediate group reported 
receptive anal sex without a condom with 10 or more partners compared to the delayed arm 
(21% vs 12%, p=0.03). There was no difference in the frequency of bacterial STIs during the 
randomised phase (p=0.74). However, it should be noted that the study only recruited very 
high risk MSM and therefore their sexual behaviour was considered high risk prior to 
enrolment, irrespective of which arm they were randomised to, thus at increased risk of STIs.  
Despite these findings from the clinical trials, there have been many other 
observational and epidemiological studies since PrEP has become increasingly popular 
among GBM and its access widened. These studies do suggest that CAI and incidence of 
STIs increase among GBM who use PrEP. Specifically, Rendina et al. (2018) examined 
changes in rectal STI incidence and behavioural HIV risk before, during, and after PrEP in a 
national sample of GBM in the US. Whilst they found that there was no change in the odds of 
rectal STI during PrEP use or after discontinuation compared to before uptake, they did find, 
compared to before PrEP use, a 156% increase in CAI with casual partners and a 410% 
increase in receptive CAI with serodiscordant partners while on PrEP. A study by Morris et 
al. (2018), which included GBM from California in the US, reported that the incidence rate of 
syphilis was over 3 times higher among those highly adherent (>1246 fmol/punch, consistent 
with 7 doses per week) to TDF-FTC at weeks 12 and 48, compared to those not highly 





GBM using PrEP and reported that STI incidence increased after PrEP use compared to 
before (IRR: 1.42; 95%CI 1.29-1.56). 
Psychological Impact. Since PrEP has been introduced, most of the research among 
GBM has focused on acceptability, adherence, and risk compensation; there has been little 
attention devoted to understanding the psychological impact of using PrEP. Given the 
efficacy at reducing HIV transmission, even in the context of CAI, PrEP may confer 
psychological benefits to its users, such as lower sexual anxiety and enhanced sexual 
satisfaction and confidence.  
The fear of acquiring HIV infection among GBM has been well researched and often 
linked to negative affect (e.g., anxiety). It has been noted that some GBM may have anxiety 
enduring for months after CAI (Godin, Naccache & Pelletier, 2000) and that some avoid 
testing for HIV for fear of receiving a positive test result (Lorenc et al., 2011). Despite this, 
given the effectiveness of PrEP in protecting users against HIV infection, it is plausible that 
these fears decrease as a result (Koester et al., 2017). Currently, there have been few studies 
published that have examined affect changes in GBM who use PrEP (Collins et al., 2017; 
Storholm et al., 2017); however, all these studies have observed decreases in anxiety 
associated with sex. GBM enrolled in an open-label extension (OLE), were noted to 
experience a reduction in anxiety relating to sexual behaviour and HIV, from a review of 
therapy progress notes (Hojilla et al., 2016). Similarly, interviews with GBM who were 
enrolled on another OLE trial revealed reduced fears of acquiring HIV and a reduction in 
HIV-related stress while taking PrEP (Collins et al., 2017; Koester et al., 2017). It is reported 
that GBM referred to PrEP as facilitating “an extra layer of protection”, “a safety net”, and 
“peace of mind”, which all convey a sense of more protection and a reduction in fear and 





It is evident that some GBM struggle to navigate between maintaining their HIV-
negative status and experiencing adequate sexual satisfaction (Shernoff, 2006). The 
psychosexual factors associated with non-adherence to condoms have been discussed earlier 
in the chapter. As PrEP is highly effective in preventing HIV infection and condom use 
decreases among GBM who use PrEP, it may result in an increase in sexual satisfaction.  
Furthermore, by definition, PrEP users are engaging pro-actively in reducing their (and their 
partners’) risk of HIV infection thereby taking control of their sexual health, which may lead 
to increase sexual esteem, through a more positive perception of their sexual ability and 
ability to effectively manage the sexual aspects of their selves (Maas and Lefkowitz, 2015). 
As has been discussed, those GBM who use PrEP are recommended to attend regular 
screening appointments at their sexual health clinic and this may lead to increased feelings of 
control over their sexual health and thus raise their sexual esteem (Whitfield et al., 2019).  
Research into the impact of PrEP on sexual esteem is lacking; however, there have 
been relevant themes emerging in the existing body of research. Specifically, one participant 
from an OLE trial stated that “...[I] feel like I’m taking care of myself” and another 
commented that he felt more “comfort and confidence” as a direct result of attending to his 
sexual health (Storholm et al., 2017). Furthermore, other participants have stated that PrEP 
provided a “heightened sense of safety” (Hojilla et al., 2016) and “replaced feelings of 
worry” (Koester et al., 2017). Despite these findings, a quantitative study (Whitfield et al., 
2019) in which 137 GBM were given psychological measures before initiating PrEP and after 
did not confer support. Specifically, following comparison of scores on the various measures 
pre-and-post and after adjusted multilevel models, there was a significant decrease in sexual 
anxiety (p=0.003) but no significant difference in sexual esteem or satisfaction.  
It is evident that PrEP may afford those who take it some psychological benefits, such 





catching HIV infection is a common experience for GBM. The next part of this chapter will 
discuss the history, prevalence, and clinical aspects of ‘HIV anxiety’ in GBM.  
Summary 
It is evident that PrEP may afford those who take it some psychological benefits, such 
as reduced sexual anxiety and increased sexual satisfaction. It is well established that fear of 
catching HIV infection is a common experience for GBM. The next part of this chapter will 
discuss the history, prevalence, and clinical aspects of ‘HIV anxiety’ in GBM.  
 
Part IV:  HIV Anxiety 
GBM and Anxiety Disorders 
GBM account for an estimated 2.6% of the UK male population (Mercer et al., 2016). 
This diverse group experiences significant mental health inequalities. In epidemiological 
studies of the distribution of mental health difficulties across the population, GBM report 
more anxiety disorders than their heterosexual counterparts, including a higher lifetime 
prevalence of obsessive-compulsive disorder and agoraphobia (Stanfort et al., 2001) and 
higher 12-month prevalence of panic disorder (Cochran et al., 2009) and generalised anxiety 
disorder (Cochran et al., 2003). There is emerging evidence from a developmental 
perspective that suggests that early parental disapproval and gender nonconforming 
behaviour may be a factor in explaining increased prevalence of anxiety disorders in this 
group (Landolt et al., 2004; Skidmore et al., 2007). Furthermore, there is an already well-
established and evidenced hypothesis that sexual orientation concealment and public self-
consciousness predict anxiety disorders in GBM (Packankis and Goldfried, 2006; Packankis 
et al., 2008). 
Minority Stress Theory 
Minority Stress Theory (Meyer, 2003) suggests that societal stigma compromises 





these processes are specific to being gay or bisexual, such as internalised homophobia 
(Newcomb and Mustanski, 2010), stigma-based rejection sensitivity (Pachankis et al., 2008), 
and concealment of sexual orientation (Pachnakis, 2007). These cognitive, behavioural, and 
affective processes are associated with an increased risk of developing anxiety disorders and 
health-compromising behaviours, which further serve to perpetuate the risk of developing an 
anxiety disorder, such as alcohol use and sexual compulsivity (Feinstein et al., 2012; 
Newcomb and Mustanski, 2011). Although, other cognitive, behavioural, and affective 
processes are disrupted by GBM’s stigma exposure, these are not specific to their sexual 
identity and serve as universal risk factors for developing anxiety disorders, as well as other 
mental health difficulties (Hatzenbuehler, 2009). Specifically, sexual minorities report more 
hopelessness, rumination, and social isolation compared to their heterosexual counterparts, 
even from an early age, which may account for why there are elevated rates of mental health 
difficulties and associated health-compromising behaviours across development 
(Hatzenbuehler et al., 2008; Saftren and Heimberg, 1999).  
 







Internalised homophobia refers to the direction of societal negative attitudes towards 
the self (Meyer, 1995). Prior to the individual becoming aware of being gay or bisexual they 
internalise societal homophobic attitudes. When adolescents or young adults recognise their 
same-sex attraction, they will begin to question their presumed heterosexuality and may 
apply a minority label to themselves (e.g., gay). Concurrently, along with self-labelling it is 
suggested that they will also begin to apply negative attitudes to themselves and the 
psychologically damaging effects of societal prejudice take hold (Meyer, 1995). Thoits 
(1985, p222) describes the process and explains: “role-taking abilities enable individuals to 
view themselves from the imagined perspective of others”.  Link (1987, p97) describes a 
similar process observed in those diagnosed with serious mental health conditions and notes 
that those negative societal attitudes now apply to the self: “... [What] once seemed to be an 
innocuous array of beliefs...now become applicable to me personally and [are] no longer 
innocuous.” It is therefore suggested that along with the emergence of a recognition on one’s 
same sex attraction, a deviant identity (Goffman, 1963) begins to emerge that in turn 
compromises the psychological health of the GBM (Hetrick and Martin 1984; Stein and 
Cohen, 1984). Whilst it is recognised that internalised homophobia is likely to be most 
pronounced at the initial stages of recognising one’s sexual identity, or early in the coming-
out process, it is understood that it is unlikely to completely abate, even in the context of self-
acceptance (Cass 1984; Troiden, 1989). As a result of the impact of early socialisation 
experiences and continued exposure to homophobic attitudes and beliefs, internalised 
homophobia remains an important factor in GBM’s psychological adjustment throughout 





As has been discussed, GBM have been associated with AIDS and HIV since the 
advent of the epidemic. It is evident that some GBM perceive the likelihood of them 
acquiring HIV as ‘inevitable’, through witnessing the epidemic unfold in their communities, 
as well as internalised homophobia (Jaspal, 2020).  
HIV Anxiety in GBM 
It is understandable that for the majority of GBM, the prospect of acquiring HIV infection 
would be extremely aversive, leading to proportionate behaviour change to maintain their 
HIV negative status (e.g., not engaging in CAI). Despite this, for a significant minority the 
pursuit to remain HIV negative prevails to such a level as to lead to disproportionate 
avoidance and reassurance seeking that would be deemed unnecessary by those around them 
(including HIV clinicians). Examples of this might include abstaining from all sexual contact, 
repeatedly taking HIV tests despite no objective risks and multiple previous negative results, 
inappropriate use of PEP and PrEP, extreme anxiety and checking after any form sexual 
contact, and body and symptom checking. Despite adopting these behaviours, some GBM 
may still erroneously believe themselves to be HIV positive. It is reported that in rare and 
extreme cases, this psychological distress can lead to deliberate self-harm and suicidal 
behaviours (Vuorio et al., 1990).  
Since the early years of HIV and AIDS, fear has been reported among GBM, as well 
as other populations (Scragg, 1995). A critical review by Scragg (1995) found that the 
phenomenon was referred to using different terminology, diagnoses, and labels: ‘pseudo-
AIDS’ (Miller et al., 1985); AIDS panic (Windgasson and Soni, 1987); and AIDS phobia 
(Jacob et al., 1989). Scragg, who is a UK-based clinical psychologist, referred to it as ‘HIV 
illness phobia’. To date, there is no universally agreed terminology to describe the 
phenomenon; however, in clinical practice it is usually referred to as ‘HIV anxiety’ 





HIV positive and not due to delusional or psychotic beliefs, or ‘AIDS variant Munchausen’s 
syndrome’ (Churchill et al., 1994).  
Historically, along with the labels above, GBM presenting with these difficulties 
would often be diagnosed with hypochondriasis (Margettes, 2012). Contemporarily, there are 
various diagnostic labels that may, at least in part, describe HIV anxiety but it is Illness 
Anxiety Disorder (APA, 2013) that most adequately captures the experience and difficulties 
and it therefore this diagnosis that is most associated with HIV anxiety (see Table 3 for 




Table 3  
Illness Anxiety Disorder classification and diagnostic criteria as per Diagnostic Statistical 







As I have previously argued in this part of the chapter, it is conceivable that anxiety 
disorders in GBM may be a result of minority stress and internalised homophobia. As 
cognitive-behaviour theory is proficient in providing explanation for cognitive, behavioural, 
and affective aspects of anxiety disorders, a variety of CBT-specific models applicable to 
HIV anxiety will now be discussed.  
Cognitive-Behaviour Framework 
Theoretical models and treatments based on cognitive behavioural therapy (CBT) 
have a critical role in the understanding, formulation, and intervention of anxiety disorders 





al., 2007; obsessive compulsive disorder, Hunot et al., 2007; hypochondriasis, Thomson and 
Page, 2007). To date, there is no theoretical model that is specific to HIV anxiety; however, 
there are several CBT disorder-specific models that give further insight into the 
conceptualisation and formulation of HIV anxiety. Specifically, the three models that lend 
themselves to HIV anxiety and will be discussed further are: specific phobia; health anxiety; 
and OCD.  
Specific Phobia.  For many GBM the fear of HIV is singular, and it therefore may be 
conceptualised as a specific phobia, which Jacob et al. (1989) historically referred to as 
‘AIDS phobia’. The DSM-V defining criteria for a specific phobia (APA, 2013) is detailed in 



















Table 4  
Specific Phobia classification and diagnostic criteria as per Diagnostic Statistical Manual of 







Using this diagnostic criterion, HIV would be considered the ‘object’ that is feared or, 
alternatively, the ‘situation’ being that one is HIV positive. In the DSM-V there are different 
subtypes, one of which is ‘blood-Injection-Injury’ (B-I-I). It is suggested that B-I-I phobias 
may have an evolutionary function (i.e., those who avoid puncturing their skin have a greater 
chance of survival) (Hamilton, 1995). It is therefore possible that a fear of an infection such 
as HIV could prove to be advantageous evolutionary (Margetts, 2013).  
Irrespective of whether HIV anxiety is considered a B-I-I specific phobia, the two- 
factor learning theory model of phobias (Mowrer, 1960) may be applicable. Specifically, this 
theory suggests that anxiety is acquired through classical conditioning – initial pairing of a 





Subsequently, this is then maintained by operant conditioning – an avoidance of the stimuli 
(either for what it represents or fear of the anxiety response) in the short-term leads to a 
subsiding of anxiety (and is therefore cyclical). However, in the long-term this prevents the 
individual from learning that the predicted adverse outcome will not be realised and/or their 
ability to cope is superior to their initial predication. It may also lead to selective attention 
and hyper-vigilance for the threat (i.e., HIV). This model is diagrammatically presented in 
Figure 19.  
 
Figure 19: CBT model of specific phobia (Westbrook et al., 2007) 
Further to conditioning, Rachman (1977) also proposed that ‘vicarious learning’ (e.g., 
observing fear through observing others) and ‘negative information’ are pathways to fear- 
acquisition. It is therefore both conceivable and understandable that GBM, with increased 
exposure to HIV-related information, in addition to perhaps observing others with the 
infection, may develop a fear of it. Despite this, the CBT model for specific phobia is not 





to the HIV virus; indeed, unlike other phobic objects the virus itself cannot be seen or 
touched (as in fear of animals) or transiently experienced (as in fear of flying). This therefore 
raises the question as to whether HIV can really be considered an ‘object’ or ‘situation’, as 
applicable to a phobia. In clinical practice, HIV anxiety tends to be characterised by a 
sustained anxiety about acquiring HIV infection, rather than an ‘immediate anxiety response’. 
A further criticism of the model is that it does not account fully for the cognitive and 
behavioural aspects of HIV anxiety. Specifically, whilst some GBM do experience anxiety 
during sex, often the anxiety is experienced before or after engaging in the behaviour. It is 
argued that such elevated anxious anticipation is more in keeping with other anxiety 
disorders, rather than a specific phobia (Craske et al., 2009).  
It is also common in clinical practice for GBM to not regard their anxiety as 
‘excessive or unreasonable’; indeed, some GBM consider their pursuit for repeated HIV 
testing, courses of PEP and abstinence as not only proportionate but vital to the preservation 
of their HIV negative status (Margetts, 2013).  
Health Anxiety.  It is often assumed that the health anxiety model (Warwick and 
Salkovskis, 1990) best explains HIV anxiety, especially if the anxiety is concurrent with fears 
of other illnesses, and cognitions related to the symptomatic profiles and death. Despite 
health anxiety (e.g., illness anxiety disorder) being the most widely adopted term for HIV 
anxiety in the field of CBT, it is diagnostically classified as a somatoform disorder (APA, 
2013), not anxiety. See Table 3 for the DSM-V diagnostic criteria.  
In relation to the diagnostic criteria for illness anxiety disorder, HIV can be 
considered as a serious illness. Specifically, as discussed in Part I of this chapter, although 
HIV is almost always manageable (in a UK context) and therefore not immediately fatal, it 
continues to pose a significant burden on the health of an individual. During seroconversion 





misinterpretations of common colds and other relatively harmless viral illness represent an 
example of misinterpreting body symptoms. It is common for GBM to palpate their glands 
and check for rashes when concerned about the possible presence of HIV infection (Margetts, 
2013). Furthermore, bodychecking and scanning can be deployed to discover possible 
infection routes (e.g., an ulcer in their mouth, micro abrasion on penis or perineum). Seeking 
reassurance from medical practitioners is also evident in those presenting with HIV anxiety: 
seeking out reassurance as to what constitutes a risk and procurement of HIV tests. The CBT 
model for health anxiety (see figure 20) contains the fear and avoidance components of the 
specific phobia model, whilst also incorporating behaviours observed in HIV anxiety, such as 
body checking and reassurance seeking.  
This model considers developmental experiences (e.g., homophobia) that may lead to 
the formation of specific beliefs about oneself, others, and the world in relation to health 
(these are termed schemas). When presented with health-related stimuli (a critical incident), 
cognitive biases then distort health related perception and information, ultimately resulting in 
anxiety. To reduce the anxiety, the individual may engage in avoidance, as well as 
reassurance seeking and body checking. Because of the arousal process that is triggered, the 
physical manifestations of stress and anxiety may well be misinterpreted as a symptom of the 






Figure 20: CBT model of health anxiety (Warwick and Salkovskis, 1990) 
 
Salkovskis and Bass (1997) have suggested that fundamental to health anxiety is the 
over-valued beliefs around the likelihood and cost of illness, and under-valued perceptions of 
one’s ability to cope with the illness. This is supported by a meta-analysis (Marcus et al., 
2007) looking at cognitive and perceptual variables associated with health anxiety in which 
the authors found that cognitive biases in health anxiety led individuals to overestimate the 
frequency of serious illness, have more restricted beliefs as to what constitutes health (i.e., 
having HIV irrespective of treatment status is always bad), and make catastrophic 





probability they will acquire HIV, believe that it would be profoundly catastrophic if they 
did, and assume that they would not be able to cope as a result.  
Importantly, however, the health anxiety model is derived from and applied to anxiety 
related to unavoidable illness such as cancer, multiple sclerosis, and motor neuron disease. 
Whilst some GBM may consider HIV inevitable (as previously discussed), it is still 
objectively avoidable. Moreover, the CBT models for specific phobia and health anxiety omit 
any reference to cognitions around perceived responsibility for acquiring HIV and/or the 
ability to infect others (in stark contrast to medical conditions which spontaneously occur). In 
turn, these considerations around contamination and loci of control spur consideration from a 
CBT OCD perspective.  
Obsessive Compulsive Disorder.  The integrated schematic model describing the 
cognitive hypothesis of the origins and maintenance of OCD (Salkovskis et al., 1998) is 
represented in Figure 21. According to this model, early experiences lead to assumptions and 
beliefs about responsibility and danger. In turn, these are then activated by a critical incident, 
and intrusions (thoughts, images, urges or doubts) occur. Whilst these are normal, they are 
misinterpreted as a need for action. In turn, distress, attentional biases, neutralising actions (to 
try and cancel out the danger) and avoidant safety strategies (to prevent danger) all follow. 
Consequently, this results in the original intrusions not being challenged or appraised 








Figure 21: cognitive-behavioural model of OCD (Salkovskis et al., 1998) 
 
The International Obsessive Compulsive Cognitions Working Group (OCCWG) have 
played a critical role in researching the assumptions and beliefs that are central to OCD 
(2003; 2005). The OCCWG have identified six key cognitive factors, which are listed in 
Table 5.  
 
Table 5  







The OCCWG acknowledges that there is an overlap between the domains, and that 
they are not exclusive to OCD (insofar as they have been observed in other anxiety 
disorders). Therefore, it is the interaction and ‘fixity’ of these beliefs (e.g., how rigidly they 
are held by the individual) that is paramount (OCCWG, 1997). Specific to HIV anxiety are 
the inflated sense of responsibility (for maintaining their HIV negative status), overestimation 
of the threat (in relation to HIV), intolerance of uncertainty (in not knowing their HIV status) 
and perfectionism (HIV being conceptualised as an ‘imperfection’). The notion of 
responsibility is very pronounced in HIV anxiety compared to other illnesses (Margetts, 
2013); Scragg (1995), for instance, reported that guilt from perceived responsibility failure is 





Abramowitz et al. (2007) found that individuals with a diagnosis of OCD did not 
differ in belief about the probability of developing a serious illness or preoccupation with 
bodily sensations, when compared to those with a health anxiety diagnosis. However, their 
anxiety regarding health was lower due to not having elevated beliefs regarding catastrophic 
negative consequences of becoming unwell. In relation to obsession in HIV anxiety, these are 
like the general themes seen in OCD (e.g., contamination, health, order, sex, and religion 
[Rachman, 2003]).  
The neutralising and counterproductive safety behaviours are deployed in 
consequence to the obsessions. Compulsions are grouped into wide ranging categories such 
as checking, washing, counting, ‘confessing’, ordering, and hoarding (Clarke, 2004). In 
relation to HIV anxiety, checking and washing are highly relevant: GBM with HIV anxiety 
may check their HIV status or the integrity of the condom repeatedly). Abramowitz et al. 
(1999, p537) distinguishes between:  
“...two different types of health-related concerns in OCD: (a) concern with illness 
stemming from environmental contaminants (e.g., AIDS), and (b) hypochondriacal 
concerns unrelated to external factors (e.g., brain tumour). Further, it appears that 
each type of concern is associated with a functionally related compulsive ritual.” 
Abramowitz et al. (1999) made parallels with Rachman and Hodgson (1980) who 
identified that cleaning rituals associated with OCD are ‘restorative’ and checking rituals are 
‘preventative’. In relation to HIV anxiety, avoidance rituals that could be considered 
‘preventative’ may include PrEP or PEP, whereas ‘restoration’ may describe those GBM who 
believe that they are HIV positive and wish to be diagnosed to access appropriate treatment 
and support (thus leading to repeated HIV tests and reassurance seeking from clinicians) 





Whilst the OCD CBT model does offer both theoretical and clinical insights into HIV 
anxiety, in common with the other two CBT models discussed, there is an absence of the role 
of stigma and shame in the manifestation of HIV anxiety. 
Biopsychosocial Model of Shame.  As discussed, disorder-specific CBT models do 
lend themselves, at least in part, to the conceptualisation of HIV anxiety. However, a 
challenge to each of the models is that they do not consider the shame and stigma that can be 
associated with HIV anxiety, such as that from revelations of a pattern of sex out of a primary 
relationship and subsequent feelings of guilt and shame. Specifically, Miller et al. (1988) 
found high levels of guilt and covert sexual experiences (e.g., GBM who were not ‘out’). 
Similarly, Scragg (1995) made a similar observation. This therefore raises the possibility that 
HIV anxiety may be not only a fear of illness but a fear of shame from acquiring HIV or the 
behaviours (i.e., homosexuality) associated with the acquisition (Margetts, 2013).  
It is important to note that shame is a transdiagnostic concept and has received recent 
theoretical and clinical interest in a range of mood disorders, with the development of 
compassion focused therapy (CFT; Gilbert, 2010a; Gilbert, 2010b). Gilbert (2010a) proposes 
that there are two forms of shame: external, referring to when other people judge one 
negatively; and, internal, when is when the judgement is directed towards oneself. The 
concept is derived from evolutionary ideas of ‘social rank theory’ (Stevens, 2016), in which 
some form of social competition (e.g., sexual partners) are linked to being attractive to others 
and ultimately to be included and chosen. If ‘unattractive’ on whatever parameter is being 
judged, then avoidance or rejection follows (Gilbert, 2006). The biopsychosocial model of 






Figure 22: An evolutionary and biopsychosocial model of shame (Gilbert, 2010a). 
 
Summary 
This part of the chapter has focused on introducing and critiquing a range of 
psychological theories and models as they apply to HIV anxiety among GBM. It is argued 
that the minority stress theory and internalised homophobia may increase the risk of GBM 
developing anxiety disorders, such as HIV anxiety. Models derived from cognitive-
behavioural therapy, as well the evolutionary and biopsychosocial model of shame, help form 
our conceptualisation of HIV anxiety among GBM. The next and final part of this chapter 
will frame the empirical study.  
 








HIV anxiety is most commonly conceputalised as ‘health anxiety’ (Margetts, 2010), 
withn a cognitive-behavioural framework.  Clinicially, this has resulted in clincians routinely 
operationalising the associated diagnostic labels, such as illness anxiety disorder (APA; 2013) 
and hypochondriasis (WHO, 2004), to categorise the distress these people present with.  
Furthermore, in accordance with the dominant evidence-base, cognitive behavioural therapy 
is recommended as a first-line intervention, which in England is primarily delivered within 
primary care services, such as IAPT (National Collaboration Centre for Mental Health, 
2021).  Despite their dominance, these diagnostic constructs and corresponding interventions 
may not capute the experiences of GBM who present with HIV anxiety.      
According to the CBT model of health anxiety (Salkovskis, Warwick, & Deacle, 
2003) the use of PrEP could be conceptualised as a safety behaviour. Safety behaviours 
include actions designed to detect a perceived impending threat, avoid it entirely, or endure it 
when avoidance is not an option (Helbeig- Lang & Petermann, 2010). Although the use of 
safety behaviours in the presence of actual threat is essential for survival, excessive and 
inflexible use of safety behaviours has been observed to maintain anxiety disorder symptoms 
(Salkovskis, 1991).  
Measuring change in sexual behaviour after commencing PrEP is a focus of many 
studies in the light of concerns that PrEP use may result in shifts towards more risky sexual 
behaviours – “risk compensation” (Blumenthal & Haubrich, 2014). GBM who are using PrEP 
may compensate for the protection afforded against HIV by having more CAI (Traegar et al., 
2018). There may also be undocumented psychological distress associated with sexually 






It is evident that PrEP may have a range of psychological and psychosexual benefits. 
However, this has been an under-studied area and the research to date has primarily focused 
on acceptability, adherence, and risk compensation. Furthermore, the evidence of 
psychological and psychosexual gains has exclusively involved those who were eligible for 
PrEP, thus considered high-risk. To date there have been no studies that have looked at the 
experiences of low risk GBM, with HIV anxiety.  
Aims 
The aim of this study is to explore the experiences of GBM, who started using PrEP, 
despite not engaging in CAI (therefore deemed low risk). More specifically, the study will 
recruit those GBM who have experienced HIV anxiety and this experience meets the 
diagnostic criteria for illness anxiety disorder. 
Research Questions 
 
1. How does HIV anxiety develop and manifest in these GBM? 
2. What motivates HIV anxious GBM to initiate PrEP? 
3. How do HIV anxious GBM make decisions around initiation of PrEP? 
4. What impact does PrEP use have on their experience of sex and sexual behaviour? 
5. What impact does PrEP use have on experiences of anxiety?
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CHAPTER TWO:  METHOD 
Chapter Overview 
The current chapter describes the ontological and epistemological stance of the study, 
drawing on the philosophical background to the critical realist position.  In defending a 
qualitative methodology, there is consideration of alternative positions and a discussion 
detailing the rationale for the undertaking of thematic analysis.  Furthermore, the primary 
researcher considers his own position in relation to the development of the research topic 
through a self-reflexive account.  The research procedure will also be outlined.   
 
Philosophical Framework 
Many of the research decision taken during research are influenced by the 
epistemological and ontological stance (Silverman, 2013), and it is therefore imperative that 
these are outlined.  Furthermore, recognising my own personal subjectivity will in turn 
facilitate an awareness of the possible bias that may subsequently emerge, and thus increases 
the credibility of the research and promotes transparency of the research process and the 
methodological decisions which may influence the research outcomes (Frost et al., 2010).  It is 
widely accepted that the philosophical framework should firstly consider the ontological 
stance, which will then aid the adoption of an epistemological stance, and in turn influence the 
selected research method. 
 
Ontology 
Ontology is defined as “a concept concerned with the existence of, and relationship 
between, different aspects of society such as social actors, cultural norms and social 
structures…. Ontological issues are concerned with questions pertaining to the kinds of things 





the question “whether or not there is a social reality that exists independently from human 
conceptions and interpretations and closely related to this, whether there is a shared social 
reality or only multiple, context-specific ones” (p.4).  Succinctly, Guba & Lincoln (1994) state 
that the ontological position is rooted in philosophy and thought about in terms of “the form 
and shape of reality”.  Various ontological theories exist, and these are best conceptualised as 
being positioned on a continuum, with realism and relativism at either end.   
Realism asserts that the worlds is separate from human interpretation and therefore 
objective measurement of reality is possible (Blaikie, 2007).  Relativism suggests that reality 
is a finite subjective experience (Denzin & Lincoln, 2005) and beyond our cognitions there is 
nothing in existence.  Reality is therefore not distinguishable from the subjective experience of 
it, from a relativist perspective (Guba & Lincoln, 2005).  A realist ontology is reflected in the 
significant body of quantitative research regarding the efficacy of PrEP, which broadly 
suggests that some quantifiable realities are known and measurable.  Notably, the significant 
reduction in HIV incidence among PrEP-using GBM reflects a known reality that exists as 
quantitative data.  There may be different explanations for this reality and multiple means of 
measurement of the data, but it has nevertheless existed in empirical research over the last 
decade.    A relativist ontology may be demonstrated by the experiences of PrEP use, insofar 
as research has consistently concluded that these are relative to the individuals and contexts.   
 
Epistemology  
Following from the ontological assumptions regarding the nature of reality, 
epistemology refers to how knowledge about reality is learned (Blaikie, 2007).  There are two 
main epistemological positions:  interpretivism and positivism (Ormston et al., 2014).   
Positivism asserts that valid knowledge is obtained through the application of scientific 





2011).  Another feature of this position is that there is a dualistic belief that there is no 
influence between the research and the participant(s) (Scotland, 2012).  Conversely, 
interpretivism rejects that the concept that knowledge is an objective account of reality.  
Therefore, knowledge is constructed thorough specific social and cultural contexts and that 
there are multiple knowledges with are subject to change over time (Patton, 2015).  A 
positivist epistemology reflects the way in which knowledge regarding the efficacy of PrEP is 
acquired (i.e., through statistical analyses of numerical data).  An interpretivist epistemology 
relates the way experiences of PrEP use are learned about, which is to say, through the 
interpretation of accounts of people who are using PrEP.  The experiences are constructed not 
only by the participant but also the research; together, they create a coherent account.   
 
Methodology 
The ontological and epistemological position subsequently informs the selection of the 
methodology.  Silverman (1993) defines methodology as the general strategy that is adopted 
by the researcher to investigate the topic of interest.  Crudely, a quantitative methodology is 
usually rooted in a positivist paradigm and is rigid in approach, such as empirical measurements 
in the context of manipulating conditions.  Research utilising this methodology is often 
hypothesis-driven and aimed at testing these through a controlled, logical, and structured 
approach (Krauss, 2005).  Furthermore, there is also an explicit assertion that the researcher is 
independent from the phenomenon under scrutiny (Hudson and Ozanne, 1988).   
 Conversely, research that is rooted in an interpretative paradigm almost exclusively 
uses a qualitative methodology.  The aim of interpretivist research is to understand, interpret 
and capture meanings attributed to subjective human experiences and participants’ perceived 
realities (Black, 2006), which are intrinsically influenced by context and time (Hudson and 





experiences of HIV anxious GBM who PrEP. In this regard, it is not possible to ascertain the 
objective truth of the phenomenon, and it was therefore concluded that the most appropriate 
methodology was qualitative.   
   
 
Self-Reflexivity  
Reflexivity refers to the “analytic attention to the researcher’s role in qualitative 
research” (Gouldner, 1971, p.16).  It is both a concept and a process (Dowling, 2006).  
Considered as a concept, it refers to a certain level of consciousness.  More specifically, 
reflexivity entails self-awareness (Lambert, Jomeen, & McSherry, 2010), which implies the 
researcher being active in the process.  A central feature is the recognition that researchers are 
very much part of the social world that we study (Ackerly & True, 2010; Shaffir & Stebbins, 
1991).  As a process, reflexivity is introspection on the role of subjectivity in the research 
process.  A continuous process of reflection by the researcher on their values (Parahoo, 2006) 
and of identifying, scrutinising, and making sense of how their “social background, location 
and assumptions affect their research practice” (Hesse-Biber, 2007, p. 17).  Jootun et al. (2009) 
suggest that the key to reflexivity is “to make the relationship between and the influence of the 
researcher and the participants explicit” (p 45). 
There is also evidence suggesting that self-reflexivity in the context of research 
adopting an interpretative paradigm, where is inevitable that a researcher will be unable to 
remain objective and outside the research subject (Palaganas, Sanches, Molintas, & Caricativo, 
2017), can improve transparency and research quality (Lietz et al., 2006).  As such, I have 
included a reflective account in this chapter.  In this reflective account, I consider my personal 





some of the reflections are deeply personal, I consider these to be pertinent to achieving 
transparency with regards to my positioning in the current research. 
I recall two experiences in my childhood where I was confronted with HIV.  The first 
one was when I was 5 years old.  I was at the park and picked up a can of Cola which was half 
empty and drank from it.  My mum became hysterical.  She snatched the can from me with 
such panic and shouted, “You could get AIDS!”.  I cried all the way home and was very 
unsettled and anxious.  Now, with hindsight, this statement is both incorrect and rather cruel.  
It is therefore important to consider the prevailing context in which this statement was made.  
I grew up in the late 1980s/early 1990’s on a council estate on the periphery of 
Edinburgh – which at the time was dubbed the ‘AIDS capital of Europe’ due to a considerable 
outbreak of HIV among people who were injecting drugs – where drugs, addiction, and crime 
were commonplace.  My mum’s partner had recently died of cancer, and she was also battling 
with her own mental health.  She had severe health anxiety, and this resulted in visiting (and 
battling!) her GP daily, often with my brother and I with her.  In line with common practice at 
the time, she was prescribed benzodiazepines.  Despite a short spell of remittance, she rapidly 
became addicted to these and would frequently overdose.  Her distress worsened and she had 
a psychiatric nurse who visited her at home.  I grow up in a very anxious environment and, 
despite my age, developed quite a sophisticated understanding of anxiety. 
The second of time was when my mum introduced me to one of her childhood friends 
in a pub, when I was 8.  The partner of my mum’s friend was there too, and I remember my 
mum referring to him as a “junkie” and that he had “AIDS” – although derogatory, this 
language was commonplace during my childhood.  I only ever met him a handful of times, but 
I remember him vividly.  He was gaunt and his face dotted with sores.  His arms were frail and 
covered in track marks from injecting heroin.  He later died from HIV in the late 1990’s.  I 





friend perhaps “catching it” from her late partner.  HIV was scary during my childhood, and 
this was perhaps exacerbated by my mum’s mental health difficulties.  The anxiety it created 
in those around me was palpable and, inevitably, contagious.   
Fast-forward to when I started college.  I had realised that I was gay but hadn’t told 
anyone.  There were other people at college who were gay and out; they got a hard time from 
people.  Some of them were referred to as “dirty poofs” and there were ‘jokes’ about them 
having “AIDS”.  I then started to make the connection between being gay and HIV, which 
worried me.  If I was gay, then that would mean I was going to get HIV?  Instead of being 
proactive about this and seeking more information, I decided to ignore the worry and push it 
the back of my mind.   
I then moved away for university.  I started having relationships with men – due to my 
ignorance, I rarely used protection.  I started to have friendships with other gay men and 
encountered conversations about HIV and was introduced to the routine of testing.  I’m not 
sure why, but at that moment, I began to experience intense anxiety regarding HIV and was 
convinced that I was infected.   
Things deteriorated, and I began behaving like my mum; I’d regularly attend the doctor 
anxiously about every ‘symptom’.  I ended up having to start taking medication to manage my 
anxiety and dropped out of university.  I could no longer concentrate and anxiety about HIV 
overtook my life.  I stopped having sex completely for fear of passing it on.  But I still wouldn’t 
test.  It was just too anxiety provoking.  What if I ended up looking like that man my mum 
introduced me to in the pub?   
Eventually, I decided to test, and it was terrifying.  It took nearly two weeks for the 
result to come back.  I had to go into clinic and if the results were negative then the receptionist 
would tell me and if any of the tests were positive, I had to wait for the nurse.  I arrived at the 





either anxious or ashamed (I was both!).  I went to reception and my heart was pounding.  She 
looked at the file and told me all my test results were fine. I left the clinic and felt an 
overwhelming sense of relief.   
Now, you would be wrong if you thought was the end of it.  Despite testing negative, 
all the cognitive and behaviour patterns I had developed that maintained my anxiety for all 
those months seemed to be ingrained in me.  It was as if they had become habit.  I continued 
medication for another year or so and wasn’t well enough to go back to university.  Eventually, 
I began to overcome the anxiety and re-applied to go back to university.  Unfortunately, I had 
lost my place at university due to amount of time I had taken out and therefore had to change 
university.   
Alongside studying, I got a job with a local HIV charity.  One of the projects I worked 
on was setting up a rapid HIV testing service to various ‘at risk’ groups.  After a few months 
of being there, I noticed many ‘worried well’ people coming through the door wanting these 
rapid tests for HIV.  Hearing their stories reminded me of myself when I was in Aberdeen.   
I enjoyed the job and was nearly ready to graduate.  I decided that I wanted to pursue a 
career in sexual health and HIV.  I started working in Birmingham and quickly earned a 
reputation for being ‘good’ with patients who were health anxious.  I then moved to London to 
work in several central London clinics, where I was diagnosing large numbers of people with 
HIV and this quickly took its toll on me.   
In a single day in 2014, I diagnosed 8 people with HIV; most were of a similar age to 
me, and all were gay men.  Later that year, one of my colleagues said that he had calculated 
that between the four of us in our team we had diagnosed 1 in 6 of the UKs new HIV infections 
among gay men that year.  In this ‘toxic’ environment, anxiety began to creep back in and 
whilst I was now a provider and not a consumer of both sexual health and mental health care, 





psychotherapy.  In psychotherapy, I spoke about my childhood and my experiences of anxiety, 
particularly health anxiety.  I also spoke about my identify as a gay man and what I thought 
this meant.  This was a very valuable experience and gave me a greater understanding of myself 
and the context in which I had lived.   
I decided that I wanted to leave sexual health and pursue a career in clinical psychology.  
I completed a MSc in health psychology and began work as an assistant psychologist, where I 
undertook some CBT training.  This gave me a framework to understand anxiety from a 
cognitive and behavioural perspective.  I applied for clinical training and was accepted onto a 
training programme, where I currently work as a trainee clinical psychologist.  As someone 
who has experienced HIV health anxiety, a gay man, and a provider of mental and sexual health 
care this has inevitably impacted my positioning in this research. 
 
Research Paradigm 
A research paradigm consists of ontological, epistemological, and methodological 
views held by the researcher (Denzin and Lincoln, 2011).  The current research takes a critical 
realist approach, which is described as a bridge between a realist ontology and an interpretivist 
epistemology (Grix, 2019).   Critical Realism makes a distinction between the ‘real’ world and 
the ‘observable’ world.  The ‘real’ world exists independently from human perceptions, 
theories, and constructions; it is not observable.  The world that we know and understand is a 
construction form our perspectives and experiences, through what is ‘observable’.  Therefore, 
critical realists assert that unobservable structures create observable events, and the social 
world can only be understood of people understand the structures that generate events.   In this 
ontological domain, the purpose of science is to identify phenomena and develop agreement 
regarding the description of the whole from glimpses or partial fragments (Bergen, Wells, & 





is argued that PrEP use is a reality.  An interpretivist epistemology is considered appropriate 
to the current research because the experiences of PrEP use and HIV anxiety are subjective 
constructions or interpretations from the participants and the researcher, rather than objective 
observations from the researcher alone.   
 
Obtaining Data 
The research question informs the methods of obtaining data to ensure that what is 
collected is relevant and useful in the pursuit of enabling understanding of the studied 
phenomenon.  For the current study, it is argued that there are insufficient academic accounts 
of the experiences of HIV anxious GBM who are using PrEP that can be analysed in service of 
the research aims, therefore novel data is needed.   
 The most common method of data collection within social science research are semi-
structured interviews (Briggs, 1986).  This method is closely associated with interpretivist and 
constructionist epistemologies and reflects an ontological position that is concerned with 
people’s knowledge, understandings, interpretations, experiences, and interactions (Lewis-
Beck, Bryman, & Liao, 2004).  The logic of semi-structured interviewing is to generate data 
interactively, and Steiner Kvale has described qualitative research interviews as “a construction 
of knowledge” (Kvale, 1996, p. 62).  Semi-structured interviews are often guided by pre-
determined topic guide, which are flexibly adhered to throughout the interview to give some 
containment over the trajectory of the interview, whilst also facilitating space to allow 
participants to provide new insights.  This method of data collection has been selected as it 
aligned to generating rich data about the participants experiences of using PrEP.  Furthermore, 
given that the topic could be considered sensitive by some and has the potential to illicit 





 Focus groups have been used as an alternative to semi-structured interviews.  Unlike 
semi-structured interviews, which usually involve only one researcher and one participant, 
focus groups facilitate the opportunity to gather data on interactions between the participants 
in attendance at the group.  During focus groups, participants are actively encouraged to remark 
on one another’s contributions and challenge comments and develop thoughts, which in turn 
can provide rich data in a less artificial de-contextualised setting (Wilkinson, 1999).  Despite 
this, the use of focus groups in the current research was deemed inappropriate for the following 
reasons: (1) the topic guide covers sensitive issues such as psychosexual functioning and 
psychological wellbeing, which are deemed sensitive.  In turn, discussion of sensitive topics in 
such a format may inhibit responses and reduce the quality of the data collected; (2) it would 
not be possible to assess whether participants meet the diagnostic criteria for Illness Anxiety 
Disorder in this context; and (3) focus groups do not allow for in-depth exploration of 
individual experiences, which is the focus of the current study.   
 
Why Thematic Analysis 
There are multiple different approaches to analysing qualitative data and each of these 
will be discussed in turn and their possible utility discussed in relation to the current study.  
Consequently, this will clarify the justification for the selection of thematic analysis in the 
current study.  Starks and Trinidad (2007) state that the aims and research questions are central 
in determining the most appropriate method of data analysis. 
 
Grounded Theory 
GT is a research method that aims to generate theory (Glaser & Strauss, 1967), which 
is ‘grounded’ in the data that has been collected and analysed systematically (Denzin & 





relationships and behaviours of groups, known as social processes (Crooks, 2001).  As this 
method is principally concerned with generating concepts and hypotheses through an inductive, 
and evolving process (Charmaz, 2000), this method is most appropriate for explorative research 
where theory can evolve from the data.  Whilst there are several advantages of this method, 
there is a lack of consistency regarding how the method is employed (Barbour, 2001), which 
in turn can result in methodological fragilities (Potrata, 2010).  I therefore concluded that this 
method was not appropriate for addressing the current research questions which focused on 
describing GBMs experience of PrEP in the context of HIV anxiety, rather than generating a 
new theoretical framework.   
Interpretive Phenomenological Analysis  
IPA (Smith, 1996) and aims to uncover what a lived experience means to the individual 
through a process of in-depth reflective enquiry.  IPA draws heavily on phenomenology, with 
the purpose to return “to the things themselves” (Husserl, 2001, p168).  There is also an 
acknowledgment in IPA that individuals are influenced by the worlds in which they live in and 
the experiences in which they encounter.  Therefore, IPA is an interpretative process between 
both the researcher and the researched, where the participant makes sense of their experiences 
and the researcher attempts to make sense and interpret the participant’s world (Smith et al., 
2009).  Some of the criticisms of IPA are that it lacks standardisation (Brocki & Wearden, 
2006).   
 IPA was not considered an appropriate method as it aims to make sense of individuals 
experience by focusing on single cases, or a small group of homogenous individuals.  In the 
current study, the participants were heterogenous (insofar as age, relationship status, and 
nationality).  Furthermore, as the current research aimed to describe participants’ experiences, 
rather than interpreting the meaning of their lived experiences, thematic analysis was ultimately 







Thematic analysis is popular and widely used in qualitative research (Roulston, 2001).  
It applies a systematic approach to identify, analyse, and report themes across a series of 
datasets from a homogenous sample (Braun & Clark, 2006).  The flexibility offered by thematic 
analysis is unique in that is does not prescribe an allegiance with a specified theoretical 
framework, data collection method, or ontological and epistemological positions.  As such, this 
method can be deployed in a range of methodologies to answer research questions.  Whilst the 
method has widely accepted guidelines, developed by Braun and Clark (2006), the techniques 
require no specific training to use it.  Furthermore, the intuitive nature of the method means 
that it highly accessible to researchers.  Braun and Clark (2006) assert that thematic analysis 
produces detailed, rich, and complex data that exceeds mere description and interpreting of 
certain aspects of the studied phenomenon (Boyatzis, 1998).  Joffle (2011) suggests that there 
is evidence to conclude that thematic analysis is a useful method to allow participants voices 
to be heard.   
  Thematic analysis was selected as the most appropriate method of analysis in the 
current study as it has utilised widely in relation to topics pertaining to individuals’ experiences 
and perceptions of studied phenomenon (Braun & Clark, 2013, p44).  A thematic analysis was 
suited to capture common themes on key areas such as motivation, psychological impact (e.g., 
anxiety), and psychosexual impact in those HIV anxious GBM who are using PrEP. 
Design 
Study Setting   
The study was a multi-centre study based at two NHS Trusts in London:  Collectively, 
these clinics see more than 300,000 attendances per year.  The participating centres were 





to those who were self-sourcing PrEP.  Clinics in south east London serve an ethnically diverse 
population and it was therefore hoped that this would increase access and to underrepresented 
populations, such as those from the BAME community, and thus increase their recruitment. 
Study Context:  Healthcare setting and CBT paradigm  
 Although the current study acknowledges there are issues associated with using 
diagnostic labels, such as illness anxiety disorder (APA, 2013), to categorise HIV anxiety, and 
the CBT model of health anxiety (Warwick and Salkovskis, 1900) to conceptualise HIV 
anxiety, it is accepted that the diagnostic criteria of illness anxiety disorder is the most widely 
adopted in clinical practice and is the most aligned conceptualisation, compared to other 
diagnostic terms (i.e., hypochondriasis (WHO, 2013)).  Given the dominance of illness anxiety 
disorder and the cognitive behavioural model in conceptualising HIV anxiety (albeit 
inadequately), in the current healthcare context those presenting with this phenomenon will be 
likely be recommended a treatment that corresponds with these conceptulisations, which is a 
course of cognitive behavioural therapy, usually delivered in a primary care setting (e.g., within 
Increasing Access to Psychological Therapies (IAPT) services. 
 As a consequence of the prevailing healthcare context, the current study has opted to 
use the illness anxiety disorder critiera to screen participants in the study, and adopt a cognitive 
behavioural framework in exploring their experiences. 
Research Procedure 
Stage 1:  Promotion of research.  I attended the recruiting clinics to introduce the 
research and promote the referral of potential participants.  I provided a short presentation to 
clinical staff on the background of the study, aims, the inclusion and exclusion criteria, 
referral process, and requirements of participants.    Study materials were also made available 





Stage 2:  Recruitment.  Figure 23 provides an overview stage 2 of the research 
procedures. Eligible participants were identified during routine sexual health consultations 
with a clinician, who introduced the research and offered the participant information sheet (PIS; 
Appendix A) to potential participants.  If participants were interested in learning more about 
the study or expressed a desire to participant, the clinician obtained consent to share their 
contact detail with me.  Consent was documented in the patient’s records.  If they accepted, the 
contact details were sent via an NHS.net email account to ensure adherence to NHS policies 
and procedures.  Alternatively, if the potential participant wanted more to discuss the research 
with other or were unsure, the were informed that they could contact the researcher via the 
contact details provided on the PIS.   
 In instances where potential participants were referred to participate or they made 
contact, I offered an opportunity for them to ask questions relating to the research.  At this 
point, I ensured that participants met the study inclusion criteria and arranged an appointment 
at their clinic with me to obtain formal consent, complete demographic sheet and health anxiety 







Figure 23.  Study flow chart detailing research procedure for stages 2 and 3. 
 
Stage 3:  Data Collection.  The recruitment and interviewing of participants occurred 
between February 2020 and December 2020.  Informed consent was obtained from participants 
(Appendix B) prior to giving them the demographic sheet (Appendix D) and HAI-18 





disruptions and to ensure confidentiality or online, using secure videoconferencing software.  
The interview began with building a rapport and introductions, the rest of the interview was 
guided by the interview topic guide (Appendix E).  The interviews were audio recorded using 
a digital Dictaphone.  After the interview, a de-brief took place if participants met the 
diagnostic criteria for Illness Anxiety Disorder, they were offered a referral for further 
psychological assessment and possible intervention, using their respective clinics established 
clinical pathway.   
 Stage 4:  Data Analysis.  Scores obtained on the HAI-18 and the clinical component 
of the interview were used to make a clinical decision if a participant met the diagnostic criteria 
for Illness Anxiety Disorder (either currently or historically), and participants were stratified 
accordingly.  The current study only analysed those who met diagnostic criteria for illness 
anxiety disorder.  Each of the interviews were transcribed by a professional transcriber and 
analysed using thematic analysis (Braun and Clark, 2006) by me (see Appendix F for a coded 
excerpt).  During write-up, any epistemological assumptions that informed the analysis have 
been made explicit and a detailed account of the analytical process including justifications of 




A topic guide (Appendix E) was developed to follow the aims of the research and to 
address the research questions.  It was constructed in consultation with supervisors, and service 
users were involved in reviewing the topic guide to ensure the terminology was accessible and 
the tone was respectful.  It is essential that topic guides are well-designed as poorly designed 
topic guides can potentially restrict the exploratory and reflective nature of qualitative research 





PrEP; (2) HIV risk perception; (3) the psychological and psychosexual impact of using PrEP; 
and (4) a clinical interview relating to Illness Anxiety Disorder (see Table 6).    
Clinical Interview 
Included in the interviews were a clinical interview to ascertain the presence (current 
or historical) of symptoms of Illness Anxiety Disorder as set out in the Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition (DSM-V; APA, 2013).   Table 6 below 
details the specific diagnostic criteria. 
 
Table 6 




A. Preoccupation with having or acquiring a serious illness. 
 
B. Somatic symptoms are not present or, if present, are only mild in intensity.  If 
another medical condition is present or there is a high risk for developing a 
medical condition (e.g., strong family history is present), the preoccupation is 
clearly excessive or disproportionate. 
 
C. There is a high level of anxiety about health, and the individual is easily alarmed 
about personal health status. 
 
D. The individual performs excessive health-related behaviours (e.g., repeatedly 
checks his or her body for signs of illness) or exhibits maladaptive avoidance (e.g., 
avoids doctor appointments and hospitals). 
 
E. Illness preoccupation has been present for at least 6 months, but the specific illness 
that is feared may change over that period of time. 
 
F. The illness-related preoccupation is not better explained by another mental 
disorder, such as somatic symptom disorder, panic disorder, generalised anxiety 
disorder, body dysmorphic disorder, obsessive-compulsive disorder, or delusional 







Illness Anxiety Disorder classification and diagnostic criteria as per Diagnostic Statistical 
















Health Anxiety Inventory 
The Health Anxiety Inventory (HAI-18; Salkovskis et al., 2002) was used to measure 
levels of health anxiety and was used in conjunction with the clinical interview to make a 
clinical judgement whether participants met the diagnostic criteria for Illness Anxiety Disorder. 
The HAI-18 is an 18-item self-reported questionnaire, which measures cognitive factors 
associated with health anxiety. Items on the HAI-18 are rated on a 4-point Likert Scale with 
higher scores reflecting higher levels of health anxiety. Previous literature has found mean 
scores of 37.9 (±6.8) to reflect populations with clinical levels of health anxiety.  The HAI-18 
Care-seeking type:  Medical care, including physician visits or undergoing tests and 
procedures, is frequently used. 






has been shown to be a valid and reliable scale (r = 0.90) for the assessment of health anxiety 
(Salkovskis et al. 2002).  
 
Data Analysis 
Following each interview, I wrote reflections of the interview, with particular 
emphasis on identifying possible areas of bias.  In turn, this facilitated increased transparency 
in allowing others to evaluate the extent to which biases may have impacted data collection 
and subsequent analysis.  The analytic process followed the six-phased approach set out by 
Braun and Clark (2006).  Figure 24 is a diagrammatic representation of the process.  I 
adopted an inductive, bottom-up approach to thematic analysis.  In doing so, I established 
explicit links between the raw data collected and the research aims and was able to 
summarise extensive data within a concise format (Braun and Clarke, 2006).  This approach 
is compatible within an interpretivist paradigm (Cohen et al., 2007).   
Thematic Analysis  
 
Figure 24.  Braun & Clarke’s (2006) six-phased approach to thematic analysis 
 
 
Phase 1:  Familiarisation with the data.  This stage started through active reading and 
re-reading of the transcripts.  It also involved making notes of any initial thoughts or points of 
interest.   
 Phase 2:  Generating codes.  Based on semantics and latent level readings of the data, 





MAXQDA was used as a tool to code the extracts manually and collate the data pertaining to 
each code.  Guided by the study aims and research questions, reading the data was done three 
times to determine the potential relevance of codes.  
 Phase 3:  Searching for themes.  This phase involved reviewing the codes compiled 
to identify similar concepts across the data set, and then clustering the codes into potential 
initial themes.  
 Phase 4:  Reviewing themes.  Themes were reviewed by checking the coded data 
extracts and examining whether each theme was supported by coherent and relevant data.  This 
process also involved discussion the initial themes and subthemes (and their relevant codes) 
with the research supervisory team, to provide verification of the representativeness of the 
codes in the themes.  Furthermore, the themes were then reviewed in relation to the dataset in 
its entirety to prevent overlooking any themes, ensure that the identified themes captured 
meaning across the dataset, and that the identified themes were meaningful in relation to the 
research questions. 
 Phase 5:  Defining and naming themes.  Themes were defined by checking relevant 
extracts and examining whether the essence of each theme had been captured.  The themes and 
extracts were then discussed with the research supervisory team to assess the utility of the 
findings.  Subsequently, the themes were organised into domains (which broadly corresponded 
with the research questions). 
 Phase 6:  Writing the report.  The final phase of analysis involved conveying the 
outcome of the analysis in a coherent and conceivable way.  Each theme and subtheme are 
evidenced with appropriate extracts from the dataset, which are particularly vivid.  In turn, the 







Participants and sampling method.    
Research that utilises an interpretivist approach often uses purposive sampling when 
identifying and selecting potential participants (Creswell, 1998).   Specifically, this method is 
used to identify and select those participants who meet pre-defined characteristics or 
knowledge relating to the subject of interest who are able and willing to participate (Cresswell 
& Piano Clark, 2011). 
 Inclusion and exclusion criteria were established after a thorough review of the 
literature and a discussion with a HIV physician.   All patients attending one of the recruitment 
site clinics considered to be low risk for HIV infection prior to commencing PrEP were eligible 
to participant.  Once a patient expressed an interest in participating in the study, the clinician 
would forward their details to the Chief Investigator, who would screen their eligibility to 
participate against inclusion and exclusion criteria, taking into consideration their capacity to 
consent. 
Inclusion Criteria 
1. Assigned a male gender at birth. 
2. Self-identify as gay or bisexual. 
3. Registered and receiving care pertaining to their use of PrEP at one of the study 
sites. 
4. Aged 18 years or older. 
5. Currently using PrEP either daily or event-based dosing for at least 90 days. 
6. Prior to using PrEP did not have condomless anal sex in the preceding 90 days. 
7. Negative HIV serology in the past 90 days. 





9. Met the diagnostic criteria for Illness Anxiety Disorder, based on current or 
historical symptoms.  *For this study only 
Exclusion Criteria 
1. Deemed by their clinician or the research to be unable to provide informed 
consent. 
Sample Size 
A sample of 22 PrEP using GBM were stratified to one of two groups: (1) Those who 
meet the diagnostic criteria for Illness Anxiety Disorder (n=10); and (2) those who do not 
meet the diagnostic criteria for Illness Anxiety Disorder (n=12).  Terry et al. (2017) 
recommends a range of 6-15 participants for doctoral-level research, therefore 10 individual 
participants in each group is considered an acceptable sample size.  Furthermore, a total of 
twenty was an agreed sample size based the capacity and capability assessment carried out at 






Note. EBD = Event Based Dosing
Participant 
Pseudonym Age Ethnicity 
Sexual 
orientation Marital status 
Highest level of 
education Occupation PrEP regimen 
Duration of 
PrEP use PrEP source 
Yusuf 33 White Turkish Gay Single Postgraduate Arts Production Daily 9 months Dean Street PrEP shop 
Finn 29 White Irish Gay Single Postgraduate Management 
Daily  
EBD 
2 years 6 
months IMPACT trial 
Dirk 23 White Dutch Gay Single Undergraduate Management Daily 4 months Dean Street PrEP shop 
Nathan 31 White other Gay Single Postgraduate Student Daily 1 year 3 months 
Dean Street PrEP 
shop 
Marcus 44 Indian Gay Single Postgraduate Management  EBD 2 years 4 months IMPACT trial 
Daniel 34 White English Gay Partnered  Postgraduate Management Daily 4 months IMPACT trial 
Jon 28 White English Gay Single Postgraduate  Journalist  Daily 5 months IMPACT trial 
Hamish 57 White Scottish Gay Married Postgraduate Publisher EBD 2 years 2 months IMPACT trial 
Mateo 28 White European Gay Single Undergraduate Civil Servant Daily 
5 years 2 
months IMPACT trial 
Paulo 53 Mixed ethnic group Gay Partnered  Postgraduate Nurse EBD 
4 years 9 




The British Psychological Society (BPS) Code of Ethics (2009; 2014) explicitly states 
the ethical standards expected in psychological research and by those who are professionally 
affiliated to the psychology profession.  Throughout this research these standards have 
informed the study design and how it was conducted.  The Code of Ethics (2009; 2014) was 
consistently adhered to, which related to the following areas. 
 
Ethical Approval  
After an ethical review by an NHS Research Ethics Committee (REC), approval was 
granted simultaneously by both the nominated REC (Appendix G) and Health Research 
Authority (HRA) (Appendix H).  Subsequently, both NHS trusts’ local Research and 
Development departments conducted a ‘Capacity and Capability’ assessment, as per HRA 
requirements, and granted the approvals for the research to commence in the designated sites 
(see Appendicies I and J).   
 
Informed Consent 
Potential participants were provided with a copy of the PIS.  The PIS clearly stated the 
aim and purpose of the study and what participation involved.  This was to support potential 
participants deciding whether to participate.  Participants were given opportunities to ask 
questions prior to obtaining formal consent.  Participants were informed that their participation 
was voluntary and could withdraw from the study at any stage, without giving a reason.  
However, it was made clear that if data had already been anonymised it would not be possible 
to retract data already collected and anonymised.  Furthermore, it was made explicitly clear in 
the PIS and consent form that withdrawing from the study would in no way affect the care they 





 Capacity was assessed by at the initial telephone contact and again prior to interview.  
This was achieved by exploring with participants their understanding of the purpose of the 
study and nature of the research, the potential benefits, and risks.  This included how data will 
be handled and confidentiality.  Furthermore, participants were asked if they had discussed 
their potential participation in the study with to establish whether there had been any element 
of coercion to take part.   
 
Confidentiality  
Participants were informed of the limits of confidentiality prior to the commencing 
the interview and that I would be duty bound to break this if they disclosed information that 
raised any safeguarding concerns for themselves or others (BPS, 2014).  They were informed 
that in the first instance I would discuss with my supervisors and if they felt it necessary to 
escalate this then I would inform their clinician at the clinic, who would take appropriate 
action in line with their respective Trust’s policies and procedures. 
 
Anonymity  
As the current study will collect data that is qualitative in nature, the results chapter 
(and subsequent publications) will include direct quotations from participants.  Whilst every 
effort was made to protect anonymity by assigning each participant with a pseudonym, the 
risk remains that participants may be identified inadvertently (Larossa et al., 1981).  
Participants were made aware of this in the PIS and consent form.  Steps were taken to 
minimise this by reminding participants to refrain from identifiable information that may lead 







The study was adhered to the Data Protection Act (2018).  The audio recordings were 
encrypted and kept under password on a University server for a period of 12 months before 
being destroyed.   Participants were each allocated a unique participant ID, with the ID key 
being kept on an NHS server and password protected.  The participant ID was used in all study 
documents in place of identifiable information.  These study documents were kept in a locked 
drawer in at an NHS clinic.  A copy of the completed consent form was stored in the 
participants medical records for a period defined by the Trust operating the clinic where the 
participant attended.  In line with the Data Protection Act (2018), participants were informed 
of data storage arrangements in relation to this study and that their transcribed data will be 




As participants were speaking about psychological issues related to their use of PrEP, 
there was potential for the interviews to elicit some psychological distress.  Furthermore, an 
assessment of whether the participants met the diagnostic criteria for Illness Anxiety Disorder 
was undertaken.  In the situations where the participant met diagnostic criteria, they were 
offered a referral for further psychological assessment.  Care pathways existed in the 
participating clinics for such instances and the PIS also included information about where 
participants could access more support.   Psychological distress was monitored throughout the 







Some participants were self-sourcing PrEP.  Whilst it is accepted that the risks 
associated with using PrEP are sufficiently mitigated by accessing regular monitoring at a 
clinic, those who self-source PrEP may not be able to access the same level of monitoring as 
those in clinical trials.  To mitigate this risk, participants were only recruited from NHS clinics 
that offered PrEP monitoring to those who were self-sourcing.   The PIS included links to NHS-
approved information accessible online to ensure participants were fully informed regarding 
the risks associated with PrEP.  If participants proposed questions pertaining to clinical issues 
regarding PrEP during the interview, they were informed to seek advice from their clinician.  
 
Quality Assurance 
The quality of qualitative research has long been a focus of criticism from those 
positioned to a positivist position.  More specifically, concepts central to positivism, such as 
reliability and validity, have proven very challenging to apply to qualitative research and have 
therefore led to some concluding that the methodology is inherently lacking in rigor (Shenton, 
2004).  In quantitative research, the notion of rigour is that an objective truth or reality is in 
existence (Burr, 2003) and this conflicts with research which utilises a qualitative paradigm, 
such as the current study.  However, there is attempts in qualitative research on adoption of 
rigorous frameworks to mitigate poor quality (Frost and Bailey-Rodriguez, 2019).  Some 
frameworks have attempted alignment with positivist criteria; however, it also argued that 
qualitative research should determine quality with concepts such as credibility, transferability, 
dependability, confirmability, and authenticity (Denzin and Lincoln, 2011).  Table 8 includes 






Quality assurance criteria (as per Lincoln et al., 2011) and corresponding statement on how each criterion was satisfied 
 
Criterion Criterion Definition How the criterion was satisfied 
Credibility  The extent to which the research findings 
appropriately reflect the respective realities of the 
participants. 
Analysis was grounded in participants verbatim experiences. 
Transferability Describes whether the research has applications 
outside of the study. 
Details of research boundaries and context are provided, as well as participants’ 
demographics.   
Dependability  Describes how well a research may be audited by 
another researcher and refers to transparency. 
A detailed research paradigm (including theoretical and philosophical assumptions) 
and operational implementation of the study is provided. 
Data collection was carried out consistently and interpretations are accompanied by 
verbatim extracts.  
Confirmability The concept of confirmability concerns whether 
reported findings reflect ideas and experiences within 
the data, or are unduly influenced by the preferences, 
characteristics, and biases of the researcher (Lincoln 
& Guba, 1985; Shenton, 2004). 
 
Researcher’s self-reflexive statement. 
Researcher engaged in clinical supervision throughout the process to monitor and 
mitigate their preconceived ideas and biases upon data collection and analysis. 
Authenticity  The extent to which the researcher is emotionally 
candid. 
Researcher’s self-reflexive statement. 
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CHAPTER THREE:  RESULTS 
Chapter Overview 
 This chapter will present themes and subthemes from participants’ data.  Themes and 
subthemes are accompanied by interview extracts to facilitate understanding of the participants 
experiences of HIV anxiety and of using HIV PrEP.  To protect anonymity and confidentiality, 
each participant has been allocated a pseudonym. 
 
Interview order 




Research interview order, duration and assigned pseudonym (N=10) 
Interview Order Assigned Pseudonym Duration of Interview (min:s) 
1 Yusuf 44:07 
2 Finn 61:04 
3 Dirk 53:49 
4 Nathan 47:02 
5 Marcus 47:01 
6 Daniel 39:26 
7 Jon 29:53 
8 Hamish 43:25 
9 Mateo 55:11 







Overview:  Themes and Subthemes 
 Twenty-two themes and forty-nine accompanying subthemes were extracted, across 





Constructed themes and sub-themes extracted from participants’ data (N=10) 
 
Domain Theme Sub-theme(s) 
Sexual identity and stigma Coming out You’re supposed to be straight 
If anyone else in this fucking family turns 
out to be gay, I’m going to kill them! 
 
 Internalised homophobia It’s just a matter of time 
Everybody gay was promiscuous 
The good gays and the bad gays 
 
 HIV stigma Seriously?  You caught HIV? 
Bitter about catching HIV 
 
Attitudes towards, and relationship 
to, sex 
It might kill me  
 I couldn’t trust anybody 
 
 
 Casual sex  
 
 
HIV anxiety It’s part of me Glass half-empty 
HIV is special  
I am the 0.0001% 
Destroyed my body 
 
 HIV anxiety is omnipresent It was a constant  
Everyone is in a high-risk category 
 
 Misinterpreting my body I had a tiny graze on my fingernail 
This is it! 
 
 I’m scared because… I’d be more concerned by the stigma 
I’m going to die 
 
 I need to keep myself safe Sex is on another land 
I’m more in control 
Reassurance 
 












Table 10 continued  
 
Note. EBD = Event-Based Dosing; STIs = Sexually Transmitted Infections’ 
 
 
Supplementary data representation is presented in Figure X, which visually presents 
patterns of coded segments for each of the five domains (adapted from Verdielli & Scagnoli, 
Domain Themes Sub-theme(s) 
Motivation for, and initiation of, 
PrEP 
I can’t tolerate the anxiety 
anymore 
She saw how distraught I was 
I wasn’t trusting condoms 
I need to enjoy myself before it’s 
too late 
 
 Responsibility It’s irresponsible for me to go and 
do that 
I’ve always been the serious one 
 
 Accessibility It’s just another forestall 
Phoney medication 
 
 Daily is best for me Things are not always planned 
I know that … there is sex going 
on 
I’m very good at maintaining a 
routine 
 
 EBD works best for me  
 
The experience and impact of 
PrEP 
Facilitating a sexual life Express myself sexually 
It’s just pleasure 
I enjoy bottoming  
More prone to doing it 
 
 Change in risk perception I’m much freer now 
 
 Disclosing I’m on PrEP You’re on PrEP and you’re using 
condoms? 
I have to justify it 





It’s more of a chore 
It’s like och 








Let my guard down 
I still have those anxieties  
There is HIV in my life now 
The next one in the line-up 
It’s going to be taken away from 
me 







2013).  The document portraits (Figure 25) demonstrate the prevalence of coded segments for 
each domain, as well as uncoded text, according to the colours assigned within the coding 
system.  Codes relating to HIV anxiety and the experiences and impact of PrEP were most 








   
Figure 25:  Document portraits for research interview transcripts, depicting the prevalence of coded segments associated with each overarching 
domain (N=10). 
 Sexual identity and stigma 
 Relationship with sex 
 HIV anxiety 
 Motivation for, and initiation of, PrEP 
 The experiences and impact of PrEP 
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Domain One:  Sexual Identity and Stigma  
 Three themes, and seven composite subthemes, were constructed summarising 
participants’ experiences of their sexual identity and stigma. 
 
Theme one: Coming out 
Participants experiences of coming out were characterised by having to negotiate 
heteronormative experiences with their own sexual identity and dealing with the turbulence 
of coming to terms with and revealing their sexuality.  Some participants consciously rejected 
their sexuality and attempted to assimilate themselves into heterosexual relationships.   
 You’re supposed to be straight.   Participants recalled growing up in cultures where 
being gay was not acknowledged and, at times, openly rejected.  Yusuf explained that 
“According to … unfortunately in Muslim cultures, so I mean you can remember 
Ahmadinejad saying that there are no gay people in Iran, so because of that culture…” (para. 
13).   Heteronormative expectations can lead to life trajectories that are fundamentally 
incompatible to embracing their sexual identity.  For example, Finn noted: 
 “I think it comes from me being in Ireland and my Catholic up-brining and first of all 
you’re supposed to be straight, you’re supposed to have, get married, have kids, and 
that’s the end all, whereas like… <chuckles> not really talked about the gay village 
kid that grows up in the city.” (para. 179) 
 
This lack of acknowledgement of difference in sexuality was evident in the sex 
education that participants received, which further alienated their sexual identities.  
Specifically, participants recalled the feeling of being ‘othered’ by the absence of talking 
about health gay sex and relationships.  In turn, by reinforcing heteronormative narratives, the 








 If anyone else in this fucking family turns out to be gay, I’m going to kill them!  
For some participants, the process of coming out was characterised by inner conflict and 
distress.  Mateo remarked that: 
“I didn't fit in with the gays, because gays were openly gay and I wasn't prepared to 
associate with those people then, but I also didn't fit in with the straights. So, I had a 
really difficult time, and I went for psychological help, and I was diagnosed with 
something called avoidant personality disorder” (para. 28) 
 
These experiences of inner conflict and distress contributed to difficulty in openly 
expressing their sexuality or coming out to their families.  Daniel recalled feeling unable to 
come out due to fear of upsetting his family.  Specifically, he said: “Well, remember what 
[my dad] said when my brother came out?  He said, ‘if anyone else in the fucking family 
turns out to be gay, I’m going to kill them’” (para. 38).  
 In response to their own discomfort with, and others’ disapproval of, their sexual 
identity, some participants suppressed their sexuality and initially attempted to live as a 
heterosexual.  Daniel explained that he “tried to be straight; I went on dates … I just wanted 
to please them, because I saw how badly that my parents took it” (para. 38).  Fear impeded 
Paulo’s willingness to accept his sexuality: “Well, sex… effectively, the first time I had sex, I 
was 23 … because I was so terrified and everything, so I had sex with girls, first” (para. 37). 
 
Theme two:  Internalised homophobia.    
Societal messages that do not value homosexuality could lead to internal distress 
regarding participants’ sexuality.   
 It’s just a matter of time.  Participants reported a perceived association between 
their sexuality and an inevitability of acquiring HIV.  Mateo conveyed: 
“… I sort of saw it as some sort of divine retribution; if you mix with those kinds of 
people and you do those things, these are the natural consequences of your behaviour, 






 Bearing witness to other gay men succumbing to HIV perpetuated the sense of 
inevitability, even in the context of using condoms.  For instance, Paulo recalled: 
“I used to ask to my friends on the beach in that time, saying, 'Who's gonna be the 
next one?' because you always … time to time we'd say, 'Oh, this person is positive 
now,' or say, 'Oh, now it's this person,' and then I remember to say with friends, I'd 
say, 'Sometimes I think that it's just a matter of time that one of us will become 
positive.' Including here in London, I said that in a conversation with friends, with 
closest friends, would say, 'Oh … sometimes I think, even used condoms, it's a matter 
of time that the group, or someone will become positive and then the other …'. (Para. 
69) 
 
Everybody gay was promiscuous.  Societal messages around promiscuity among 
gay men are internalised by some.  Daniel reflected on how a conversation with his mum led 
him to associate promiscuity and being gay:    
“…she would sort of like, 'Oh, my colleague, Danny, he's very– he's gay and he's got 
lots of friends, and he's promiscuous' and everything. So everything came to this 
whole thing that everybody gay was promiscuous. I was sort of like, 'I don't want to 
be that bunch,' because it would scare my mum.” (Para. 71) 
 
Mateo cited the national press as a source of his perception that gay men are 
promiscuous, stating that “it is a narrative that’s out there, for the gays to get drunk or high 
and have bareback sex with strangers in a group context; this was in the national press” (Para. 
65).   
 The good gays and the bad gays.  Adoption of heteronormative behaviours and 
rejection of gay identity was associated with increased social rank and acceptability.  Mateo 
suggested that: 
“…I think there's still a perception these days that there's the good gays and the bad 
gays; and the good gays assimilate in society and stuff, on a more heteronormative 
lifestyle, I suppose, so they just happen to be gay. I didn't have that reference back 
then, there was just normal people and … the gays, who weren't part of normal 
society.” (Para. 26) 
 
 
Theme three:  HIV stigma.   
HIV stigma was related to shame due to inferences made about how an individual 





homophobia, bourne out of their lack of internal and/or external acceptance and adjustment to 
their sexuality.  Ironically (given the sense of inevitability some reported), there was also a 
belief that HIV was wholly avoidable and those gay men who did go on to acquire HIV were 
viewed as a failure in sone way.  Marcus conveyed: 
“See, it's different than if it was a non-preventable disease, including like a COVID 
thing; it's like, that's so random, when you might catch something that you can't even 
control as much. Whereas this feels very controllable, so honestly, you kind of think, 
'Seriously? You caught HIV? After all the education we have?' You know, that's the 
kind of mentality I had towards it …” (Para. 63) 
 
 A perception that some gay men who are infected with HIV may be motivated by 
their despair to infect those who are negative appeared to exacerbate HIV stigma.  These 
beliefs mirror societal depictions of those with HIV in the media and and serve to increase 
participants risk perception of HIV in sexual situations.  Mateo surmised that: 
“And the level of anxiety while having sex too, because I was thinking, ‘What if … 
are they trying to,' that sort of thing. I also had this kind of belief that inevitably there 
would be some people who would be bitter about having contracted HIV and would 




Domain Two:  Attitudes towards, and Relationship with, Sex.   
Three themes were constructed summarising participants’ relationship to sex. 
 
Theme one:  It might kill me 
Sex between men is viewed as dangerous and has the potential to lead to serious 
consequences, even in the context of condoms.  Finn explained that the increased prevalence 
of STIs among gay men leads to sex being viewed as inherently dangerous: 
“… because I think life in the gay community, we do have a lot more STD cases and 
it happens and a lot more my friends who are gay have caught STDs versus my 






Sex is viewed as dangerous and even with a condom, is not ‘safe’.  Hamish reflected 
that “because it wasn’t 100%, so you’d always think, ‘Well, maybe that was the time.  You 
know, maybe the time the condom breaks, or you forget to use it or… the one time that you 
can get it from oral sex or even just touching.” (Para. 46). 
The consequence of sex on gay men’s health is perceived as potentially fatal, due to 
the possibility of acquiring HIV infection, which in turn inflicts psychological distress.  
Yusuf thought that “having … seeing sex as a … doing this enjoyable activity, but it might 
kill me, every time.  That was how it was seen by me.  And seeing it like that, and it just 
really … it caused a lot of damage” (Para. 61).    
 
Theme two:  I couldn’t trust anyone 
Instances where partners have taken the condom off without consent have exacerbated 
lack of trust in future partners.  Yusuf explained that he “always had this fear of HIV and it 
got worse through experience, through loss of trust in other people, because people lie” (Para. 
17).  Mateo recalled an incident with a partner which led him to be suspicious of future 
sexual partners: 
“[he] tried to take the condom off, without me noticing. So, that gave me a lot of 
anxiety in terms of, I couldn't really … I didn't really trust anyone in the first place, 
but this didn't help. I couldn’t trust anyone sexually, so I always had to be in a 
position where I could be in control of … like, visual … I could visually see that no 
one was taking off the condom or sabotaging it.” (Para. 79) 
 
 Negative experiences where partners have deliberately taken off the condom led to 
participants needing to be hypervigilant during sex.  Yusuf recalled: 
“…the guy tried to take off the condom during sex, and I felt it on my feet and that 







 Paulo reflected on his time as an HIV nurse and noticing that some patients on the 
ward had been infected by their partners, which left him feeling unsure of future sexual 
partners fidelity: 
“the stories I've been reading in notes of patients that got infected because the partner 
was cheating. But you know, you're not completely sure that your partner can't be 
cheating you; so, I have to risk, I just want to be happy.” (Para. 37) 
 
 Stories in the media reporting on people being deliberately infected with HIV have 
also contributed to a narrative that sex is dangerous.  Yusuf explained that: 
“Like last year, BBC for example had this media of this guy who was positive, and he 
was willingly making other people positive because he said it makes him feel 
powerful.”  (Para. 15). 
 
 Partners that are sourced using geospatial social networking applications (e.g., Grindr) 
are viewed as especially untrustworthy.  Dirk recalled that he was “very worried about not 
being able to trust anyone, especially when meeting someone on an app” (Para. 55).  Partners 
that use geospatial apps are viewed as more promiscuous.  Daniel explained that: 
“It just made me anxious and clam up; I remember dating some people years and 
years ago, when I first came to London and it was the fact that you went on a date … 
<laughs> I mean this the hypocritical– the funny side, it's sort of, I would go onto 
Grindr to see afterwards if they'd gone online; sort of like, 'Oh that date was terrible,' 




Theme three:  Casual sex    
Casual sex is perceived to be higher risk and can trigger anxiety.  For instance, Dirk 
reflected:   
“I would feel a little bit dirty afterwards, not because I was ashamed of having sex, 
but just because I was like, 'I don't if I can trust this person, and whether this was the 
best idea. But I've done it now, so where do we take it from there?' There was a lot of 
anxiety, especially with strangers.” (Para. 55) 
 
 Categorising casual sex as high risk and thus a trigger for anxiety can be a 





couldn’t … ‘cause that incident related to having sex with a one-night-stand partner, I just 
relate dramatic experiences to one-night-stands <laughs> so I couldn’t really enjoy sex” 
(Para. 68).   Even in the context of using condoms, casual sex can be perceived as risky: “… a 
one-night stand even if I’ve taken all the precautions, I still think the risk is there” (Finn, 
para. 68). 
An association between causal sex and HIV can be instilled through others.  For 
example, Daniel concluded that “… this probably stems back to when I first came out to my 
parents age of 21.  They grew up in the era of AIDS and everything, the late eighties, and 
essentially, I got from them was, ‘Don’t be promiscuous’” (Para, 10).   
 
Domain Three:  HIV Anxiety 
 Six themes and fifteen sub-themes were constructed summarising participants 
experiences of HIV anxiety, prior to using PrEP.   
 
Theme one:  It’s part of me   
HIV anxiety was often considered to be intrinsically part of the individual.  Finn 
stated “… if I could get a screwdriver and open up my brain it’d probably be just an absolute 
mess of different sort of shelving units with loads of different scenarios that’ll work its way 
out, but it is what it is.” (Para. 186). HIV anxiety can be made sense as a manifestation of 
other mental health difficulties.  Yusuf concluded that “because of my obsessive-compulsive 
disorder, I was incredibly afraid of HIV” (Para. 12). 
HIV anxiety also appeared to be an intrinstic component of participants personalities.  
Specifically, HIV anxiety is attributed to being pessimistic by nature.  However, there were 
also instances where participants speculated that the anxiety was instilled in them from 





HIV is special.  HIV anxiety is considered distinctly different to other sources of 
anxiety, perhaps due to its pervasive nature and the omniprescence of HIV infection in their 
communities.  Marcus noted that he was not generally anxious about his health: 
“… I used that word as a joke, but I'm not a hypochondriac in my regular health life, 
at all, I mean not really. But in this area, I seem to be risk-averse, quite risk-averse. 
So, it doesn't even matter if it's actually penetrative sex. (Para 21) 
 
 Marcus reflected that “as far as I can figure the HIV one has a special kind of like fear 
factor to it, versus everything else.” (Para. 23).   Participants described that even sexual acts 
considered low risk generated HIV anxiety.  Furthermore, a discrepancy between 
acceptability of risk between HIV and other illnesses was noted.  Hamish elaborated that: 
“Even though I could tell myself that rationally there was very little chance of 
catching it, considering what I'd done. Well, probably zero chance in most cases, but 
somehow, I always used to think, 'It could be this time,' 'You could be the 0.1%.' And 
somehow, 0.1% of catching HIV is a terrible thing, whereas 0.1% of catching any 
other <laughs> disease; you'd say, 'Oh! Well, no chance of that, is there?'” (Para. 46) 
 
 Participants appeared motivated to mitigate any potential risk where possible.  For 
instance, Daniel recalled thinking “‘What if, what if, what if’, I’m always about trying to get 
to zero risk, or minimise it to the closest point to zero percent chance.” (Para 10).  Intolerance 
to any risk of HIV can lead to safety behaviours, such as repeated testing.   
 
 Destroyed my body.  Subjectively, HIV anxiety can result in negative long-term 
consequences on health, which can persist even in the context of no longer experiencing 
acute anxiety.  Finn said that “… it was horrible.  My body wasn’t the same after, and I just 
… I totally … destroyed my body in that sense.” (Para. 39).  Hamish reported that HIV 
anxiety impacted various domains in his life, not just his sexual behaviour: “…it affects all 
the other aspects of your life, as well.  Yes, at times it did have an impact on my mental 






Theme two:  HIV anxiety is omnipresent 
The acuity of HIV anxiety is dynamic, with peaks and troughs of intensity but 
omnipresent background fear.  This persistence is attributed by participants to a sence of 
inevitability, which appears to be cognitive feature of HIV anxiety, in becoming infected and 
their low threshold for perceiving risk.  HIV anxiety is perceived to be a reality for gay men 
that must be managed to engage in sexual behaviour.  For example, Paulo said: “… before the 
PrEP, you always have this question of the HIV back there in your mind, because this is our 
… is the reality.  So, it was a constant situation that didn’t disappear, (Para. 93) 
Participants reported feeling a lack of control in their ability to remain HIV negative, 
despite being objectively low risk.  This can lead to rumination about becoming infected with 
HIV and development of the belief that this is inevitable.  For instance, Yusuf reflected on 
when he first moved to London: “I can’t … that is … it’s like entering the terror zone back 
then, in my mentality, it was a bit like entering the … walking on minefields.” (Para. 19) 
The perceived lack of control over maintaining their HIV negative status can result in 
a diminished locus of control.  For instance, Paulo lost confidence in his ability to remain 
negative and thought he “tried to be careful … using condoms and everything.  But at the 
same time, I thought it might be just a matter of time…” (Para. 69.) 
Paradoxically, testing does not always reinforce that behaviours are not high risk 
through repeated negative results.  Moreover, it can perpetuate a sense of inevitability 
through a perceived inertia towards changing sexual behaviours.  Mateo reflected on his 
testing experience: 
“… after [testing] it was a relief, but it was also a bit of a curse, because then I sort of 
thought, ‘Well, now I need to maintain it, and I haven’t made any changes to my life, 
so it will happen’.” (Para. 59) 
 
Everyone is in a high-risk category.  HIV anxiety is often frequently and repeatedly 





considered high risk based on their sexuality (irrespective of behaviour).  There appears to be 
an inflated sense of risk associated with sexual partners.  Ultimately, partners, especially 
casual partners, are deemed to be dangerous and vectors for HIV infection.   
 
 
Theme three:  Misinterpreting my body 
In keeping with various cognitive-behavioural models of anxiety, HIV anxiety can 
lead to becoming preoccupied with the body and, crutially, interpreting bodily changes as 
evidence of HIV infection, when in fact they are benign or entirely normal.  This is often 
triggered after sexual contact.  Mateo said he was focused on his body to ensure he noticed 
changes: 
“you can present the nodes, you can present the rashes; and of course, all the time you 
have to be … you used to looking your body, if you had symptoms and things like that, you 
know, the sarcomas and … yeah, for sure.”  (Para. 41). 
 
I had a tiny graze on my fingernail.   Hypervigilance for symptoms that may be 
suggestive of HIV infection can often be triggered after sexual contact.  For example, Daniel 
recalled a pattern of anticipatory anxiety relating to the onset of seroconversion illness after 
having sexual contact with a sexual partner: 
“I would go on a date, we had sex and all the other stuff, and then I would sort of be 
clock-watching, 'Oh, it's been five days I’m fine, seven days, oh, I think I've got a 
tickle in the back of my throat,' or 'I think I'm coming down with a cold.' It was those 
sorts of things, or you end up psychologically making yourself think you're ill, when 
you're not. And I don't know why I did it …” 
 
 
Hypervigilance for symptoms that are suggestive of HIV infection is not confined to 
participants’ own bodies but could also include observing others (especially sexual partners) 
for signs and symptoms of HIV infection.  For example, Mateo talks reflected on his 
tendency to look for signs of ARV use in others, such as lipodystrophy and lipoatrophy: 
“I think I've repressed this thought, when I was out in a gay bar, or I met anyone who 
was gay, I would look at them really closely, to see any signs of antiretroviral use. As 





them for a very long time have certain physical signs, which if you looked really 
closely, sometimes you can see. But they may not be because of HIV, they may be 
related to their genetics, or their diets.”  (Para. 51) 
 
 Paulo also reported looking for physical symptoms that might be associated with 
behaviours considered to increase HIV risk to risk-assess potential sexual partners.  For 
example: 
“… what people in gyms term ‘bacne’, sort of like a rash in the back area, which I 
think is more due to steroids than anything else; I've never done them, so I wouldn't 
know. I sort of connected it with a certain lifestyle that some people follow in 
London, where you go to the gym and then go on those parties that go on for days and 
have unprotected sex with as many people as you can find, who are doing a drug 
binge for …” (Para. 53) 
 
Body scanning after sexual contact also has the potential to induce anxiety and may 
not always result in reassurance, despite that being that being one of the motivators.  Hamish 
told of scanning his body for entry routes for HIV after having sexual contact with a partner: 
“… even just touching, and I think … I remember thinking, ‘Ooh, I had a tiny graze on my 
fingernail or something, that could have been a chance to get HIV’.” (Para. 46).  Reassurance 
from others can have a limited impact in reducing anxiety.  For instance, Jon observed: 
“That's definitely been a contributing factor. So yeah … well, I think I've always been 
very much symptom-conscious anyway, which, my friends will go, 'Why are you 
panicked?' 'Why are you worried about it?' 'You've always had safe sex,' but it's a case 
of … I don't know, I am quite symptom-conscious really.” (Para. 43) 
 
This is it!  Distress associated with the appraisal that symptoms were a result of HIV 
infection is common, especially in the context of seroconversion.  Paulo recalled “… when 
you have fever, you always have to think, lots of things … in that time I remember being very 
conscious, and think of, ‘That could be HIV’” (Para. 47).  This anxiety can sometimes build 
up in between HIV tests.  For example, Mateo said: 
“What I … had was anxiety building up during that time, not just health anx– I saw it 
as health anxiety; everything I saw was a sign of damage to the immune system. You 
know, a cold and I was thinking, 'Oh God! This is it! I'm gonna have to go into 







Theme four:  I’m scared because…    
There is variance in the core fears that perpetuate HIV anxiety.  Specifically, although 
some participants were fearful of the potential impact on their physical health (which is 
consistent with cognitive behavioural models of health anxiety), and even death, others were 
fearful of the perceived stigma and social consequences of an HIV infection (which appears 
more consistent with cognitive behavioural models of obsessive-compulsive disorder and also 
the biopsychosocial model of shame).   
 I’d be more concerned about the stigma.  HIV anxiety cognitions can be less about 
the infection itself and more about the perceived social consequences of being HIV positive.  
Finn said: “I don’t think I’m necessarily overly anxious … I think if I caught HIV tomorrow, 
I think I’d be more concerned about the stigma attached to it rather than the disease itself, and 
that’s being totally honest with you.” (Para. 165).  In the context of anxiety relating to how 
others may negatively view them if they were to acquire HIV, shame acts as a feeder for the 
anxiety.  Furthermore, HIV anxiety in this context may be conceputalised as protective, 
insofar it keeps then safe (i.e., HIV negative) and therefore protects them from the shameful 
experience (i.e., becoming HIV positive). 
 
 Stigma associated with being HIV positive was thought to be related to others 
viewing them as promiscuous if they were to test positive.  Jon explained that: “I think with a 
lot of people, there's still that kinda cliché around HIV and promiscuity. That I suppose I 
would have shame being associated with, although that’s not always the case and people can 
transmit HIV in all sorts of ways” (Para.  23).   HIV anxiety in the context of being fearful of 
loss of social rank appears to be a manifestation of homophobia, both externally (via previous 
experiences and societal narratives) and internally (via their own negative beliefs about 
homosexuality and HIV).  This can be illustrated in perceived differences between how 





Mateo thought that there may be a difference between how gay and straight people may think 
or respond when finding out someone is HIV positive:   
“I think still … these days you go to a straight person and I think if you ask them 
what's the first thing that comes to your mind if told you they were HIV-positive, it 
would probably be something like disgust or fear, rather than surprise or compassion, 
or anything else …” (Para. 29) 
 
 It was perceived that an HIV infection may result in social isolation and being 
ostracised by those in their lives.   Finn reflected on his fear of his relationships breaking 
down: 
When I was catastrophizing that, when I was having a breakdown, it wasn’t my 
compromised immune system. It was, when I think back it was more about what 
would people think. I felt like I’d never have a boyfriend, who’d want me, my mum 
and dad would disown me, other such thoughts, which is completely untrue. However, 
at that moment in time …” (Para. 166) 
 
 The fear of stigma can be so pronounced that it can prompt suicidal thoughts at the 
thought of being HIV positive.  For instance, Mateo reflected on his decision to not collect 
the results of his first ever HIV test:  
“So, I never collected the results. Back then … I think my perception has changed 
now, but I remember how I saw it then, it was … for me it would have been 
preferable to be dead, than to be living with HIV, because of the huge, huge stigma 
that it had.” (Para. 22) 
 
 I’m going to die.  Despite drastic improvements in the prognosis associated with 
HIV, the impact of the early years of the epidemic has had a lasting impression.  There 
appears to be a legacy effect.  The fear of death makes HIV different from other sexually 
transmitted infections.  Marcus said “and then, also … well, there’s the whole … the fact that 
it likes death, right?  That’s what makes it different to the other ones” (Para. 27).  Daniel 
commented that notoriety of HIV being associated with death is linked to his experience of 
HIV anxiety: “it’s been because the fear of the HIV is that one that, ‘Oh, well, that’s a kil–' 
you know, other people’s mindsets, ‘Oh, if I’ve got HIV, I’m going to get AIDS, I’m going to 






Theme five:  I need to keep myself safe.   
Motivation for taking PrEP stems from a desire to safeguard their HIV negative 
status.   
 Sex is on another land.  Avoiding having any sexual contact with other people can 
be used as a strategy to manage HIV anxiety.  For instance, Yusuf recalled: “Then the first 
three years [in London] I was also celibate … I read on the internet that London is the HIV 
capital of Europe, and one out of seven gay men are positive.” (Para. 19) 
 Although for some this strategy eliminates their subjective risk of becoming HIV 
positive, it does not fully abate anxiety in others.  For example, Yusuf said that despite “being 
celibate for five years” (Para. 17), “I felt … again I was aware that if I continue to be celibate, 
I’m not going to, most probably I’m not going to get, but …” (Para. 35).  Avoiding sex 
completely may adversely indirectly impact self-care due to low self-esteem and a sense of 
hopelessness.  For instance, Yusuf elaborated: 
“… because sex was not a potential thing for me anymore, there was no reason for me 
to look after myself … and I was so used to the practice of … on the street I see this 
guy, oh he’s very handsome, and that is it – the potential of that following into 
anything else was dead to me. So, it sort of … I felt like sex is on another land and I 
am on this other land. So, there is no reason for me to be sexually attractive.” (Para. 
66) 
 
 Setting rules around what sexual activities are acceptable, in terms of the level of 
anxiety elicited, can help avoid becoming HIV anxious after sexual contact with a partner(s).  
Hamish for instance, said: “So yes, what I would allow myself would be basically mutual 
masturbation, and anything else would be a source of worry; oral sex, fingering, all that kind 
of thing …” (Para. 88).  However, due to the fluctuating nature of HIV anxiety, and thus 
changes in cognitive patterns (i.e., decision making), these boundaries are unrealistic and 





 HIV anxiety may lead to rumination before, after and during sex, which can sexually 
inhibit; this in turn reduces sexual satisfaction.  For instance, Finn said: 
“I know it sounds really stupid, it’s the last think you’d think you’d be thinking about 
after engaging in sex, but I always had it there and I couldn’t get rid of that, and it 
would make me be a lot more reserved when it comes to sex or just not fully engaged 
in that moment. I was more, my mind was elsewhere even though my body was 
somewhere else.” (Para. 78) 
 
I’m more in control.  Seropositioning can afford an increased sense of control.  Finn 
reflected that he is normally the insertive partner during anal sex as this gives him a greater 
sense of control over the situation and therefore helps reduce anxiety: “I just feel like I’m 
more in control of the situation when I’m topping because I’m putting on the condom and I’m 
kind of more …” (Para. 88).   
 Being the receptive partner during anal sex can give rise to anxiety about giving the 
other partner(s) more control during the sex, which increases a sense of risk.  Increased 
control during sex can extinguish anxieties that the other partner(s) may deliberately tamper 
or remove the condom.  Mateo said: “I couldn’t trust anyone sexually, so I always had to be 
in a position where I could be in control of … like, visually … I could visually see that no 
one was taking off the condom or sabotaging it.” (Para. 79). 
Reassurance.  Access to PEP can be problematic for people with HIV anxiety when 
the subjective risk does not correspond with the objective risk.  This can be perceived as 
unfair as it does not factor in anxiety.  Mateo, for example, said of access to PEP in the UK 
NHS: 
“The way I saw it is, there is a risk, more than a theoretical one. It may be low, so 
what they're going to be doing is … essentially, you're rationing PEP, because it's 
very expensive for a publicly funded health system …I felt that in this situation, I was 
entitled to accept … to decide what the benefit was, and for me, the benefit was more 
than producing a low chance.” (Para. 69) 
 
 
 Commencing PEP may have a paradoxical effect in the context of HIV anxiety; 





periods of anxiety after engaging in a perceived risk behaviour.  The pursuit of PEP in the 
context of low-risk situations can lead to a person providing the health care professional with 
an inaccurate history, to inflate the level of risk, to ensure that they access the treatment.  For 
example, Mateo said: “I had one course once and then that kind of increased the anxiety, so 
then I would find myself lying; I sort of knew what the criteria were for PEP, which boxes I 
had to tick …to ensure that I would be prescribed PEP when I felt I needed it.” (Para. 39) 
Seeking reassurance can temporarily alleviate anxiety at times of acute 
distress.  For instance, Finn said “obviously the team here are great and calmed me down and 
did everything they could to reassure me and get me out of that period, but it definitely 
wasn’t a great time” (Para. 35).  Similarly, Dirk described seeking reassurance from a health 
care professional at the sexual health clinic after a low-risk sexual contact:   
“Oral and … there was contact, and it went in like, once accidentally, which [the 
clinic] then reassured me that that was very unlikely to have happened anyway. And 
he said that he was on successful treatment for like, 22 years, which is a long time.” 
(Para. 53) 
 
Despite inherent difficulties with reassurance, it can be seen as being responsible and 
helps maintain health by being ‘safe’.  For instance, Dirk said: “…but I do, as soon as 
something feels out of the ordinary, get worried that it could be something really serious and 
I'd rather be safe than sorry, by knowing.” (Para. 47) 
 
 
Theme six:  HIV testing    
Testing for HIV can be traumatising and trigger memories of the early days of the 
epidemic in their communities.  Paulo reflected on his experience of HIV testing: “I … it has 
rescued all those feelings that I have in the late eighties, and the beginning of nineties, that's 






 Finding it difficult to wait.  The latency between having a perceived risk and being 
able to have a valid HIV test is associated with increased anxiety, which can impede 
functioning.   For instance, Hamish reflected on the impact of having to wait to be out of the 
window period: “…I would start to get quite anxious and really worried and … finding it 
very difficult to wait those three months, the window to get tested.” (Para. 46). 
 HIV testing is rarely a one-off event, and the expectation of regular testing is also 
associated with increased anxiety.  Jon reflected on his experience of being reminded that he 
was due to be tested: “… let’s say, I’d get a notification; it’s like, ‘Oh, it’s been three months 
since you’ve been, are you gonna go in for another test?’ and that’s probably when the 
anxiety would come.  So, I think it was always more around testing, really” (Para. 36).  
Anxiety induced by the frequency of HIV testing can result in avoiding being tested.  Daniel 
explained the reasons why he did not engage in testing as much as he would have liked: “Not 
as frequently as I’d like, and there would always be … so, I would be waiting to get the test 
and it would always be worst-case scenario in my head” (Para. 50). 
 Waiting for the result of an HIV test is associated with acute anxiety that impedes 
ability to engage with other demands, such as employment and self-care.  Nathan explained 
that “for me, how they were? Oh, <sighs> I would get very little done, thinking about this 
and that … and keep thinking about it constantly, so not a really pleasant experience overall” 
(Para. 16).    
 
 You’ve reset.  Although the experience of having an HIV test is aversive, in anxiety 
both before having the test and when waiting for the result, the experience of receiving a 
negative result provides psychological relief.  For instance, Paulo said of receiving a negative 
result: “when you had the results that is negative, is like you feel that's a huge weight is lift 





 The potency of a negative result has the potential to temporarily eliminate anxiety 
through certainty of being HIV negative: “… because I always felt like, once you go into the 
clinic and the clinic was like, ‘You’re fine!’, it kind of felt like you’ve reset or something, 
like you’re, ‘I’m totally fresh’, something like that” (Marcus, para. 51). 
 Given the psychological relief that is associated with receiving a negative HIV result, 
this can be used as a strategy to elevate HIV anxiety.  Hamish said this of his pattern of 
testing: “I have used it to relieve anxiety, but it is painful to get to that stage; because of the 
three-month window, it could be a long, painful wait.” (Para. 72) 
 
 
Domain Four:  Motivation for, and initiation of, PrEP 
Five themes and ten subthemes were constructed summarising participants’ 
motivations for, and the experiences of initiating, PrEP. 
 
Theme one:  How did I manage it?  I just didn’t!    
The persistence and intensity of HIV anxiety can overwhelm and be experienced as 
unmanageable and intolerable, which serves as motivation for initiating PrEP.  Finn said this 
of his of his HIV anxiety: “How did I manage it?  I just didn’t!  I just … I ended up just 
probably drinking too much as well …” (Para. 74).   Presenting to sexual health clinics in an 
anxious state can lead to clinicians to tentively recommending PrEP to reduce psychological 
distress, especially in the context when participants repeadedly attended.   
I wasn’t trusting condoms.  It is acknowledged that condoms significantly reduce 
HIV risk, but they are conceptualised as problematic.  Marcus said that “I recognise condoms 
are pretty fail-safe; except sometimes” (Para. 76).  A sense of a lack of control regarding 





because I never trust 100% in a condom, because … things happen … and I could be 
infected.  It’s not 100% reliable and it’s just a barrier …” 
In the context of a condom failure, this can be internalised as a personal failing and 
lead to negative cognitions regarding responsibility.   
When condoms fail it can be challenging to reassure the other partner, which can lead 
to feelings of guilt when unable to negotiate the conversation.  Daniel reflected: “…the 
condom broke, and the other person said, 'Oh, no, I'm fine, I'm a nurse,' and all this stuff, 'Are 
you OK?' and I was like, 'Oh, yeah, yeah!' But I didn't really know … that was a wrong thing 
of me.” (Para. 20) 
Initiating PrEP is a means to mitigate against the lack of reliability of condoms.  
Marcus remarked: “Condoms have their breaks, but this is like the insurance policy, that’s the 
way I kinda look at it” (Para. 8).  This lack of trust in condoms can also lead to ambivalence 
and resentment.  Mateo stated that “I was starting to get a bit of condom-fatigue” (Para. 16). 
I need to enjoy myself before it’s too late.  Participants expressed a sense of urgency 
to engage in sexual behaviour that is absent of anxiety.  There appeared to be a sense of 
sadness and loss, in relation to their sexuality, as a consequence of HIV anxiety.  PrEP was 
perceived as a route out of this and gave a sense of hope.  HIV anxiety is associated with 
sexual inhibition which can lead to a resentment and frustration.   This is perpetuated by a 
perception that they would no longer be sexually attractive and be able to engage in sexual 
activity.  Yusuf said: “I want to experience more because if I’m not going to experience a lot 
soon, then I won’t experience as much as I want” (Para. 110).   
Because of HIV anxiety, sex is not as enjoyable and therefore PrEP offers a way to 
reconnect to their sexuality by muting anxiety.  For example, Marcus said that: 
“I'd say, 'Oh, it's OK, I don’t think I've ever enjoyed sex anyway.' Like, I'd said 
something flippantly like that in different ways and they took it as like, 'Have you –' 





happened, that I was referred to [the clinic], because I got referred to, or it was 
suggested, 'D'you wanna speak to a counsellor?'” (Para. 35) 
 
 Perceived ageism in the gay community, especially in the context of those in sexually 
submissive roles, can increase the sense of urgency to engage in sexual behaviour and 
therefore increase motivation to initiate PrEP.  Yusuf explained: 
“…because I feel like there was this party going on, and I arrived at the party, it was 
about five minutes before the closing, so I need to … I feel like I need to make the 
best of it, because the entire gay and kink community is telling me that in two years I 
need to forget about sex and being a sub” (Para. 109)    
           
  
Regret over abstaining or inhibiting sexual activity can result in people feeling like 
they have missed out, in comparison to their peers.  For instance, Daniel said this of his 
motivation to start PrEP: “I probably didn’t have as much fun as I should have done, when I 
was a lot younger.  And in some ways … I regret that I didn’t have what a lot of other people 
had …” (Para. 15) 
 
Theme two:  Responsibility   
Initiating PrEP is viewed as being responsible and a way to proactively reduce 
subjective HIV risk.  For instance, Marcus reflected: “But it’s just like, what a great insurance 
policy PrEP is.  And I use that phrase, because it’s happening in the back … sorry, it’s taking 
care or something without you having to do anything and …” (Para. 63) 
 It’s irresponsible of me to go and do that.  There is a tension between the view that 
anal sex without a condom is irresponsible and yet this being the sex that is sought by some.  
Initiating PrEP results in condomless anal sex being viewed as more responsible, and 
therefore more favourable.  Nathan explained: “I accept that if I want to play that way, there 
are possibilities that can happen and that it’s my duty to myself but also to others, to be as 





 Condomless anal sex within relationships is something that can be missed when the 
relationship ends.  In this instance, PrEP can offer an opportunity to facilitate anal sex 
without compromising a self-view of being responsible.  Dirk said this of his desire to start 
using PrEP: “But then after that, that relationship ended and I was like, ‘OK, I do still really 
like unprotected sex, <laughs> but it’s irresponsible of me to go and do that with just anyone 
I meet online, or anyone I meet in general’” (Para. 24). 
The sense of responsibility is not confined just to their own health but also to that of 
their partners.  Taking PrEP is a means to protect other people; for instance, Dirk said “this is 
the responsible thing to do, because I don’t wanna unknowingly have something and then 
give it other people’” (Para. 47).  Daniel likened his motivation for taking PrEP to health 
behaviours associated with COVID-19: 
“… everyone has a responsibility to wear a mask in a shop, and to socially distance 
where they can. And to me that's equally the same, it's another virus that instead of 
you transmitting through coughing, you transmit it through blood and semen and 
stuff. And why wouldn't you want to safeguard other people?” (Para. 87) 
 
 Anxiety associated with the possibility of infecting others with HIV can result in a 
reluctance to engage in sexual behaviours.  Initiating PrEP can be motivated by a desire to 
reduce this anxiety due to the perceived increased protection it affords the user (and by proxy, 
their partners).  For instance, Dirk explained: “Not very frequent; because of the whole 
situation, I just felt a lot less … eager to have sex.  No, that’s not true! <Laughs> I think I just 
generally felt like I could have been putting people at risk, which … so I don’t know why I 
thought that.” (Para, 105). 
 I’ve always been the serious one.  Being responsible in relation to the preservation 
of our own health is viewed as a pro-social behaviour and therefore valued.  Dirk said this of 
his decision to initiate PrEP:   
“And I also wanna protect myself, so I started looking into it more; there's a few 
people I follow online who are also like advocates for PrEP, as well. It became more 





myself and the people I was possibly having unprotected sex with, or any form of sex 
with.” (Para. 24) 
 
 Pursuing behaviours that are seen as responsible (i.e., taking PrEP) can be a 
consequence of the roles we have in our lives and the expectations associated with these.  
Daniel said: “I’ve always been the serious one in the family, so there’s always been an 
expectation that I would be the responsible, or that’s the burden that I’ve always felt from 
them …” (Para. 12).  Paulo explained that he felt as a nurse it was his responsibility to take 
PrEP after a condom failure: “Oh, my God!  How can I, as a nurse and believing that the 
condom is a good thing and protect effectively, how can I be failing so basic act that just 
protect myself and other person?” (Para. 12).   
 The motivation for initiating PrEP can also be associated with a view that it is 
responsible to reduce anxiety-associated behaviours, such as seeking repeated testing.  Daniel 
explained: 
“And I think everyone should be able to be in charge of their own bodies… you get 
some people that are so worried about themselves that they go and get a medical 
every six weeks sort of stuff and pay fortunes for private check-ups and scans and 
ancestry and blood tests and DNA and all the other stuff, because they're worried 
about … I'm not to that level, but it's sort of like … my mindset is, 'Well, why 
wouldn't you want to protect yourself?'” (Para. 52) 
Theme three: Accessibility 
Socioeconomic factors, such as income and employment status, can impact on an 
individual’s ability to access PrEP.  Mateo reflected on his inability to purchase PrEP: “…at 
first, I was a student and then I was unemployed for a few months and then I was on 
minimum … well, not minimum wage; I was on a very low wage. So, I couldn't really afford 





 The IMPACT trial can be viewed as an attempt to placate those pushing for increased 
access, whilst continuing to not offer universal access to those who would benefit.  Mateo 
said of the trial: “… I know there wasn’t really a trial, it was a manoeuvre by the NHS to pay 
less for it and delay the roll-out.” (Para. 103).  The view that PrEP should only be accessible 
to those who are high risk is contested and undermines personal choice.  Daniel explained 
that he would continue to access PrEP privately if he was unable to access it via NHS:  
“I think it's important that everyone has a choice; everyone has autonomy over 
themselves, and I think everyone should be able to do what they need to do. If it 
wasn't on the NHS in the future, I would still pay for it privately, that's my position 
because it's providing me with a level of reassurance.” (Para. 52) 
 
 It’s just another forestall.  The impressive outcomes reported in the clinical trials 
can be difficult for some to believe.  Hamish recalled his initial impression of PrEP as a 
strategy to reduce HIV infection: “It seemed a bit too good to be true, and I was like, ‘Well, 
yes, maybe it’s an improvement, but unless it’s pretty near 100%, then it’s just another 
forestall’, I suppose” (Para. 28).   Anecdotal reports that PrEP is close to 100% are not 
viewed as supported by clinical trial data; its efficacy was therefore initially met with caution.  
For example, Yusuf said: 
“I would love to say … it is actually 100%, but the cases where the people actually 
quoted was, they didn’t take it properly and stuff. But I don’t know if that is saying, 
not taking properly, it doesn’t sound very scientific to me.” (Para. 54) 
 
Phoney medication.  PrEP that is self-sourced and a generic formulation of the drug 
can result in anxiety over the authenticity (and thus efficacy) of the treatment.  Nathan said 
“well, it made me think that if I get it from an official source and I know that at least I’m not 
getting phoney medication.  Which is a bit of a terrifying thought, but for something like that 
I will never consider that” (Para. 44).   
 Engaging in pharmacokinetic testing to determine the effectiveness of the medication 
via NHS clinics provides some, albeit fleeting, reassurance for those who are sourcing 





clinic] were sort of saying, ‘We can’t give you the PrEP itself, but we can test you to see if 
you have the right levels of it’.  I was sort of on and off because I didn’t trust it that well; it 
was fairly new, I could never be certain …” (Para. 16). 
 
Theme four: Daily is best for me.   
There are various factors that motivate one to take PrEP daily.  For instance, Finn 
explained:  
“I’m trying to get back into daily because occurrence is probably not … it’s kind of 
hard to plan when you’re gonna have certain experiences <laughs> like that, so … 
even though I would persist in using condoms during sex, it’s still … I still like to 
know that I’ve taken it…”  (Para. 41)\ 
 
 Things are not always planned.  Using PrEP daily is associated with the ability to 
engage in sexual behaviour spontaneously and without the need to forward plan.  Dirk 
explained that “… and I don’t like the idea of having to plan out sex, if that is gonna happen, 
like that you have to take one dose 24 hours before and then two doses afterwards or 
something” (Para. 37).  In the era of geospatial applications to facilitate meeting others for 
sex, planning for sex is not always practical.  Yusuf said “… and these things are not, 
especially in the era of Grindr, these things are not always planned.  It’s very spontaneous 
and everything” (Para. 33).   
 Daily PrEP may result in a decrease in HIV risk and therefore afford opportunities to 
engage in spontaneous sex.  Jon said this of his choice to take PrEP daily: “Yeah, because I 
kind of think, if the mood does strike me and I suddenly think no, get over yourself, if I start 
to feel a bit better, I wanna just be able to … just get on with it, <laugh> and not have that 





Uncertainty regarding the effectiveness of event-based dosing and one’s ability to 
manage the regime can undermine confidence.  Conversely, taking PrEP daily reduces 
uncertainty, increases confidence and, ultimately, trust in its effectiveness.  Dirk explained:  
“I think the reason I don't just wanna use it when I am about to have sex, is just 
because I feel like, 'What if I didn't take it long enough in advance? Or, too long in 
advance? The 24 hours; what if it was 19 hours? Or what if it was too long ago?' I 
don't know the science well enough to trust that aspect of it, or myself, so it just seems 
to … makes more sense to me.” (Para. 43) 
 
 I know that … there is sex going on.  In the context of an open relationship, daily 
PrEP offers an increased sense of safety to both the user and their partner.  Daniel reflected 
on his decision to take PrEP after opening his relationship with a partner: 
“[He is] going to a number of different parties with lots of friends that he's recently 
met and it's sort of made me a bit nervous, because I know that … there is sex going 
on and stuff, so I just want to make sure that … I don't know whether it's always 
protected sex, so I always wanted to safeguard myself as much as possible.” (Para. 
26) 
 
 I’m very good at maintaining a routine.  The taking of PrEP daily allows for it to be 
incorporated into one’s routine.    Daniel explained that “…and for me, a routine … I’m very 
good at maintaining a routine, it’s sort of like … it removes that what-if situation in my head 
again” (Para. 24).  In turn, this is perceived to make it less likely to be taken incorrectly 
(therefore maximising protection).  For instance, Paulo said: “I felt I could be more protect, 
because taking every single day, even though they say it's OK taking one situation.  I think 
for me to be organised and to avoid forgetting to take the PrEP, I built up, wrote in every 
single day to take the tablet in the morning.” (Para. 22) 
 
Theme five:  EBD works best for me 
Although most participants reported taking daily PrEP, some did use event-based 
dosing (EBD).  Taking medication daily in the absence of sexual contact can be viewed as 





weekends when something … sometimes for longer periods … Well, because I wasn’t having 
sex all the time, and it didn’t seem necessary to take medication all the time when it wasn’t 
necessary.” (Para. 32-34) 
 
 
Domain Five:  The experience and impact of PrEP 
 Five themes and seventeen composite subthemes were constructed summarising 
participants’ experience and the impact of using PrEP. 
 
Theme one: Facilitating a sexual life   
Taking PrEP impacts positively on sexual functioning and satisfaction and therefore 
facilitates a sexual life that is congruent with one’s sexuality.  For instance, Yusuf said: 
“I’m actually taking all precautions that science allows me to take, so… I wanna have 
sex. <Laughs> I wanna have a sexual life. And I’m incredibly sexual…I’ve always 
been incredibly sexual. And a bit kinky <laughs> as well. So, I was like yeah, I wanna 
live my life and taking PrEP … was one of the best things that happened to me.” 
(Para. 24) 
 
Express myself sexually.  Using PrEP can facilitate engagement in sexual behaviours 
that were previously avoided due to HIV anxiety.  Marcus said this of the changes in his 
sexual behaviour: 
“I'm 44, I almost never performed oral sex, and not because I didn't want to, but 
because I just saw it as like super-high risk, even though I knew the … people like you 
with … clinicians would say, 'No, that's not exactly the case,' and all that. So, I could 
never … and since PrEP, although again I just think in general, it's just quite personal, 
so I don't really like to do … unless I really like the guy I don't do that kind of thing, but 
I have engaged in it, which is like, and it's been enjoyable, just because of PrEP. That is 
100% PrEP.” (Para. 99) 
 





sexual desires.  Hamish reflected on the role of PrEP in sexual expression: “I always had a bit 
of a terror of HIV, back in the eighties, nineties.  And somehow I seem to have got to a stage 
in my life that I’ve moved on from that and this gave me an opportunity to express myself 
sexually in a way that I hadn’t really tried to do before” (Para. 14). 
It’s just pleasure.  Before taking PrEP, sex was often associated with significant 
stress and anxiety, which impacts sexual satisfaction.  After taking PrEP, the reduction or 
removal of HIV anxiety facilitates increased sexual satisfaction.  Yusuf had this reflection: 
“The fear bit is completely, it’s been stripped away and … now it is what it’s supposed to be.  
It’s just pleasure … well, and pain if you want to!” (Para. 98).   
The negative consequences associated with sexual contact are weakened and this 
results in greater sexual satisfaction.  Finn explained: “And now I’m a lot more … though I 
have, as I said, a bit of anxiety, it’s not massive, and I think it’s not massive, but I definitely 
don’t link catastrophe to sex anymore <laughs> which is the main thing.  And it allows me to 
enjoy sex” (Para. 84).   
Increased sexual satisfaction is also a by-product of feeling more protected against 
HIV and the associated positive affect and confidence.  For example, Paulo said: 
“I can tell you, I feel more relaxed and more confident at the same time, even though I 
have this perception that risk might be high, I think I'm more protected. So, it's 90% 
more of protection that I hadn't before, so that gives me more confidence and I can 
enjoy more sex without concerns. Or, not much concerns.” (Para, 87) 
The reduction in the cognitive load associated with HIV anxiety, allows for attention to 
be focussed on arousal and sexual enjoyment.  Nathan, for instance, noted: 
“Well, I guess that being able not to worry specifically about that, means that your 
mind, or in this case my mind, can be fully focused on the actual enjoyment. Of course, 
I'm sure that you will know that, I mean being a man yourself, that when we are in the 
heat of the moment, we really don't think that much. Because like someone I knew once 
said, 'The Lord gave us both brain and genitals, but only enough blood to get one of 






I enjoy bottoming.  PrEP use is associated with changes in sexual positioning.  
Specifically, receptive anal sex is an activity that one engages more frequently.  For instance, 
Hamish said “… it’s made me better able to express what I want to be, as a gay man, yes” 
(Para. 166).  Satisfaction during receptive anal is also increased; for example, Nathan said: 
“… because even now, I’m still very surprised at how much I enjoy bottoming” (Para. 198). 
In the context of latex allergy, receptive anal sex is more enjoyable as it allows for 
condoms not to be used.  For instance, Nathan reflected: 
“… because of the allergy, yes. And when I go without it, these problems have been 
minimised. Of course, one could argue that the risk of becoming HIV- positive 
outstrips the risk of suffering a little bit from piles or whatever they're called, 
haemorrhoids, or things like that, which is where PrEP comes into account.” (Para. 
161) 
 
More prone to doing it.  A reduction in anxiety and increase in sexual satisfaction 
results in engaging in sex more frequently and with more partners.  Nathan said: “But being 
able to it do it with greater serenity and without all the collateral issues that I mentioned 
before, have definitely made me a little bit more prone to doing it” (Para. 196).   PrEP 
recalibrates risk tolerance through less thorough and sensitive risk assessments.  Marcus, for 
example, said: “… actual sexual activity I would say, increased, because I have less … fear 
around it, so there’s less of a decision tree in my head, like, ‘Is it really worth it?’, like, I’d 
kind of say, ‘Is it really worth hooking up with this guy’” (Para. 98). 
 
In the context of sex within a relationship, an increase in sexual activity is associated 
with the reassurance PrEP gives in protecting against the acquisition of infection from their 
partner.  For instance, Daniel stated: 
“It happens more often, because every time that we used to do it, I would be thinking, 
'Oh, he was at a party the other night; Oh, what if this happened?' Again, worst-case 
scenario, so sometimes it'd be like, 'Oh, I'm not in the mood, he's probably had his 







Theme two:  Change in risk perception 
Activities that were once considered to be high risk are downgraded after using PrEP.  
I’m much freer now.  The protection afforded by PrEP results in engaging in sexual 
practices that were previously deemed too high risk.  For example, Mateo said: “So yeah, to 
answer your question, I think it can be for a lot of people, because in a way it's a sort of get-
out-of-jail-free card, if that makes sense? So, a lot of people wouldn’t have put themselves … 
wouldn't have joined certain scenes if it weren't for this, I suppose.” (Para. 139).   There is a 
sense of being liberated from risk; for example, Hamish said: “Now, I’m much freer now.  
Now I will have anal without condoms, fisting … no, I feel much more liberated in what I 
can do.” (Para. 110). 
Although some may not seek out ‘riskier’ situations, their tolerance of risk is higher.  
Finn, for example said this: 
<Pause> I mean in a really honest way, I suppose … if an incident happened that I … I 
suppose I’d be a lot more comfortable with letting someone … letting my body touch 
someone’s body without a condom. Not necessarily inserting but like just really edging 
and stuff like that, that I wouldn’t have done before. And I wouldn’t be so fearful about 
it anymore. (Para., 88) 
 
As the threshold for risk increases, this is not always welcomed and can lead to regret 
and shame.  Yusuf, for instance, spoke of using drugs during sex for the first time: 
“I once … there was this cute guy who invited me to a chill-out. I didn’t even know 
what a chill-out meant. I asked him to explain to me what it is and I went there. Oh my 
god! They were … pumping stuff up their holes. I don’t know what it was. And I was 
like, I tried G there for the first time in my life and I don’t think I want to try it again.” 
(Yusuf: 134) 
 
Theme three:  Disclosing I’m on PrEP 





Oh, you’re on PrEP and you’re also using condoms?  It is perceived to be 
uncommon to use PrEP and condoms simultaneously and therefore potential sexual partner(s) 
are perceived to sometimes make negative judgements.  For instance, Yusuf said: “But of 
course one of the things that people are always very surprised that, ‘Oh, you’re on PrEP and 
you’re also using condoms?’ That is … stupid to many people.  They can’t understand.” 
(Para. 103). 
 Geospatial applications used by gay and bisexual men have the option for users to 
display whether they use PrEP or not.  Dirk said this of people contacting him on an app: “I 
have put it on dating app profiles … Oh God! … it's on my Grindr. I don't know if that makes 
people assume that I really want to just have bareback sex with them. I've had people reach 
out to me specifically because of that.” (Para. 149-150) 
I have to justify it.  The association between PrEP and high-risk sexual behaviour 
leads to some having to justify their motivation for using PrEP to mitigate any negative 
judgements that may be made by others.  Finn, for example, said: 
“I always had … it’s weird, I always have to justify, if I talk to my friends about it, 
‘cause they ask about it or have a conversation and I kind of explain what it is and 
then I always have to explain that it’s not because I’m having loads of sex; it’s just 
because … I have to justify it, in a way, which … is absolutely ridiculous when you 
think about it. But –” (Para. 177) 
 
It’s good for people who have anxiety.  There is a motivation to promote the 
positive experience of using PrEP, in the context of HIV anxiety.  Daniel said this: 
“because I wanted to demonstrate that it's good for people that have anxiety to be able 
to access it, 'cause it means that they will go and test, they'll go to the clinic, they'll be 
more … they'll have more open, frank conversations, they'll have a more active and 
enjoyable life and … I know I have stopped doing stuff in the past, because I just 







Theme four: STIs    
Other sexually transmitted infections (STIs) generate less distress than HIV. 
It’s more of a chore.  Testing positive for, or being informed you are a contact of a 
person with, an STI is perceived as inconvenient due to having to physically attend a clinic.  
For instance, Nathan said: 
“It’s more of a chore to actually go there and get the injection and being really 
assertive to health operators on the phone; because apparently, the health policies of 
sexual health clinics keep changing about whether to give the preventive shot or not, 
or to simply not, or keep monitoring. I was more bothered about actually having to go 
there, rather than from the actual thing itself.” (Para. 87) 
 
It’s like ‘och!’  Although testing positive for an STI is stigmatised, this appears 
to be less impactful than stigma associated with HIV.  This may be a result of the transient 
nature of STIs.  Finn reflected on his experience of being diagnosed with STIs since using 
PrEP: 
“With gonorrhoea and chlamydia, it's like ‘och!, what’s the clinic gonna think?’ I’m 
kind of rationalising it, I’m not gonna see those people again, they’re there for a 
reason, there’s no judgement there, I don’t need to tell my friends and family, they 
don’t to know about it, we can treat it.  I can kind of package it differently, whereas 
with HIV it’s a lot more ‘cause I’m like I’ve gotta take pills for the rest of my life, my 
parents are gonna disown me, they’re gonna know because I’ll have pills with me all 
the time, all this stuff goes on in my head and it’s just like it’s absolutely tiring for my 
mind to think like that, and I don’t know why I think like that.” (Para. 170) 
 
It’s a short-term issue.  The impact of STIs on one’s health is perceived to be less 
severe and therefore they are associated with less distress.  Marcus explained that “I guess 
realistically, if you were to get something else, or a lot of things you can get, you could take 
an injection for, pill for, whatever; it’s a short-term issue … HIV is just like capital letters in 
red, you know, very bright kind of thing, whereas the others are just like a whole suite of 
crap.  But this is just different, so that dropping off has completely reduced my anxiety, yeah” 






 The imagined guilt one would experience if they passed on an STI to their sexual 
partner(s), compared to HIV, is less.  Consequently, the distress associated with the potential 
of an STI is less.  For instance, Dirk reflected: 
“I know that they're treatable, most strands; there is some untreatable ones, but I'm 
pretty sure they're very rare. So, I know that they're treatable, and so I think it's a case 
of there's less worry about … it feels less serious… this is the wrong phrasing, but it 
feels less serious to give someone gonorrhoea or chlamydia, than it is to give them 
HIV, because HIV will define the rest of their life, whereas gonorrhoea defines the 
rest of their next three weeks while they take antibiotics, or however long depending 
on the infection. But yeah, it feels less serious; obviously it's still not ideal and you 
should be responsible with your sexual health and the sexual health of others, but I 
think it feels, for me it feels less of a horrible thing to do to someone, even if you are 
doing it without knowing.” (Para.130) 
 
Theme Five:  HIV Anxiety  
Taking PrEP results in a reduction in HIV anxiety.  Nathan stated “Well, by taking it, 
it means that I no longer have to worry constantly about becoming positive” (Para. 104).  The 
association between being gay and HIV is weakened.  For instance, Mateo said “because I 
think a lot of people had a lot of HIV anxiety and trust issues, which are now irrelevant.  So, 
please feel that they’re in control again and that that … the link between gay sex and disease 
and social stigma is no longer relevant” (Para. 105). 
 The reduction, or in some instances, the removal of HIV anxiety can lead to less stress 
in one’s life and thus promote psychological wellbeing.  Jon explained: 
“I see it as a way of just taking a little bit of worry out of my life, knowing that if I 
have sex and anything were to go wrong, I've just got that extra bit of protection … in 
the same way that contracepti– you know, that condoms do that, or the same way that 
getting a vaccina– getting the hepatitis B vaccination or getting the HPV vaccination 
gives that … it just gives me a little bit less worry in my life. And I kinda think, 'I've 
got enough worry in my life as it is, so why not take something that's just gonna make 
it even easier?'” (Para, 68) 
 
PrEP is a relatively easy way to control anxiety that does not require a lot of effort.  





“… it's sounds a bit weird to say this, but you know with this COVID thing? You'd 
think, 'Oh, sure you just have to wipe your hands,' or you think, 'Oh, but maybe you 
did use your phone when you were coming back from Waitrose, and then you did 
reach into your pocket when you were coming to get your keys, so now, even if you 
wash your ha –' you know, it's that thing where you're like, it's too … it’s not 
something we can control … whereas PrEP, <clicks fingers> it just took care of all 
that.”  (Para 43-17) 
 
Let my guard down.  The reduction in anxiety associated with sex is often gradual 
and incremental.  Consequently, changes in sexual behaviour are often not instantaneous.  
Marcus, for example, said this: 
“…I was fully conscious of where everything was, but that's exactly correct, yes. And 
I notice the difference, but what's interesting is, I didn't notice the difference for 
example in performing oral sex, I didn't really clock it 'til I think it took me a year of 
being on and off PrEP… before I let my guard down.” (Para. 101) 
 
 I still have those anxieties.  HIV anxiety can remain, especially post sexual activity.  
However, the intensity is less.  Specifically, Finn said this: “But now I’m a lot more 
comfortable being … I feel more comfortable being myself and … although I still have those 
anxieties and sensations afterwards, it’s a lot more minimal than where it was.” (Para. 76).  
Despite the impressive protection offered by PrEP, some continue to worry about being the 
exception.  Paulo, for example, said: “<Pause> It’s … <sigh> because what say the evidence 
when I start to read that was like 90% is … 95 or 90 or almost 99% effective and the question 
is … ‘What if I am the 1% that is not effective.’” (Para. 73) 
There is HIV in my life.  Because of using PrEP, avoidance of people who are living 
with HIV to mitigate anxiety is reduced which has made exposure to previously feared 
stimulus more tolerable.    For instance, Mateo said “So, I think going on PrEP not only made 
those things irrelevant, but it also allowed me to expose myself to what was a really 
irrational, paralysing fear.  And thanks to that exposure, kind of overcome it” (Para. 109).  In 
turn, this allows for social and sexual connections to develop with PLWH.  Mateo said this of 





“I think about it, but in an unemotional way … if that makes sense? For example, my 
… this person that I mentioned that I met, who was living with HIV, has now become 
my best friend, because we have lots of things in common, not for any other reason. 
So, <sighs> there is HIV in my life and I also know that his experience of dating, for 
example, is very different to mine …” (Para. 93) 
 
The next one in the line-up.  Despite a reduction in HIV anxiety, some develop new 
targets for anxiety.  Dirk said:  Yeah, it’s been less so recently, thankfully, because I’ve been 
on many other things that are also a little bit scary, such as coronavirus” (Para. 81).  These 
targets are often other STIs.  For example, Marcus made this observation: 
“because I had this HIV fear factor… I quite accept that if I take PrEP and I use a 
condom… I should be OK <laughs>. Mostly what I think of the condom would be 
feel uncomfortable, but maybe PrEP I feel somehow, I've got some invisible 
protection, right? But I realised that once that left the equation, the next most … the 
next one after that, the next STI or the next one in the line-up of fear factors, took its 
place. Which is interesting, I didn't quite expect that. Less so; of course, it's not HIV.” 
(Para. 30) 
 
Despite anxiety persisting – albeit regarding another target – the intensity is less.  
Marcus said: “… yeah, that is interesting, isn't? That was a bit of a downer, when I realised 
that, to be honest. Although logically there's no change, it's just a better situation than before, 
but I did … yes it's a bit of a downer.” (Para. 78-80) 
It's going to be taken away from me.  There is anxiety around the possibility that 
the positive impact of taking PrEP on one’s psychological wellbeing may be transient.  Yusuf 
shared this: “But right now, also because I’d just started living an actual sexual life that I 
wanted to live, and it’s going to be taken away from me is how I’m feeling.  That is the 
constant reason for anxiety for me right now.  That is why I can’t really say my mental health 
is well” (Para. 160).   
 Bouts of anxiety that I can kind of manage.  PrEP is viewed as a tool that assists 
those with HIV to overcome their anxiety and live their lives more fully.  Jon said this of his 





opportunity doesn’t present itself as much anymore, I think I’ve gotten better at managing it” 
(Para. 61).   
 
 PrEP is seen as a more attractive intervention for HIV anxiety than anxiolytic or 
antidepressant medications, due to the lack of side-effects.  For example, Finn said this: 
“‘cause I think for me, a lot of anxiety came around this and for me it’s easier for me to take 
PrEP with no psychological effects, rather than me self-medicate on anti- anxiety medication 
or the antidepressants or anything like that. Because it doesn’t have any psychological 
effects, but it keeps my mind level and then when I do have bouts of anxiety I can kind of 
manage those.” (Para. 18) 
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CHAPTER FOUR:  DISCUSSION 
Chapter Overview 
In this final chapter, there will be a summary of the findings in relation to psychological 
theory and previous research.  There will also be a critical appraisal of the current study, 
highlighting key limitations and strengths.  A discussion on the clinical implications of this 
thesis will be presented, along with recommendations for future research.  Finally, I will 
conclude this chapter and thesis with a reflexive statement where I will re-consider my own 
position in this research. 
 
 
Summary of Findings 
Twenty-two themes and forty-nine accompanying subthemes were extracted from 
participants’ data, reflecting the five key research aims.  Findings for each of the research aims 
are presented and discussed below, with reference to psychological theory (particularly 
cognitive-behaviour theories and models) and previous research.    
 
How does HIV anxiety develop and manifest in these GBM? 
Development of HIV anxiety.  Participants discussed growing up in heteronormative 
societies and frequently felt pressure to reject their homosexuality and try and adopt 
heterosexual relationships.  For some participants, this experience of heteronormativity was 
perpetuated by prevailing cultural and religious expectations in their families and communities.  
In some cases, it seemed that the privileging of heterosexuality led to internalised homophobia.  
More specifically, some participants experienced negative reactions when disclosing their 
sexual identity to their family and friends.  This finding is in keeping with previous research 





gender nonconforming behaviour (i.e., homosexuality) in GBM developing anxiety disorders 
in adulthood (Landolt et al., 2004; Skidmore et al., 2007).   
As previously mentioned in the introduction chapter, Meyer’s Minority Stress Theory 
(2003) suggests that societal stigma compromises GBM’s mental health through several 
psychosocial stress processes, which are unique to this group.  Several of these proposed 
processes were evident in the experiences of participants.  Firstly, Pachnakis et al. (2008) 
proposed that stigma-based rejection sensitivity may predispose GBM to developing anxiety 
disorders.  Several participants described that they had learnt to anxiously anticipate rejection 
because of previous experiences with prejudice and discrimination towards homosexuality.  
This experience appeared to be more acute in the context of participants who had conflicting 
group memberships, such as instances where homosexuality was incompatible or pathologised 
in their religion or cultural identity.  Secondly, Pachnakis (2007) also suggested the process of 
concealing one’s sexual identity can lead to psychological distress.  Participants discussed their 
experiences of supressing their homosexual identities, either through splitting (i.e., not 
integrating their authentic sexuality into other areas of their life) or rejection (i.e., pursuing 
heterosexual relationships and resisting pursuing activities associated with homosexuality).  
Some participants even discussed being hypervigilant of their own ‘sex-atypical’ behaviours 
(Sylva et al., 2009) and actively trying to moderate these behaviours to maximise concealment 
of their authentic sexual identity; in doing so, they protected themselves against being exposed 
and therefore also from the possible harassment and discrimination they may have experienced.   
As mentioned above, internalised homophobia is thought to be particularly potent in 
the development of anxiety disorders in GBM (Meyer, 1995, 2003).  In relation to HIV anxiety, 
internalised homophobia appears to be particularly relevant.  Specifically, in the context of 
prevailing narratives of HIV being a ‘gay disease’ and commonly associated with promiscuous 





participants discussed the fusing of HIV and homosexuality. These terms were intrinsically 
related; being homosexual meant that you were going to acquire HIV, or you were already 
infected.  These beliefs regarding HIV and homosexuality become more alarming as the 
participants sexual identity became more apparent to them.  In turn, this appears to trigger 
psychological distress in the form of anxiety about acquiring HIV.   
It is thought that whilst the impact of internalised homophobia is most acute in the 
initial stages of recognising one’s authentic sexual identity (Cass 1984; Troiden, 1989), it is 
something that persists throughout the life course of many GBM and directly impacts on 
psychological wellbeing (Hetrick and Martin, 1984; Stein and Cohen, 1984).  In the current 
study participants discussed their own experiences with internalised homophobia, especially in 
relation to HIV; in turn, there appears to be a relationship between internalised homophobia 
and HIV-specific stigma, and the development of HIV anxiety.  However, it should be noted 
that whilst internalised homophobia narratives that include HIV-specific stigma appears to be 
a common phenomenon among GBM (Berg and Ross, 2014; Smit, 2012), not all GBM go on 
to experience HIV anxiety (Odets, 1995; Scragg, 1995).   
It is conceivable that because of internalised homophobia and pervasive HIV-specific 
stigma, participants may have developed negative attitudes towards sex, which inform their 
subsequent sexual behaviours, and which in turn are conducive to HIV anxiety.  Specifically, 
participants often had sex-negative attitudes towards sexual expression of GBM and 
themselves, such as sex, especially causal sex, being associated with danger.  Furthermore, the 
two-factor learning model theory model of phobias (Mowrer, 1960) posits that anxiety is 
generated through classical conditioning – pairing of a stimulus with a perceived aversive 
experience, which results in anxiety.  This is then maintained by operant conditioning – an 
avoidance of the stimuli in the short-term leads to a reduction in anxiety (and it is therefore 





associated with anxiety and catastrophic predictions (i.e., acquisition of HIV infection and the 
perceived consequences) and, for some, this led to avoidance of sexual activity.  According the 
two-factor learning model of phobias (Mowrer, 1960), this avoidance prevents the individual 
learning that the predicted adverse outcome will not be realised and/or their ability to cope is 
superior to their initial prediction.  As such, this avoidance may have strengthened anxiety 
around sex and resulted in cognitive patterns (i.e., hypervigilance and selective attention) that 
serve to perpetuate and maintain HIV anxiety. 
Another important theoretical concept to consider in the development of HIV anxiety 
in these participants is ‘vicarious learning’ and ‘negative information’ (Rachman, 1977); these 
may serve as a pathway to HIV anxiety.  Specifically, some participants reported direct 
exposure to HIV, through caring roles for example, which was particularly pertinent for those 
who had been sexually active in the ‘pre-HAART’ era, where the consequences of HIV were 
drastically (and objectively) different.  While other participants had very limited direct 
experience of HIV, insofar as they had not witnessed illness or loss because of HIV, most 
participants did tell of their experience of homophobia and the pervasiveness of HIV-related 
stigma, which may be considered ‘vicarious learning’ and/or ‘negative information’.  
Furthermore, some participants had negative sexual experiences where a partner (often in the 
context of casual sex) attempted to remove the condom or, according to the participants, was 
the source of an STI.  Non-consensual removal of condoms, colloquially referred to as 
‘stealthing’ (Brodsky, 2017), is a common practice.  A cross-sectional survey conducted in a 
sexual health clinic in Melbourne, Australia, found that a fifth of GBM involved in the study 
reported being the victim of stealthing on a least one occasion (Latimer et al., 2018).   Despite 
this, it is unclear as to whether this precipitated HIV anxiety or occurred within the context of 





Experience of HIV anxiety prior to PrEP.   Participants told of their experience of 
HIV anxiety which involved a variety of cognitive patterns and behavioural responses.  
Participants concluded that HIV anxiety was part of them and conveyed a chronicity to its 
duration.  Specifically, some participants thought that it may be a component of a mental health 
diagnosis, such as obsessive-compulsive disorder, and others thought that personality traits 
were conducive to HIV anxiety (i.e., being naturally pessimistic).   HIV appeared to have a 
special status that could induce intense fear.   
 
HIV anxiety was omnipresent (although at varying degrees) for participants.  It was 
considered a reality for GBM, in the idea that becoming infected was inevitable, due to their 
identity as a GBM.   Participants appeared to overestimate their risk of HIV and, to a greater 
extent, the risk other GBM posed to them.  This may be considered an example of 
‘overestimation of threat’, which is defined as “an exaggerated estimation of the probability or 
severity of harm” (Morrison and Westbrook, 2004, p102-103).  This is a common feature in 
those presenting with anxiety disorders, especially in OCD. 
The experience of being vigilant to the presence of physical symptoms of HIV was a 
common experience among participants. Some participants also recalled their experience of 
scanning their bodies to reveal potential entry routes.   Furthermore, it was also common for 
benign body changes or sensations to be interpreted as dangerous and ultimately a sign of being 
infected.  These experiences are captured within the cognitive behavioural model of health 
anxiety (Warwick and Salkovskis, 1990) and OCD (Salkovskis et al., 1998).  Within the health 
anxiety model, it is suggested that the arousal process, which is triggered by anxiety, generates 
bodily changes which are in turn misinterpreted as illness (i.e., HIV).  Although participants 
did experience physical manifestations of anxiety, they also experienced unrelated symptoms 





Furthermore, participants often experienced intrusions and urges to check their bodies before, 
during and/or post sexual contact.  This experience is therefore most adequately captured in 
the OCD model, in which this checking behaviour may be considered a neutralising action 
(e.g., ritualistic behaviour that extinguishes the anxiety). 
As previously discussed in the introduction chapter of this thesis, the role of shame has 
been highlighted as a main challenge to cognitive-behavioural models used by some to 
conceptualise HIV anxiety.   Some participants’ fear of HIV was around the possibility of 
illness and death; however, for some, it was the stigma and shame that is associated with HIV 
and not a fear of any physical manifestation of the virus.  Specifically, participants were 
particularly fearful of the perceived negative judgement and rejection they may face if HIV-
positive.  This is considered external shame (Gilbert, 2010a), and therefore highlights the 
importance of including theoretical models of shame into our understanding of HIV anxiety, 
which is largely absent in cognitive-behavioural models.   
Participants engaged in a variety of behaviours aimed to preserve their HIV negative 
status.  One of the most common experiences was restricting or avoiding sexual contact.  
Further to this, participants also told of their experiences of imposing rules on what they did 
(or did not do) sexually.  For instance, participants discussed being the insertive partner during 
anal sex, as this was associated with less risk and, crucially, more control.  Seeking reassurance, 
which is common among a range of anxiety disorders, was particularly evident.  Interestingly, 
for some participants this behaviour was valued and viewed as being responsible; if they did 
not seek reassurance from professionals then this, they felt, would have been irresponsible.   
Testing for HIV prior to commencing PrEP was associated with psychological 
discomfort.  Participants struggled to tolerate the wait for their result, and this impacted on 
their functioning.  Participants’ experiences of HIV testing appear to be like other GBM, who 





How do HIV anxious GBM make decisions around initiation of PrEP? 
Some participants shared that their motivation for starting PrEP stemmed from their 
perceived inability to cope with the intensity, pervasiveness, and persistence of HIV anxiety.  
Participants told of having a lack of trust in condoms and that this ultimately meant they were 
at perpetual risk of HIV, subjectively.  This finding may be made sense of from the cognitive-
behavioural model of health anxiety (Salkovskis and Bass, 1997; Warwich and Salkovskis, 
1990), which suggests that those with health anxiety experience cognitive biases that lead to 
over-valued beliefs about the likelihood of events that contribute to illness (i.e., condom 
failures). Although understandable in the context of how HIV anxiety manifested in this group 
of participants, it is nonetheless a novel finding.   
Furthermore, given that most participants were often not engaging in sexual behaviour 
that they enjoyed, such as receptive anal sex, due to anxiety about HIV acquisition, some shared 
that they were motivated to initiate PrEP to have a more fulfilling sex life.  Specifically, they 
hoped that through the mitigation of their perceived HIV risk – and thus the subsequent HIV 
anxiety – they would be liberated to engage in sexual behaviours of which they had previously 
deprived themselves, despite these behaviours often being part of their erotic template.  
Although previous research has consistently highlighted sexual liberation to be a key 
motivation for initiating PrEP among GBM, it is usually considered in terms of a preference 
for condomless anal sex (Garmel and Golub, 2015).  However, in the current study, although 
some participants did report that they wanted to have condomless anal sex, they appeared to be 
more motivated by being able to engage in sexual activity with a condom but without HIV 
anxiety.   
The suppression of their sexuality, insofar as restricting sexual activity to avoid HIV, 
had led to a sense of loss and regret:  participants thought that HIV anxiety had held them back 





identity as GBM.  In turn, especially in the context of those who were highly restricted in their 
sexual practices and/or who had experienced HIV anxiety for many years, there was a sense of 
urgency to engage in sexual behaviours that had previously evaded them.  In this regard, the 
motivation for PrEP was a central prop to operationalise the desire to be more sexually 
expressive and less restrictive.  Although not specific to this population or PrEP users, it is a 
common observation that those who experience anxiety disorders and avoid or restrict to reduce 
their anxiety can experience sadness and regret with regards to perceived losses accrued 
because of an anxiety disorder (Bandelow and Michaelis, 2015). 
 Another cited reason for initiating PrEP among the participants was a desire to be 
responsible.  Specially, in those participants who wanted to actively pursue a more fulfilling 
sex life, taking PrEP was viewed as an important tool not only to reduce their perceived HIV 
risk (and thus HIV anxiety), but also to preserve their health and that of others.  PrEP was 
viewed as a pro-social behaviour and was therefore valued – it promoted social rank.  As 
discussed above, some participants experienced anxiety about the possibility of them infecting 
partners with HIV.  In this regard, some viewed taking PrEP as their responsibility to protect 
others from potential harm that they may pose.  Although previous studies, which have not 
exclusively recruited GMB with HIV anxiety, have reported a desire to protect one’s health as 
a major motivator for taking PrEP, this desire to protect others has not been widely reported 
(Bistoquet et al., 2021; Gilmore et al., 2013). 
 
 The desire among some participants to take PrEP to principally protect others may be 
conceptualised as something beyond altruistic behaviour.  Specially, it is acknowledged that 
‘inflated responsibility’, which is a key cognition domain in obsessive compulsive disorder 
(OCD) from Morrison and Westbrook (2004), is common across a range of anxiety disorders, 
including health anxiety (OCCWG, 1997).  Inflated responsibility in this regard is defined as 





feeling obligated to take every possible action to prevent the feared consequence …” (Morrison 
and Westbrook, 2004, p102-103).  The notion that inflated responsibility may be a key 
cognitive feature in those with HIV anxiety has been suggested previously (Margetts, 2013; 
Scragg, 1995).  Within a cognitive-behavioural framework, it is conceivable that these 
participants may be taking PrEP to ‘neutralise’ the threat of infecting others and thus 
extinguishing anxiety.   
 
What impact does PrEP use have on their experience of sex and sexual behaviour? 
It was apparent that PrEP facilitated the removal, or a significant reduction, in HIV 
anxiety, which allowed participants to engage in sexual experiences that had previously been 
perceived as too risky or anxiety inducing.  Participants noted a wide range of changes in their 
experience of sex and the sexual behaviours that they engaged in.  Specifically, most were 
engaging in sex more frequently and attributed this to a recalibration of what they considered 
risky and the absence of HIV anxiety.  This was cyclical in that the removal of anxiety meant 
that sex was more enjoyable and therefore they sought out sexual experiences more frequently.  
Furthermore, there were changes in sexual positioning – some participants shared that they 
were engaging in receptive anal and oral sex more frequently and deriving greater sexual 
satisfaction from this.  Overall, participants’ experience of sex was that it had improved in 
quality and was now congruent with their erotic templates.  There appeared to be concurrent 
gains in being able to express their sexuality and no longer restrict or subjugate part of 
themselves. 
 Whilst this subjective improvement in psychosexual functioning is not specific to GBH 
who present with HIV anxiety (Collins et al., 2017; Storholm et al., 2017), it is arguably more 





of HIV anxiety.  In this regard, the subsequent changes in psychosexual functioning 
experienced by participants may be considered transformative. 
 Participants shared their experiences of disclosing their use of PrEP to prospective 
sexual partners and noted that the association between PrEP and high-risk sexual behaviours 
had led some prospective partners to assume that they wanted to have condomless anal sex.    
Participants shared that some prospective sexual partners reacted negatively when participants 
explained that they use condoms and PrEP concurrently.  In turn, this had led some participants 
to not disclose their PrEP use to avoid such conversations.  Participants also experienced having 
to justify their PrEP use when disclosing their use of it, to mitigate negative reactions.   
 PrEP stigma has been noted since its inception (Calabrease and Underhill, 2015; Grace 
et al., 2018) and as such there is a strong and well-established narrative that PrEP use is only 
for those that are high risk among GBM (Dubov et al., 2018) and health care professionals 
(Mayer et al., 2020).   This perception is perhaps maintained by sample characteristics (i.e., 
high risk behaviour) of those enrolled in clinical trials and subsequent clinical guidelines, such 
as those issued by the British Association for Sexual Health & HIV (BASHH; 2020).  Although 
a somewhat unsurprising finding, it is important given the increasing prevalence of PrEP use 
in the GBM community.   
 Whilst taking PrEP, some participants had experiences of being diagnosed with 
sexually transmitted infections (STIs).  Participants reflected that the impact of an STI is less 
problematic than HIV.  Specifically, the burden of an STI was more related to the 
inconvenience of having to go to the clinic for treatment, rather than any associated anxiety.  
Moreover, it was acknowledged that stigma associated with STIs was less pervasive than the 
stigma associated with HIV.  Participants made sense of this by suggesting the short-term 
nature of most STIs meant it was perceived differently to HIV.  This finding is particularly 





group of participants appeared to be manageable and did not result in in the same cognitive or 
behavioural patterns associated with HIV anxiety.  Furthermore, given that participants are 
engaging in more sex (some of which is now condomless) there is an increased chance of 
acquiring STI, as has been demonstrated from observation and epidemiological studies (Morris 
et al., 2018; Redina et al., 2018). 
 
What impact does PrEP use have on experiences of anxiety? 
All participants in the current study reported that PrEP had a positive impact on their 
experience of HIV anxiety, as well as their overall wellbeing.  Specifically, associations 
between being gay and inevitably acquiring HIV, and sex and danger appeared to weaken.  In 
turn, this may have led to shifts in unhelpful beliefs and cognitions, which served to perpetuate 
HIV anxiety.  Despite this improvement, some participants continued to experience residual 
and transient episodes of anxiety related to HIV acquisition; although these were less intense 
than prior to taking PrEP and appeared to lessen over time.  This may be explained by positive 
reinforcement of negative HIV test results in the context of subjectively increased risk (e.g., 
having sexual contact).  In this regard, PrEP may facilitate new experiences in which 
participants learn to recalibrate their HIV risk and therefore resulting in less anxiety.   
 Some participants shared their experience of developing new anxieties after starting 
PrEP, in place of HIV anxiety.  Specifically, some participants became anxious that their 
perceived liberation, facilitated by PrEP, would result in them engaging in risk compensatory 
behaviours, such as chemsex or risky sexual behaviours.   Other participants became anxious 
about other STIs which were chronic, such as herpes.  This evolution of anxiety targets is 
commonly seen in those with OCD, although the intensity of the symptoms tends to escalate 





may experience new anxieties, all reported that these were relatively mild and not associated 
with becoming acopic, compared to HIV anxiety. 
 
Clinical Implications 
Is HIV anxiety the same as health anxiety? 
The findings of the current study suggest that the experience of HIV anxiety for GBM 
is qualitatively different to that of health anxiety.  As discussed in the introductory chapter of 
this thesis, health anxiety is the most widely used clinical term that refers to diagnostic 
classification of illness anxiety disorder (Diagnostic and Statistical Manual of Mental 
Disorders, 5th Edition; APA, 2013) and hypochondriasis (International Statistical Classification 
of Diseases and Health Related Problems, 10th Revisions, 5th Edition; ICD-10; WHO, 2016), 
which are used to conceptualise HIV anxiety in clinical populations.  However, neither of these 
diagnostic classifications adequately capture the experiences HIV anxiety among GBM.   
Specifically, the DSM V diagnostic criteria for illness anxiety disorder states that: 
“There is a high level of anxiety about health, and the individual is easily alarmed about 
personal health status” (DSM V; APA, 2013).  Whilst some participants did allude to 
experiencing more global anxiety regarding their health, most experienced anxiety that was 
confined to HIV.   Despite this, the stipulated criterion does go some way to capturing the 
experiences of GBM presenting with HIV anxiety, especially regarding the presence of 
“excessive health-related behaviours” (e.g., repeatedly checking body for rashes/signs of 
seroconversion) and the exhibition of “maladaptive avoidance” (e.g., avoiding sex). 
The ICD-10, which is the diagnostic system most used in the NHS (Clark et al., 2017), 
diagnostic criteria for hypochondriasis appears to be even less of a ‘fit’ for the experiences of 
HIV anxious GBM.  Specifically, the criterion states that the individual must have “[a] 





symptom or symptoms, even though repeated investigations and examinations have identified 
no adequate explanation …” and “[a] persistent refusal to accept the advice and reassurance of 
several different doctors that there is no physical illness or abnormality underlying the 
symptoms.”  Although some participants did share their experience of misinterpreting physical 
symptoms and attributing these to HIV infection, the belief that these where a sign of HIV was 
quashed when they received a negative HIV result.  Despite this, HIV anxiety appeared to be 
most commonly cyclical among GBM (as opposed to consistently persistent, which is common 
in hypochondriasis).  
The validity of psychiatric diagnoses is widely contested, especially within clinical 
psychology (Jablensky, 2016).   It is important to note that although this study is highlighting 
that the current diagnostic classifications are perhaps not fit for purpose, as applied to the 
experience of HIV anxiety in GBM, it is not suggesting that HIV anxiety should be considered 
a phenomenon that would benefit from its own diagnostic classification.  Moreover, given the 
marginalisation that GBM already face, it is conceivable that pathologising their experience 
further could serve to perpetuate stigma and, in turn, be of detriment to their mental health.  
However, it is important to consider the fit of diagnostic classifications that are used to capture 
the experiences of GBM with HIV anxiety.  Specifically, diagnostic classification is often used 
in conjunction with psychological theories and models which inform treatment protocols 
(National Collaborating Centre for Mental Health, 2020).  This is especially true in primary 
care services, where the majority of GBM presenting with HIV anxiety would likely either seek 
treatment or be referred.  In England, psychological therapies in primary care are delivered by 
Improving Access to Psychological Therapies (IAPT) services. 
Patients who attend IAPT with HIV anxiety would most likely have their difficulties 
conceptualised and treated within the CBT health anxiety model (Warwick and Salkovskis, 





the effectiveness of the psychological treatment offered.  Specifically, it would not target 
central clinical themes that are evident in this population, such as shame or the perpetual nature 
of HIV anxiety given their sexual identity.   Furthermore, although the health anxiety model 
does consider developmental information (e.g., homophobia), which may lead to the formation 
of specific beliefs about oneself, others, and the world, at a largely superficial level, it does not 
adequately identify the specific psychosocial processes that appear to be implicated in the 
development of HIV anxiety among GBM, such as internalised homophobia (Newcomb and 
Mustanski, 2010), stigma-based rejection sensitivity (Pachankis et al., 2018) and concealment 
of sexual orientation (Pachnakis, 2007).  This absence may be seen as rather reductionist and 
serve to maintain the narrative that the problem is located within the individual, rather than 
acknowledging the role of psychosocial processes and wider cultural and contextual 
determinants.  
In this regard, it would be a clinical imperative to ensure that those GBM presenting 
with HIV anxiety are offered a psychological intervention that explores and acknowledges their 
experience fully, beyond the health anxiety model.  Furthermore, given the identification of 
shame and stigma in the experience, the psychological intervention may benefit from diverging 
from the health anxiety treatment protocol to include some concepts from compassion focused 
therapy (Gilbert, 2010a; Gilbert, 2010b). 
 
PrEP as a safety behaviour or an adaptive strategy? 
Behavioural avoidance and safety seeking strategies are common features across all 
anxiety disorders (Strohle et al., 2018).  Cognitive behavioural models emphasise the 
maintaining effects of safety behaviours in anxiety disorders and therefore explicitly advocate 
targeting them in therapy, either by modification (Parrish et al., 2008; Rachman et al., 2008) 





behaviours are frequently associated with functional impairment and are, therefore, often used 
as a proxy of severity.  Consequently, safety behaviours are considered a crucial domain in the 
description and future classification of anxiety disorder (Shear et al., 2007).   
It is acknowledged that clinicians frequently struggle in distinguishing safety 
behaviours from adaptive coping strategies (Thwaites and Freeston, 2005).  This difficulty is 
compounded by a lack of agreed consensus within the literature as to what constitutes a safety 
behaviour.  In response to this, Helbig-Lang and Petermann (2010) conducted a systematic 
review on the effects of safety behaviours across anxiety disorders and began their paper by 
offering a helpful summary of the literature as to how safety behaviours are defined.  
Specifically, they offer the following summary: 
 
(a) Anxiety-related behaviours can be both adaptative as well as inadequate strategies 
of coping with emerging anxiety. 
(b) In case of real threat, anxiety-driven behaviours are most often adaptive as they 
serve the survival of the individual. 
(c) Safety behaviours are dysfunctional emotional regulation strategies.  They can be 
differentiated from adaptive coping depending both on the situations in which they 
occur (actual threat versus overrated or no real threat) as well as their function 
(preventing feared outcomes that are unlikely to happen versus habitual behaviour 
or behaviour unrelated to the occurrence of anxiety).   
  
Based on this summary, it is conceivable that PrEP use may be classified as a safety 
behaviour among some HIV anxious GBM who are not objectively at risk of HIV.  However, 
even if GBM consistently use condoms for anal sex they remain collectively ‘at risk’ by their 





Furthermore, there is a significantly greater prevalence of HIV among GBM, compared to their 
heterosexual counterparts (PHE, 2020) and therefore the potential consequences of a condom 
failure are quantitatively different.  Concordantly, it is conceivable that taking PrEP could be 
considered an adaptive coping strategy.  Indeed, it should be noted that many low risk GBM 
who are not HIV anxious choose to use PrEP.  In the absence of anxiety, their motives – to 
keep themselves and others safe by preserving their HIV negative status – would seem more 
like a community adaptive coping strategy than a safety behaviour. In any case, determining 
the function of taking PrEP is a clinical imperative.   
  Another important consideration is the assumption that safety behaviours universally 
result in functional impairment.  In the current study, PrEP use was transformational and was 
experienced as a tool that did not impede functioning but facilitated functioning (i.e., 
psychosexual functioning). This finding accords with emerging evidence that safety 
behaviours, far from being universally unproductive or unhelpful, may even be helpful in the 
management of anxiety disorders (Rachman et al., 2008).  While evidence on inclusion of 
safety behaviours in the treatment of health anxiety appears to be absent, there are studies, 
albeit with inconsistent results (Helbig-Lang and Petermann, 2010), that have evaluated the 
effects of promoting certain safety behaviours in similar disorders, such as OCD (Abramowitz 
et al., 2001) and panic disorder (Campbell-Sills et al., 2006).   In a review, four out of five 
studies showing positive effects of safety behaviours focused on specific phobias, and 
specifically on phobias assumed to be biologically prepared.  It is hypothesised that the positive 
effects of safety behaviours in exposure therapy may stem from a predominantly biological 
vulnerability, suggesting different mechanisms of action and change, compared to other anxiety 
disorders (Helbig-Lang and Petermann, 2010).  HIV anxiety, unlike specific phobias, is 
characterised by various fears, some of which are not related to the virus itself, but rather the 





therefore unclear as to whether using PrEP in conjunction with psychological therapy for HIV 
anxiety would yield superior results compared to taking PrEP or engaging in psychological 
therapy in isolation.   
The results of the current study do raise an ethical dilemma for clinicians and 
psychological therapists.  Specifically, if conceptualised as a safety behaviour then clinicians 
and psychological therapists may have a duty to discourage PrEP use in the context of HIV 
anxiety, and instead prioritise psychological therapy.   Despite this, the experiences of the GMB 
in this study do not demonstrate the impact of PrEP on the maintenance and exacerbation of 
anxiety, through negative reinforcement, which is the central tenet as to why safety behaviours 
are considered unhelpful (Salkovskis et al., 1997, 2003).  This thesis would therefore argue that 
the emerging phenomenon of low risk GBM, including those who are HIV anxious, choosing 
to use PrEP may be best conceptualised as a community adaptive coping strategy, as a legacy 
of the HIV epidemic that is felt so acutely by this population.  As such, clinicians and 
psychological therapists may need to reconsider the assumption that PrEP is a safety behaviour 
and be open, albeit tentatively, to its utility in HIV anxious GBM. 
 
PrEP use in low risk GBM? 
Irrespective of whether clinicians and psychological therapists endorse PrEP use in this 
population or not, PrEP continues to be widely available from non-NHS sources. It is therefore 
likely that its use in this population will continue.  This scenario appears to be even more likely 
in the context of the results of this thesis, in which all the participants reported a positive 
experience overall.  It is therefore important that this population are continued to be afforded 
PrEP monitoring as part of their NHS care, irrespective of the source of the medication, to 
ensure optimal safety.  Although PrEP monitoring was available in most clinics for those self-
sourcing, this was in the context of it not being available through the NHS.  In turn, it is unclear 





use on the NHS.  It is conceivable that PrEP monitoring will only be available to those who are 
prescribed PrEP via an NHS clinic, with prescribing being informed by the British HIV 
Association/British Association of Sexual Health & HIV (BASHH/BHIVA, 2018) guidelines 
on the use of PrEP.  It is therefore important that policy decision makers continue to be aware 
that PrEP-users may continue to access PrEP from non-NHS sources when making commission 
decisions. 
 The PrEP guidance states that PrEP should only be prescribed in the context of someone 
being objectively high risk.   It is therefore likely that this population will need to embellish 
their sexual health history to meet the criteria to obtain PrEP on the NHS.  Seven of the 
participants obtained PrEP through the IMPACT trial, which had similar inclusion criteria as 
the BASHH/BHIVA guidelines, suggesting that participants were required to embellish their 
sexual health histories and/or that clinicians were applying the criteria liberally.  This study 
highlights the dilemmas facing clinicians – both physicians and psychological practitioners – 
in balancing the apparent benefits conferred by PrEP use in this population with the potential 
psychological and physical risks that may result from using PrEP in objectively low risk people 
belonging to an ‘at-risk’ group such GBM.  Although this study offers emerging evidence of 
the benefits it is also prudent to consider the risks.  Specifically, it is also conceivable that 
inclusion in the PrEP guidelines may perpetuate beliefs, at an individual, community, and 
population level that GBM are at greater risk of HIV infection than is objectively accurate. 
 
Strengths and Limitations 
In pursuit of a robust critique of the current study, the Critical Appraisal Skills 
Programme (CASP; 2018), which is the most widely recognised appraisal tool for qualitative 
studies, was used as framework.  The results of this appraisal are presented in Appendix X.  





through the CASP appraisal procedure.  The approach to the methodological critique is 
informed by the qualitative study design and its epistemological position (i.e., critical realist).    
Experiences of HIV anxious GBM using PrEP 
The current research is unique in exploring the experiences of GBM who are (or 
where) HIV anxious and are using PrEP.  Previous research has exclusively focused on high-
risk GBM’s experience of PrEP with the aims and research questions usually focused on 
efficacy of PrEP in reducing HIV (Molina et al., 2015; McCormack et al., 2016), risk 
compensation or barriers to update in high-risk groups (Rendina et al., 2018).  Although there 
is research highlighting the psychological impact of PrEP, this only includes participants 
whom PrEP is traditionally aimed at (Hojilla et al., 2016).   As such, the current study adds 
rich qualitative data about lived experiences, rather than dominant quantification and 
correlations.  In particular, the current study highlights the lived experiences of HIV anxious 
GBM, who are often excluded from PrEP research because of their low-risk status.  Despite 
this, this thesis does not presume to represent a comprehensive or definitive account of the 
experiences of HIV anxious GBM using PrEP.  This naturally has limitations, but the 
findings nonetheless contribute to understanding and highlight the need for further research 
with this group.   
 
Study Sample 
The sample size for the current study (N=10) was within normal parameters, with the 
suggested range being 6 – 10 participants (Flick, 2008).   A total of 22 participants 
volunteered to participate in the current study (with 12 participants not meeting the criteria 
for HIV anxiety), suggesting that the recruitment strategy was relatively well conceived.  
However, there remains scope for recruitment improvements.  Specifically, participants were 





subsidised private prescriptions (e.g., PrEP Shop) and thus engaged in the recommended 
monitoring.  I formulated that given the participants who were included in the current were 
highly educated (8 out of 10 had achieved a postgraduate qualification), they may have been 
more able to engage with information regarding clinical trials and therefore less likely to be 
self-sourcing online.  The experience of self-sourcing PrEP may be qualitatively different 
from those included in the current sample.    
Participant’s age ranged from 23 to 61 years.  Therefore, the sample included was 
multigenerational.  This is particularly important given that the generational experiences of 
being gay (Grierson et al., 2005) and HIV (Hunt et al., 2019) are inevitably different, given 
the ever-changing socio-political context.  Furthermore, the sample only included gay men – 
although the inclusion criteria did not specify sexual orientation, just behaviour – with no 
representation of bisexual men.  Bisexuality is often stigmatised in both the heteronormative 
society and the gay community (Callis, 2003; Eliason, 2000).   
It was noted from the outset of the study that recruitment of those who identify as 
BAME would be important, as this group experience unique barriers in accessing sexual 
health care (Witzel et al., 2019).  To mitigate this, the study sites included several clinics 
situated within south east London (serving predominantly BAME communities).  Despite 
this, none of the participants identified as black, highlighting a potential issue with the 
recruitment strategy.  Furthermore, a central thrust of the argument in this thesis is the 
cumulative nature of minority stress and how this impact on mental health (e.g., development 
of HIV anxiety) (Meyer, 2003).  It is therefore conceivable that GBM who are a racial 
minority may be especially vulnerable to poorer mental health outcomes (Balsam et al., 
2011).  Furthermore, there is growing evidence to suggest that PrEP outcomes are worse 





crucial that the results of this research may not adequately capture the experiences of HIV 
anxious black GBM who are using PrEP. 
 
HIV Anxiety Classification 
As highlighted throughout this thesis, the phenomenon of HIV anxiety is relatively 
poorly understood and therefore conceptualisation – especially prior to analysing the results – 
is challenging.  In the current study, the DSM-V illness anxiety disorder (APA, 2013) was 
used as proxy for HIV anxiety, given that the experience of HIV anxiety maps onto this 
anxiety disorder most closely vs. that of hypochondriasis (WHO, 2016).  The clinical 
interview (which was incorporated into the semi-structured interview) was used to illicit 
‘symptoms’ of illness anxiety disorder, as related to HIV anxiety.  In conjunction with this, 
participants were asked to complete the Health Anxiety Inventory (HAI-18; Salkovskis et al., 
2002).  This proved problematic for various reasons.  Firstly, asking participants 
retrospectively as to the presence and nature of HIV anxiety is somewhat unreliable, 
especially given that anxiety symptoms tend to wax and wane but tend to persist long-term.  
In turn, participants ability to convey their experience of HIV anxiety may have been 
diminished.  Secondly, although the HAI-18 is the most widely utilised psychological 
measure for health anxiety, which is used routinely with those accessing IAPT services 
(National Collaborating Centre for Mental Health, 2020), it is specifically designed to illicit 
symptoms pertaining to hypochondriasis and not illness anxiety disorder and proved to be an 
inappropriate selection.   
 
Interpretivist Paradigm 
A critical realist approach was a strength of the current study in comparison to 





epistemology in previous research is understandable, especially given PrEP is conceived, first 
and foremost, as a biomedical intervention.  However, psychological research has been 
criticised for reducing human experiences, and, moreover, leading to policies which prioritise 
technocratic objectivity at the expense of meaningful social improvement (Fischer, 1998; 
Darlaston-Jones, 2007).  This is perhaps best represented by the fact that GBM continue to be 
disproportionately affected by HIV and psychological distress, which is often made sense of 
through diagnostic criteria, despite an abundance of positivist research highlighting these 
inequalities.   An interpretivist epistemology led to the current study incorporating the 
experiences of GBM who were HIV-anxious beyond the quantitative data.  Furthermore, 
where there has been qualitative exploration into the experiences of PrEP, this has not 
incorporated those who are deemed objectively low risk and experience distress in the form 
of HIV anxiety.  Thus, applying an interpretivist paradigm to the experiences of these GBM 
provides further subjective understanding of both HIV anxiety and PrEP use.   
 
Future Research  
The role of minority stress (Meyers, 2003) and its associated psychosocial process 
(e.g., internalised homophobia) have been empirically demonstrated to mediate the 
expression of mental health difficulties among GBM.  Whilst it is conceivable that these 
processes are implicated in the development of HIV anxiety among GBM (and this is 
supported by the current study), there needs to be more research to test this hypothesis.  
Specifically, as Odets (1995) and Scragg (1995) pointed out in their respective papers on the 
phenomenon, not all GBM go onto develop HIV anxiety.  Thus, critical questions requiring 
attention:  Why do only some GBM go onto to develop HIV anxiety?  Is it solely due to 
experiences of minority stress and its associated psychosocial processes?  Improving our 





 Earlier in this chapter, the issues pertaining to the diagnostic criteria being used to 
‘capture’ HIV were discussed.  It is evident that there is little beyond anecdotal reports that 
describe the hallmarks of HIV anxiety, among GBM, in its entirety.  Specifically, whilst 
some of the dominant cognitive-behaviour models of anxiety disorders do offer some 
explanatory components towards the experience of HIV anxiety, none of these adequately 
offer a sufficiently comprehensive model, especially in relation to the psychosocial processes 
related to minority stress.  As such, future research would benefit from focusing on 
development of a theoretical and clinical model of HIV anxiety (not diagnostic criteria), 
among GBM, to aid psychological formulations.  This would, in turn, help clinicians plan 
more effective interventions and hopefully improve clinical outcomes. 
 There remains a critical question as to whether PrEP is efficacious as an intervention 
for HIV anxiety among GBM.  This answer to the question may be contributed to in various 
ways.  For example, it may be prudent to ascertain clinicians view on prescribing PrEP in this 
context.  Based on how PrEP was accessed by the current participants, there may be positive 
views among clinicians about the individual and community benefits of prescribing PrEP in 
this context.  In any case, future research would benefit from engaging with a larger sample 
in the medium and long-term to determine the risks and benefits, both clinical (i.e., risk 
compensation) and psychological (i.e., anxiety symptoms). 
 
Final Reflections 
Conducing this research has had a profound impact on me.  Revisiting the experiences 
of HIV anxiety was challenging.  Not only was it difficult – and at times quite triggering – 
hearing the psychological pain these men had been in, given my own personal experiences; but 
it also led me to question the psychological theories and models we use to conceptualise and 





toxicity of homophobia and the deleterious effects on GBM.  I suspect this is because 
homophobia is so insidious and often subtle.  I notice more now than before but I am unsure if 
‘mainstream’ clinicians would have similar insights or reflections?  If not (which I suspect to 
be the case) then I consider this a problem within the psychological professions. 
I am conscious that the study sample is relatively small, and it would not be clinically 
or methodologically appropriate to generalise the findings and declare that PrEP is a magic pill 
that will mute HIV anxiety in GBM.  That said, I do believe that PrEP may have a role in 
helping GBM (both at an individual and community level) to overcome anxiety related to HIV.  
As such, I genuinely hope that clinicians will remain open minded in its deployment.  I will be 
taking up my first qualified post in HIV and Sexual Health and hope that I can continue this 
conversation and perhaps agitate for further research.   
I have decided to end this thesis by sharing a poem that I have written, which is inspired 
by my own and the participants experiences of HIV anxiety.  I hope the poem conveys the 



















The heat rising  
From my stomach to my head. 
Doom, dread, dead 
There is a storm raging in my head. 
 
Why did I do it?   
Because you’re stupid  
An impending lesson that is stern  
You’re going to learn! 
 
The invasion in my body is taking hold 
Virus swirling around my veins  
Seeding my lymph nodes 
Obsessing over transmission modes 
 
It’s a rash 
It’s a lesion 
Seroconversion is feared  
I was the one that steered 
 
I’m tainted and broken 
(More than before) 
I cannot stop checking  
This is my own reckoning  
 
Begging for reassurance 
Unable to focus  
Incapacitated by the fear 
They look back at me from the rear 
 
I’ve never felt worse 
Consumed by the velocity of living 
Yet unable to survive 
The seed of doubt thrives 
 
It’s boiled  
The balance has tipped 
and it’s now test time 
I wait in line  
 
I’m begging for mercy  
I’ll be good from now on 
This will be the last time 
Oh.. I’m fine 
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Participant Information Sheet 
 
A study exploring the experiences of low risk men who have sex with men who are using HIV 




We invite you to take part in a research study 
• Before you decide whether to take part, it is important for you to understand 
why the research is being done and what it will involve. 
• Please take time to read the following information carefully.  Discuss it 
friends, relatives and your sexual health clinician if you wish. 
• You are free to decide whether or not to take part in the study.  If you choose 
not to take part, this will not affect the care you are receiving from your sexual 
health clinic. 
• Ask us if there is anything that is not clear or if you would like more 
information.   
Important things that you need to know 
• We want to find out what the experiences are of men who have sex with men 
who are taking HIV pre-exposure prophylaxis (PrEP). 
• If you choose to participate then you will be asked to complete a questionnaire 
and take part in a one-to-one interview with a trained researcher. 
• It is unlikely that the study will evoke any significant psychological distress. 
• This study can fit into your normal clinic appointments, so there will be no 
extra visits, unless you wish to be interviewed at a more suitable time.  There 
is also an option to interview remotely (using secure computer software). 








Who is conducting this study? 
This research is being carried out by Mr Christopher McCormack who is a Trainee Clinical 
Psychologist from the University of Essex and Essex Partnership University NHS Foundation 
Trust.  The research is being supervised by Professor Gill Green from the School of Health & 
Social Care at the University of Essex, and Dr Caroline Coffey (Lead Clinical Psychologist in 
HIV & Sexual Health) from Central & North West London NHS Foundation Trust. 
 
What is the purpose of the study? 
The purpose of this study is to try and better understand the experiences of men who are 
having sex with men who are using PrEP and are considered to be low risk (i.e. not having 
condomless anal sex).  The study is being carried out as part of the requirements of the 
Doctorate in Clinical Psychology training course at the University of Essex.  The study will 
involve talking to men who are using PrEP.  All participants will be asked about their 
motivations for starting PrEP and to reflect on the impact taking PrEP has had on them.  It is 
hoped that the interviews will provide us with a better understanding of the experiences of 
taking PrEP in this group.  The study aims to recruit 20 participants.   
 
Why have I been invited? 
We are inviting men who have sex with men who are currently using PrEP and were 
considered to be low risk (i.e., not having condomless anal sex) of HIV infection, prior to 
starting PrEP.  We believe you may fit these criteria and that is why we have invited you to 
take part. 
 
What does participating involve? 
If you decide to take part in the study, you will be asked to: 
1. Let the clinician who told you about the study know that you are happy to learn more 
about the study and they will pass your details to Christopher McCormack who will 
contact you (via telephone or email). 
2. Christopher will give you more information about the study, answer any questions 
you have and if you still would like to take part, he will arrange an appointment with 
you.  This appointment will take place at your sexual health clinic or remotely using 
secure computer software. 
3. Before you begin the interview, Christopher will ask you to sign a consent form to 
agree to take part in the study.  If you are participating remotely, you will be emailed 
a link to complete the form using secure computer software. 
4. Christopher will then ask you to complete an 18-item questionnaire that will ask you 
questions about anxiety. 
5. Your interview will last around one hour and will be an informal discussion.  
Christopher will ask you some questions about what motivated you to start taking 





You can take a break at any time during the interview, and you don’t have to answer any 
questions that you don’t want to.  The interviews will be audio recorded to make sure that 
what is written down in the study matches exactly what each participant says.  Some quotes 
from your interview may be included in the research paper, but you will not be identified 
from any of the information. 
 
 
Do I have to take part? 
No.  Your decision to take part or not to take part is entirely up to you.  If you agree to take 
part, you will be asked to sign a consent form before you start your interview, so that there is 
a record of your consent.  You will also be given a copy of the signed consent form.  
However, if you do not wish to take part then this is absolutely fine; it will in no way impact 
the care you are receiving from your sexual health clinic.   
Furthermore, should you initially agree to participate and then change your mind then this is 
also okay and would in no way impact the care you are receiving from your sexual health 
clinic. However, due to the nature of the study any data already anonymised will be retained 
following your withdrawal from the study.  You can withdraw from the study by contacting 
someone in the study team (the specific contact details are included at the end of this 
information sheet).   
 
What happens to the information? 
Data protection regulation requires that we state the legal basis for processing information 
about you.  In the case of research, this is ‘a task in the public interest’.  The Data Controller 
is the University of Essex and the named person is Sara Stock (University Information 
Assurance Manager) who can be contacted by emailing dpo@essex.ac.uk.   
   
We will be using information from you in order to undertake this study and will use the 
minimum personally identifiable information possible.  We will keep identifiable information 
about you for 12 months after the study has finished.  This excludes any research documents 
with personal information, such as consent forms, which will be held securely at the 
University of Essex for 5 years after the end of the study. 
The audio recordings and any written information will be encrypted and kept under password 
on a locked computer.  A professional transcriber (who has signed a confidentiality 
agreement) will transcribe the audio recordings.  This information will then be transferred to 
a secure University of Essex network once the study has concluded.  The data will be kept 
here for up to 12 months, after which time the information will be destroyed.  The 
information will be stored in accordance with the Data Protection Act 2018, which means 
that we lock it securely and cannot reveal it to others without your prior permission.   
 
Your name and personal information will be known to the researchers but will be saved 
separately from your audio recording.  Sometimes, representatives of the study sites, Chelsea 
& Westminster Hospital NHS Foundation Trust and Guy’s & St Thomas’ NHS Foundation 
Trust, may look at your personal information and records.  This is to ensure that the research 
team is conducting the study correctly.  
A copy of the completed consent form will be archived in your sexual health records and 
stored in accordance with Trust policy for the retention of medical records.  
The results of this study may be published in academic journals, conference proceedings and 
as a piece of work for a doctoral qualification in Clinical Psychology.  Some direct quotes 
from your interview may be included in these reports/publications and whilst every effort will 






At the end of the study, a standard feedback letter will be offered to each participant 
summarising the study findings.  This is not a requirement to participate in the study; 
participants will consent to ‘opt-in’ and provide an e-mail address for the Chief Investigator 
to send the standard feedback letter to.  This e-mail address will be stored separately to the 
audio recordings and will only be used in the context of sending the standard feedback letter; 
they will not be linked to any other personal information.   
 
Data protection regulation provides you with control over your personal data and how it is 
used.  When you agree to your information being used in research, however, some of those 
rights may be limited in order for the research to be reliable and accurate.  Further 
information about your rights with respect to your personal data is available at 
https://www1.essex.ac.uk/records_management/policies/data_protection_and_research.aspx 
You can find more about how we use your information by contacting anyone on the study 
team.  Their contact details are included at the end of this information sheet.  
  
What are the possible benefits of taking part? 
Your participation will help develop an understanding of the experiences of PrEP-using men 
who have sex with men who are relatively low risk of acquiring HIV infection.  It is hoped 
that you may find some benefit from having an opportunity to talk and reflect on your 
experiences. 
 
At any point, if you feel distressed during or after the interview, we will ensure that you have 
information to access appropriate support, if you need to. 
 
What are the possible risks of taking part? 
There is the potential for the interview to elicit some psychological distress.  The questions 
might also highlight that you may be experiencing anxiety related to HIV or your sexual 
health.  The researcher will be able to help you with any distress that may occur as a result or 
in response to the interview, this may involve offering you a referral for further support.  
Based on your responses to the questions, the researcher may identify a possible anxiety 
disorder called Health Anxiety (which is also sometimes referred to as Illness Anxiety 
Disorder).  You can read more about Health Anxiety at 
https://www.nhs.uk/conditions/health-anxiety/ . If this is the case, you will be offered an 
onward referral to a specialist for further assessment and possible psychological intervention. 
There are also risks associated with taking PrEP that you should be aware of.  Your clinician 
at the clinic will have discussed these with you.  However, if you want to find more 
information regarding the risks associated with PrEP use please see the NHS endorsed iBase 
PrEP information Leaflet (this can be found at http://i-base.info/guides/wp-
content/uploads/2019/11/UK-guide-to-PrEP-Nov-2019-FINAL.pdf).  
 
It is acknowledged that some participants will be acquiring their PrEP online.  Whilst the 
main risk arises from taking PrEP without having any baseline tests, you should always 
discuss where you are sourcing PrEP with a health advisor, nurse or doctor at the clinic.  
They can advise you further regarding the safety risks associated with this, as NHS clinics are 
only responsible for the medication which they supply.  It is important to adhere to any 
recommendations made by the clinicians at your clinic regarding ongoing monitoring whilst 
you are using PrEP, to ensure that you are taking PrEP as safely as you can. 
 





All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect participants’ interests.  This study has been reviewed and given 
a favourable opinion by the London-Camberwell St Giles Research Ethics Committee. 
 
What if you have a complaint about any aspect of the study? 
If you have any concerns about any aspect of the study or have a complaint, in the first 
instance please contact the chief investigator of the project, Christopher McCormack, using 
the contact details below. If are still concerned, you think your complaint has not been 
addressed to your satisfaction or you feel that you cannot approach the chief investigator, 
please contact either their supervisor or the departmental Director of Research in the 
department responsible for this project, Dr Ewan Speed (esspeed@essex.ac.uk). If you are 
still not satisfied, please contact the University’s Research Governance and Planning 
Manager, Sarah Manning-Press (e-mail sarahm@essex.ac.uk). University of Essex, 
Wivenhoe Park, Colchester, Essex, C04 3SQ. 
 
How to make a complain to Patient Advice and Liaison Service (PALS)? 
If you are unhappy about any aspect of the study and wish to make a complaint, please 
contact the researcher in the first instance but the normal NHS complaints procedure is also 
available to you.  This can be accessed by contacting the Patient Advice and Liaison Service 
(PALS) via telephone (020 7188 8801), email (pals@gstt.nhs.uk), or in writing (PALS, St 
Thomas’ Hospital, Ground Floor, Westminster Bridge Road, SE1 17EH).  Further 




If you have any further questions? 
We will give you a copy of the information sheet and signed consent form to keep.  If you 
would like more information, the researcher contact details are below: 
 
 
Researcher(s) Contact Details: 
Professor Gill Green 
School of Health & 
Social Care 






Tel:  01206 874144 
 
 
Mr Christopher McCormack 
School of Health & Social Care 






Tel:  01206 874144 
 
Dr Caroline Coffey 
Clinical Health Psychology 
Psychological Medicine Unit 
South Kensington & Chelsea 
MHC 




























                            
   
 
IRAS ID: 266963 
 
Centre Number:  
Study Number: 
Participant Identification Number for this study: 
CONSENT FORM 
Title of Project: The experiences of non-high-risk men who have sex with men who are using HIV pre-
exposure prophylaxis (PrEP) 
 
Name of Researcher:  Christopher McCormack 
Please 
initial box  
1. I confirm that I have read the information sheet dated 27 April 2020 (version 2.1) for the 
above study. I have had the opportunity to consider the information, ask questions and have 
had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I agree to be interviewed either in person or remotely (using Zoom).  
 
4. I agree to my interview being audio recorded.  
 
5. I agree to completing the questionnaire.  
 





    only to the members of the research team directly involved in the project and a professional 
 transcriber, and that confidentiality will be maintained. 
 
7. I understand that my fully anonymised data will be used for publication in academic journals,  
conference proceedings and as a piece of work for a doctoral qualification in clinical psychology. 
 
8. I understand that anonymised quotes from the interviews will be included in the study write up. 
 
9. The results will be disseminated to those who participate in the form of letter summarising the  
 findings.  These will be sent via email.  This is entirely optional:  If you would like to receive 
 the letter please initial the corresponding box; if you do not wish to receive the  
 letter, please leave blank. 
 
 
10. I understand that the information collected about me will be used to support 
other research in the future and may be shared anonymously with other researchers. 
 
 
11. I agree to take part in the above study. 
 
 
NOTE:  1 copy of this consent form will be retained by the researcher; 1 copy will be uploaded onto 




            
Name of Participant  Date    Signature 
 
            








































































What age are you? 
 
In the box, please write your age in years 
 
What is your ethnic group? 
Choose (tick) one option that best describes your ethnic group or background 
White 
English/Scottish/Northern Irish/Welsh/British   
Irish  
Gypsy or Irish Traveller  
Any other white background, please described:  
Mixed/Multiple ethnic groups 
White and Black Caribbean  
White and Black African  
White and Asian  
Any other Mixed/Multiple ethnic background, please describe:  
Asian/Asian British 
Indian  
Pakistani   
Bangladeshi  
Chinese  
Any other Asian background, please describe:  
Black/African/Caribbean/Black British 
African  
Caribbean   
Any other Black/African/Caribbean background, please describe  
Other ethnic group 
Arab  







What is your sexual orientation? 
 
Choose (tick) one option that best describes your sexual orientation 
 
Gay   
Bisexual  
Heterosexual  
Any other sexual orientation, please described:  
 
 
What is your marital status? 
 
Choose (tick) one option that best describes your marital status 
 
Single   
Partnered  
Married   
Divorced  
Any other marital status, please describe:  
 
What is your highest educational qualification? 
 





Bachelor’s degree  
Postgraduate  
Any other educational qualification, please describe:  
 
What is your occupation? 
 




How long have you been using PrEP? 
 
Years:    Months: 
 
How do you take your PrEP? 
 
Choose (tick) one option that best describes how you take PrEP 
 
Daily  
Event based dosing/On demand/Intermittent/ 2-1-1  






How do you access PrEP? 
 
Choose (tick) one option that best describes how you source PrEP 
 
Buy online   
Private health provider  
IMPACT trial   





















































Interview Topic Guide 
 
The experiences of non-high risk men who have sex with men who are using HIV pre-
exposure prophylaxis (PrEP) 
 
Research Questions: 
1. What are the reasons for non-high risk MSM deciding to start using PrEP? 
2. What impact does using PrEP have on non-high risk MSM’s perceptions of their risk 
of HIV? 
3. What are the psychological and psychosexual impacts on non-high risk MSM using 
PrEP? 
4. Is there a difference between those who have high levels of health anxiety and those 
who do not? 
 
(a) Introduction, overview of research, and confidentiality (~5 minutes): 
 
• Welcome and introduction to researcher; 
• Instructions regarding the interview:  We are interested in the experiences of 
relatively low risk men who have sex with men’s experiences of using PrEP.  
In particular, to find out why you started using prep, what impact it has had 
on you with regards to how you think about your HIV risk, as well as the 
psychological and psychosexual impact. 
• Confidentiality:  Outline the scope and limitations of confidentiality.  
Confidentiality will only be broken in exceptional circumstances if there are 
significant grounds for concern about a response given, and this would be 
discussed with you beforehand.  You have the option to withdraw from the 
interview throughout. 
 






• Reasons for starting PrEP? 
i. Probe: anxiety; beliefs around responsibility (to self and others); peer 
pressure 
• Length of use 
• Regime 
i. Probe:  rationale; self-efficacy  
• Sourcing  
i. Probe:  safety  
 
(c) Health Anxiety (~10 minutes): 
 
• Preoccupation 
i. Probe:  time spent thinking about HIV  
 
 
• Symptom interpretation 
i. Probe:  seroconversion/primary HIV infection symptoms 
• Health anxiety levels, easy alarmed 
i. Probe:  risks 
• Excessive health-related behaviours 
i. Probe:  body checking; frequent testing; avoidance. 
 
(d) HIV Risk perception (~10 mins) 
 
• Prior to taking PrEP… 
i. Probe:  likelihood of diagnosis; perceived vulnerability 
• On PrEP… 
i. Probe:  likelihood of diagnosis; perceived vulnerability 






(e) Psychological and psychosexual impact (~20 minutes) : 
 
• Anxiety 
i. Probe: trajectory of anxiety (if present), different from before; 
management of anxiety; intensity of anxiety 
• Sexual behaviour (before and after) 
i. Probe: number of partners; partner selection; sexual activity; condom use; 
chems/drugs; sexual satisfaction; receptive anal sex  
• Identity/image as a gay man 






































London - Camberwell St Giles Research Ethics Committee 

















30 January 2020 
 
Mr Christopher P McCormack 
Trainee Clinical Psychologist 
Essex Partnership University NHS Foundation Trust 






Dear Mr McCormack  
 
Study title: The experiences of non-high risk men who have sex 
with men (MSM) who are using pre-exposure 
prophylaxis (PrEP) 
REC reference: 19/LO/1954 
IRAS project ID: 266963 
 
Thank you for your response received on 13th January 2020, responding to the Committee’s 
request for further information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair. 
 
Confirmation of ethical opinion 
Please note:  This is the 
favourable opinion of the 
REC only and does not allow 
you to start your study at NHS 
sites in England until you 











On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
[as revised], subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or NHS 
management permission (in Scotland) should be sought from all NHS organisations involved in 
the study in accordance with NHS research governance arrangements. Each NHS organisation 
must confirm through the signing of agreements and/or other documents that it has given 
permission for the research to proceed (except where explicitly specified otherwise). 
 
Guidance on applying for HRA and HCRW Approval (England and Wales)/ NHS permission for 
research is available in the Integrated Research Application System. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of management permissions from host 
organisations 
 
Registration of Clinical Trials 
 
It is a condition of the REC favourable opinion that all clinical trials are registered on a 
publicly accessible database. For this purpose, ‘clinical trials’ are defined as the first four project 
categories in IRAS project filter question 2. Registration is a legal requirement for clinical trials 
of investigational medicinal products (CTIMPs), except for phase I trials in healthy volunteers 
(these must still register as a condition of the REC favourable opinion). 
 
Registration should take place as early as possible and within six weeks of recruiting the first 
research participant at the latest. Failure to register is a breach of these approval conditions, 
unless a deferral has been agreed by or on behalf of the Research Ethics Committee ( see here 
for more information on requesting a deferral: https://www.hra.nhs.uk/planning-and-improving-
research/research-planning/research-registration-research-project-identifiers/  
 
As set out in the UK Policy Framework, research sponsors are responsible for making 
information about research publicly available before it starts e.g. by registering the research 




You should notify the REC of the registration details.  We will audit these as part of the annual 
progress reporting process.  
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 










After ethical review: Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
• Notifying substantial amendments 
• Adding new sites and investigators 
• Notification of serious breaches of the protocol 
• Progress and safety reports 
• Notifying the end of the study, including early termination of the study 
• Final report 
 
The latest guidance on these topics can be found at https://www.hra.nhs.uk/approvals-
amendments/managing-your-approval/.  
 




The favourable opinion applies to all NHS/HSC sites listed in the application subject to 
confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or 
management permission (in Scotland) being obtained from the NHS/HSC R&D office prior to the 




The final list of documents reviewed and approved by the Committee is as follows: 
Document   Version   Date   
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Insurance]  
V1  01 August 2019  
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Insurance]  
V2  01 August 2019  
Interview schedules or topic guides for participants [Topic Guide]  V1  31 October 2019  
IRAS Application Form [IRAS_Form_19112019]    19 November 2019  
IRAS Checklist XML [Checklist_13012020]    13 January 2020  
Letter from sponsor [Sponsor Letter]  V1  18 November 2019  
Non-validated questionnaire [Demographic Questionnaire]  V1  21 November 2019  
Other [Email from applicant responding to queries ]    12 January 2020  
Participant consent form [Consent Form V2]  V2  07 January 2020  
Participant information sheet (PIS) [PIS GSTT V2]  V2  07 January 2020  
Participant information sheet (PIS) [PIS CW V2]  V2  07 January 2020  
Research protocol or project proposal [Protocol]  V0.2  31 October 2019  
Summary CV for Chief Investigator (CI) [CV CMcCormack]  V1    
Summary CV for student [CV CMcCormack]  V1    
Summary CV for supervisor (student research) [CV Green]  V1    
Summary, synopsis or diagram (flowchart) of protocol in non 
technical language [Flow Chart]  














Validated questionnaire [HAI-18]  V1    
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 




The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received and 
the application procedure. If you wish to make your views known please use the feedback form 
available on the HRA website: http://www.hra.nhs.uk/about-the-hra/governance/quality-




We are pleased to welcome researchers and research staff to our HRA Learning Events and 
online learning opportunities– see details at: https://www.hra.nhs.uk/planning-and-improving-
research/learning/ 
 
19/LO/1954                          Please quote this number on all correspondence 
 











Enclosures:  “After ethical review – guidance for researchers”  
 



















Mr Christopher P McCormack 
Trainee Clinical Psychologist 
Essex Partnership University NHS Foundation Trust 








30 January 2020 
 





Study title: The experiences of non-high risk men who have sex 
with men (MSM) who are using pre-exposure 
prophylaxis (PrEP) 
IRAS project ID: 266963  
REC reference: 19/LO/1954   
Sponsor University of Essex 
 
I am pleased to confirm that HRA and Health and Care Research Wales (HCRW) Approval 
has been given for the above referenced study, on the basis described in the application form, 
protocol, supporting documentation and any clarifications received. You should not expect to 
receive anything further relating to this application. 
 
Please now work with participating NHS organisations to confirm capacity and capability, in 
line with the instructions provided in the “Information to support study set up” section towards 
the end of this letter. 
 
How should I work with participating NHS/HSC organisations in Northern Ireland and 
Scotland? 
HRA and HCRW Approval does not apply to NHS/HSC organisations within Northern Ireland 
and Scotland. 
 
If you indicated in your IRAS form that you do have participating organisations in either of 
these devolved administrations, the final document set and the study wide governance report 
(including this letter) have been sent to the coordinating centre of each participating nation. 
The relevant national coordinating function/s will contact you as appropriate. 
HRA and Health and Care 











Please see IRAS Help for information on working with NHS/HSC organisations in Northern 
Ireland and Scotland.  
 
How should I work with participating non-NHS organisations? 
HRA and HCRW Approval does not apply to non-NHS organisations. You should work with 
your non-NHS organisations to obtain local agreement in accordance with their procedures. 
 
What are my notification responsibilities during the study?  
  
The standard conditions document “After Ethical Review – guidance for sponsors and 
investigators”, issued with your REC favourable opinion, gives detailed guidance on reporting 
expectations for studies, including: 
• Registration of research 
• Notifying amendments 
• Notifying the end of the study 
The HRA website also provides guidance on these topics, and is updated in the light of 
changes in reporting expectations or procedures. 
 
 
Who should I contact for further information? 
Please do not hesitate to contact me for assistance with this application. My contact details 
are below. 
 







Email: nrescommittee.london-camberwellstgiles@nhs.net  
 
  
Copy to: Ms Sarah Manning-Press, University of Essex, Sponsor  
 
 












List of Documents 
 
The final document set assessed and approved by HRA and HCRW Approval is listed below.   
 
 Document   Version   Date   
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Insurance]  
V1  01 August 2019  
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Insurance]  
V2  01 August 2019  
Interview schedules or topic guides for participants [Topic Guide]  V1  31 October 2019  
IRAS Application Form [IRAS_Form_19112019]    19 November 2019  
IRAS Checklist XML [Checklist_13012020]    13 January 2020  
Letter from sponsor [Sponsor Letter]  V1  18 November 2019  
Non-validated questionnaire [Demographic Questionnaire]  V1  21 November 2019  
Organisation Information Document [Master]  1  15 November 2019  
Other [Email from applicant responding to queries ]    12 January 2020  
Participant consent form [Consent Form V2]  V2  07 January 2020  
Participant information sheet (PIS) [PIS GSTT V2]  V2  07 January 2020  
Participant information sheet (PIS) [PIS CW V2]  V2  07 January 2020  
Research protocol or project proposal [Protocol]  V0.2  31 October 2019  
Schedule of Events or SoECAT [Master]  1  02 December 2019  
Summary CV for Chief Investigator (CI) [CV CMcCormack]  V1    
Summary CV for student [CV CMcCormack]  V1    
Summary CV for supervisor (student research) [CV Green]  V1    
Summary, synopsis or diagram (flowchart) of protocol in non 
technical language [Flow Chart]  
V1  18 November 2019  
































IRAS project ID 266963 
 
Information to support study set up 
 
The below provides all parties with information to support the arranging and confirming of capacity and capability with participating NHS 






Expectations related to 
confirmation of 
capacity and capability 











per the protocol 
and other study 
documents will 





should not commence at 
participating NHS 
organisations in England 
or Wales prior to their 
formal confirmation of 
capacity and capability 





and the sponsor is 
not requesting and 
does not expect 
any other site 
agreement to be 
used.  







is expected at 
participating NHS 
organisations.  
Where arrangements are not 
already in place, research staff 
not employed by the NHS host 
organisation undertaking any of 
the research activities listed in 
the research application would 
be expected to obtain a Letter of 
Access based on standard DBS 
checks and occupational health 
clearance. 
 
Other information to aid study set-up and delivery 
This details any other information that may be helpful to sponsors and participating NHS organisations in England and Wales in study set-up. 








Chelsea & Westminster NHS Foundation Trust Approval 
  
Version 1.0. 24 August 2015. 





Department of Research and Development  
Research Delivery Team Office 
Unit G2, Ground Floor, Harbour Yard 
Chelsea Harbour 
London SW10 0XD 
 
 
31st January 2020 
 
Mr Christopher McCormack 
Trainee Clinical Psychologist 
Essex Partnership University NHS Foundation Trust 
The Lodge, Runwell Chase 
Runwell 







Letter of Access for Research 
 
This letter should be presented to your nominated manager at each participating site within this 
organisation before you commence your research at Chelsea and Westminster Hospital NHS 
Foundation Trust. 
 
In accepting this letter, Chelsea and Westminster Hospital NHS Foundation Trust confirms your 
right of access to conduct research through this organisation for the purpose and on the terms and 
conditions set out below. This right of access commences on 31st January 2020 and ends on 1st 
January 2021 unless terminated earlier in accordance with the clauses below.  If you require an 
extension to your letter of access, you must inform the Research and Development office, at 
least one month in advance. 
 
This letter of access is for research activities in relation to the following only: 
 
Study title: The experiences of non-high risk men who have sex with men (MSM) who are 
using pre-exposure prophylaxis (PrEP) 
IRAS reference: 266963 
REC reference: 19/LO/1954 
Local reference: C&W19/081 
 
You have a right of access to conduct such research as confirmed in writing in the letter of 






Version 1.0. 24 August 2015. 
Based upon NIHR Version 2.3.   Page 2 of 3 
note that you cannot start the research until the Principal Investigator for the research project has 
received a letter from the department of research and development giving confirmation of their 
agreement to conduct the research. 
 
The information supplied about your role in research at this organisation has been reviewed and 
you do not require an honorary research contract with this organisation. We are satisfied that 
such pre-engagement checks as we consider necessary have been carried out. Evidence of checks 
should be available on request to this organisation. 
 
You are considered to be a legal visitor to the organisation premises. You are not entitled to any 
form of payment or access to other benefits provided by Chelsea and Westminster Hospital NHS 
Foundation Trust to employees and this letter does not give rise to any other relationship between 
you and this organisation, in particular that of an employee.  
 
While undertaking research through this organisation you will remain accountable to your 
substantive employer but you are required to follow the reasonable instructions of this 
organisation or those instructions given on their behalf in relation to the terms of this right of 
access. 
 
Where any third party claim is made, whether or not legal proceedings are issued, arising out of or 
in connection with your right of access, you are required to co-operate fully with any investigation 
by this organisation in connection with any such claim and to give all such assistance as may 
reasonably be required regarding the conduct of any legal proceedings. 
 
You must act in accordance with this organisation’s policies and procedures, which are available to 
you upon request, and the Research Governance Framework.  
 
You are required to co-operate with this organisation in discharging its duties under the Health 
and Safety at Work Act 1974 and other health and safety legislation and to take reasonable care 
for the health and safety of yourself and others while on the organisations premises. You must 
observe the same standards of care and propriety in dealing with patients, staff, visitors, 
equipment and premises as is expected of any other contract holder and you must act 
appropriately, responsibly and professionally at all times.  
 
If you have a physical or mental health condition or disability which may affect your research role 
and which might require special adjustments to your role, if you have not already done so, you 
must notify your employer and Chelsea and Westminster Hospital NHS Foundation Trust prior to 
commencing your research role. 
 
You are required to ensure that all information regarding patients or staff remains secure and 
strictly confidential at all times. You must ensure that you understand and comply with the 
requirements of the NHS Confidentiality Code of Practice and the Data Protection Act 1998. 
Furthermore you should be aware that under the Act, unauthorised disclosure of information is an 
offence and such disclosures may lead to prosecution.  
 
You should ensure that, where you are issued with an identity or security card, a bleep number, 
email or library account, keys or protective clothing, these are returned upon termination of this 










Version 1.0. 24 August 2015. 
Based upon NIHR Version 2.3.   Page 3 of 3 
at all times, or are able to prove your identity if challenged. Please note that this organisation does 
not accept responsibility for damage to or loss of personal property. 
 
This organisation may revoke this letter and terminate your right to attend at any time either by 
giving seven days’ written notice to you or immediately without any notice if you are in breach of 
any of the terms or conditions described in this letter or if you commit any act that we reasonably 
consider to amount to serious misconduct or to be disruptive and/or prejudicial to the interests 
and/or business of this organisation or if you are convicted of any criminal offence.   You must not 
undertake regulated activity if you are barred from such work. If you are barred from working with 
adults or children this letter of access is immediately terminated. Your employer will immediately 
withdraw you from undertaking this or any other regulated activity and you must stop 
undertaking any regulated activity immediately. 
 
Your substantive employer is responsible for your conduct during this research project and may in 
the circumstances described above instigate disciplinary action against you.  
 
No organisation will indemnify you against any liability incurred as a result of any breach of 
confidentiality or breach of the Data Protection Act 1998. Any breach of the Data Protection Act 
1998 may result in legal action against you and/or your substantive employer. 
 
If your current role or involvement in research changes, or any of the information provided in your 
Research Passport changes, you must inform your employer through their normal procedures. You 
must also inform your nominated manager Dr Alan McOwan in this organisation and the 







Research Delivery Operations Manager 
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GSTFT ref: LOA 1035 
 
 
Date: 31st January 2020 
 
Dear Mr McCormack, 
 
 
Letter of access for:  The experiences of non-high risk men who have 
sex with men (MSM) who are using pre-exposure 
prophylaxis (PrEP) 
IRAS Reference:   266963 
REC Reference:   19/LO/1954 
 
 
This letter should be presented to Guy’s and St Thomas’ NHS Foundation Trust 
research team before you commence your research at that site. 
 
In accepting this letter, Guy’s and St Thomas’ NHS Foundation Trust (GSTFT) 
confirms your right of access to conduct research through the organisation for the 
purpose and on the terms and conditions set out below. This right of access 
commences on 31/01/2020 and ends on 01/04/2021 (the palnned end date of the 
study) unless terminated earlier in accordance with the clauses below.  
 
As an existing NHS employee you do not require an additional honorary research 
contract with the participating organisation(s). The organisation(s) is/are satisfied that 
the research activities that you will undertake in the organisation(s) are 
commensurate with the activities you undertake for your employer. Your employer is 
fully responsible for ensuring such checks as are necessary have been carried out.  
Your employer has confirmed in writing to this organisation that the necessary pre-
engagement checks are in place in accordance with the role you plan to carry out in 
the organisation(s). Evidence of checks should be available on request to Guy’s and 
St Thomas’ NHS Foundation Trust.    
 
You have a right of access to conduct such research as confirmed in writing in the 
letter of permission for research from this organisation. Please note that you cannot 
start the research until the Principal Investigator for the research project has received 
a letter from us giving the organisation(s) permission to conduct the project. 
 
You are considered to be a legal visitor to Guy’s and St Thomas’ NHS Foundation 
Trust  premises. You are not entitled to any form of payment or access to other 
benefits provided by Guy’s and St Thomas’s NHS Foundation Trust to employees 
and this letter does not give rise to any other relationship between you and Guy’s and 
St Thomas’s NHS Foundation Trust, in particular that of an employee.  
 
While undertaking research through Guy’s and St Thomas’ NHS Foudation Trust, 
you will remain accountable to your employer, Essex Partnership University NHS 
Foundation Trust, but you are required to follow the reasonable instructions of the 
Principal Incestigator (Dr Achyuta Nori) or those given on her/his behalf in relation to 
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Where any third party claim is made, whether or not legal proceedings are issued, 
arising out of or in connection with your right of access, you are required to co-
operate fully with any investigation by [Insert organisation] or this organisation in 
connection with any such claim and to give all such assistance as may reasonably be 
required regarding the conduct of any legal proceedings. 
 
You must act in accordance with Guy’s and St Thomas’ NHS Foundation Trust 
policies and procedures, which are available to you upon request, and the Research 
Governance Framework.  
 
You are required to co-operate with Guy’s and St Thomas’ NHS Foundation Trust in 
discharging its duties under the Health and Safety at Work etc Act 1974 and other 
health and safety legislation and to take reasonable care for the health and safety of 
yourself and others while on Guy’s and St Thomas’ NHS Foundation Trust premises. 
Although you are not a contract holder, you must observe the same standards of 
care and propriety in dealing with patients, staff, visitors, equipment and premises as 
is expected of a contract holder and you must act appropriately, responsibly and 
professionally at all times.  
 
If you have a physical or mental health condition or disability which may affect your 
research role and which might require special adjustments to your role, if you have 
not already done so, you must notify your employer and each participating [Insert 
organisation] prior to commencing your research role at each site.  
 
You are required to ensure that all information regarding patients or staff remains 
secure and strictly confidential at all times. You must ensure that you understand and 
comply with the requirements of the NHS Confidentiality Code of Practice and the 
Data Protection Act 2018. Furthermore you should be aware that under the Act, 
unauthorised disclosure of information is an offence and such disclosures may lead 
to prosecution.  
 
The organisation(s) will not indemnify you against any liability incurred as a result of 
any breach of confidentiality or breach of the Data Protection Act 2018. Any breach 
of the Data Protection Act 2018 may result in legal action against you and/or your 
substantive employer. 
 
You should ensure that, where you are issued with an identity or security card, a 
bleep number, email or library account, keys or protective clothing, these are 
returned upon termination of this arrangement. Please also ensure that while on the 
premises you wear your ID badge at all times, or are able to prove your identity if 
challenged. Please note that the organisation(s) accept no responsibility for damage 
to or loss of personal property. 
 
This letter may be revoked  and your right to attend the organisation(s) terminated at 
any time either by giving seven days’ written notice to you or immediately without any 
notice if you are in breach of any of the terms or conditions described in this letter or 
if you commit any act that we reasonably consider to amount to serious misconduct 
or to be disruptive and/or prejudicial to the interests and/or business of the 
organisation(s) or if you are convicted of any criminal offence.  You must not 
undertake regulated activity if you are barred from such work. If you are barred from 
working with adults or children this letter of access is immediately terminated. Your 
employer will immediately withdraw you from undertaking this or any other regulated 
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Your substantive employer is responsible for your conduct during this research 
project and may in the circumstances described above instigate disciplinary action 
against you.  
 
If your circumstances change in relation to your health, criminal record, professional 
registration or suitability to work with adults or children, or any other aspect that may 
impact on your suitability to conduct research, or your role in research changes, you 
must inform the organisation that employs you through its normal procedures. You 





Dan Walker, R&D Governance Facilitator, Guy’s and St Thomas’ NHS 
Foundation Trust 
 














 Welcome to the Integrated Research Application System
 IRAS Project Filter
The integrated dataset required for your project will be created from the answers you give to the following questions. The
system will generate only those questions and sections which (a) apply to your study type and (b) are required by the
bodies reviewing your study. Please ensure you answer all the questions before proceeding with your applications. 
Please complete the questions in order. If you change the response to a question, please select ‘Save’ and review all the
questions as your change may have affected subsequent questions. 
Please enter a short title for this project (maximum 70 characters) 
Low risk gay men who are using PrEP:   A qualitative study Version 1.0
1. Is your project research?
 Yes  No
2. Select one category from the list below:
 Clinical trial of an investigational medicinal product
 Clinical investigation or other study of a medical device
 Combined trial of an investigational medicinal product and an investigational medical device
 Other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice
 Basic science study involving procedures with human participants
 Study administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative
methodology
 Study involving qualitative methods only
 Study limited to working with human tissue samples (or other human biological samples) and data (specific project
only)
 Study limited to working with data (specific project only)
 Research tissue bank
 Research database
If your work does not fit any of these categories, select the option below:
 Other study
2a. Please answer the following question(s):
a) Does the study involve the use of any ionising radiation?  Yes       No
b) Will you be taking new human tissue samples (or other human biological samples)?  Yes       No
c) Will you be using existing human tissue samples (or other human biological samples)?  Yes       No
3. In which countries of the UK will the research sites be located?(Tick all that apply)
 England
 Scotland

















 This study does not involve the NHS
4. Which applications do you require?
 IRAS Form
 Confidentiality Advisory Group (CAG)
 Her Majesty's Prison and Probation Service (HMPPS)
Most research projects require review by a REC within the UK Health Departments' Research Ethics Service. Is
your study exempt from REC review? 
 Yes       No
5. Will any research sites in this study be NHS organisations?
 Yes       No
5a. Are all the research costs and infrastructure costs (funding for the support and facilities needed to carry out
research e.g. NHS Support costs) for this study provided by a NIHR Biomedical Research Centre, NIHR Collaboration for
Leadership in Health Research and Care (CLAHRC), NIHR Patient Safety Translational Research Centre or Medtech and
In Vitro Diagnostic Cooperative in all study sites? 
Please see information button for further details.
 Yes       No
Please see information button for further details.
5b. Do you wish to make an application for the study to be considered for NIHR Clinical Research Network (CRN)
Support and inclusion in the NIHR Clinical Research Network Portfolio? 
Please see information button for further details.
 Yes       No
The NIHR Clinical Research Network provides researchers with the practical support they need to make clinical studies
happen in the NHS e.g. by providing access to the people and facilities needed to carry out research “on the ground". 
If you select yes to this question, you must complete a NIHR Clinical Research Network (CRN) Portfolio Application Form
(PAF) immediately after completing this project filter question and before submitting other applications. Failing to complete
the PAF ahead of other applications e.g. HRA Approval, may mean that you will be unable to access NIHR CRN Support for
your study.
6. Do you plan to include any participants who are children?







 Yes       No
7. Do you plan at any stage of the project to undertake intrusive research involving adults lacking capacity to consent
for themselves?
 Yes       No
Answer Yes if you plan to recruit living participants aged 16 or over who lack capacity, or to retain them in the study following
loss of capacity. Intrusive research means any research with the living requiring consent in law. This includes use of
identifiable tissue samples or personal information, except where application is being made to the Confidentiality Advisory
Group to set aside the common law duty of confidentiality in England and Wales. Please consult the guidance notes for
further information on the legal frameworks for research involving adults lacking capacity in the UK.
8. Do you plan to include any participants who are prisoners or young offenders in the custody of HM Prison Service or
who are offenders supervised by the probation service in England or Wales?
 Yes       No
9. Is the study or any part of it being undertaken as an educational project? 
 Yes       No
Please describe briefly the involvement of the student(s): 
This is a student-led project as part of doctoral qualification clinical psychology.   The student will be the Chief
Investigator.
9a. Is the project being undertaken in part fulfilment of a PhD or other doctorate?
 Yes       No
10. Will this research be financially supported by the United States Department of Health and Human Services or any of
its divisions, agencies or programs?
 Yes       No
11. Will identifiable patient data be accessed outside the care team without prior consent at any stage of the project
(including identification of potential participants)?
 Yes       No







 NOTICE OF SUBSTANTIAL AMENDMENT
Please use this form to notify the main REC of substantial amendments to all research other than clinical trials of
investigational medicinal products (CTIMPs). 
The form should be completed by the Chief Investigator using language comprehensible to a lay person.
Details of Chief Investigator:
 Title  Forename/Initials  SurnameMr  Christopher P  McCormack







For guidance on this section of the form refer to the guidance
Full title of study: The experiences of non-high risk men who have sex with men (MSM)who are using pre-exposure prophylaxis (PrEP)




Ref.Number Description Reference Number
Name of lead R&D office: Guy's & St Thomas' NHS Foundation Trust
Date study commenced: 1 February 2020
Protocol reference (if applicable), current
version and date: V2.0 27 April 2020
Amendment number and date: Amendment number 1, 27 April
Type of amendment
(a) Amendment to information previously given in IRAS
 Yes       No
If yes, please refer to relevant sections of IRAS in the “summary of changes” below.








(b) Amendment to the protocol
 Yes       No
If yes, please submit either the revised protocol with a new version number and date, highlighting changes in
bold, or a document listing the changes and giving both the previous and revised text.
 
(c) Amendment to the information sheet(s) and consent form(s) for participants, or to any other supporting
documentation for the study
 Yes       No
If yes, please submit all revised documents with new version numbers and dates, highlighting new text in bold.
Is this a modified version of an amendment previously notified and not approved?
 Yes       No
Summary of changes
Briefly summarise the main changes proposed in this amendment. Explain the purpose of the changes and their
significance for the study.
If this is a modified amendment, please explain how the modifications address the concerns raised previously by the
ethics committee.
If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value
of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not
additional scientific critique has been obtained.
Interview transcription (A41).
Currently, the interview transcription is carried out by Mr Christopher McCormack (Chief Investigator).   We would like
permission to use a professional transcription service.  
Any other relevant information
Applicants may indicate any specific issues relating to the amendment, on which the opinion of a reviewing body is
sought.
List of enclosed documents
Document Version Date
Consent Form V2.1 30/04/2020
Participant Information Sheet V2.1 27/04/2020
Protocol V2.0 27/04/2020
Declaration by Chief Investigator
1. I confirm that the information in this form is accurate to the best of my knowledge and I take full responsibility
for it.
2. I consider that it would be reasonable for the proposed amendment to be implemented.
 
 
This section was signed electronically by Mr Christopher McCormack on 07/05/2020 14:04.










Job Title/Post: Trainee Clinical Psychologist
Organisation: Essex Partnership University NHS Foundation Trust
Email: christopher.mccormack@nhs.net
Declaration by the sponsor's representative
I confirm the sponsor's support for this substantial amendment.
This section was signed electronically by Sarah Manning-Press on 07/05/2020 14:30.
Job Title/Post: Research Governance and Planning Manager
Organisation: University of Essex
Email: sarahm@essex.ac.uk









CASP quality appraisal of the current study  
 































































Note. * contribution of the study to existing knowledge, consideration of findings in relation to current practice, policy, or literature base, areas identified for further 
research, transferability of findings discussed; 2 = yes; 1 = can’t tell; 0 = no 
 
 
 
 
